A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Reference |
|---|
| "The diagnosis of schizophrenia is established principally by the presence of certain psychological symptoms which although subjective can be reliably assessed by standardized interviewing procedures." | ( Crow, TJ, 1979) |
| "Schizophrenia is to be found in the biological families of schizophrenic adoptees but not in the adoptive families." | ( Zerbin-Rüdin, E, 1979) |
| "The hypothesis that schizophrenia is caused by the release of prostaglandin E into the hypothalamus and may sometimes be accompanied by an elevation of temperature was examined by a clinical trial of the prostaglandin E suppressant N-acetyl-p-amino-phenol (paracetamol, acetaminophen)." | ( Falloon, I; Lubbe, K; MacDonald, A; Shepherd, M; Watt, DC, 1978) |
| "Schizophrenia is a major psychiatric problem common in the younger population." | ( Barrett, JJ; Syed, GM; Toone, BK, 1992) |
| "Pharmacotherapy of schizophrenia is a complex matter." | ( Finzen, A, 1991) |
| "Schizophrenia is a disorder that by definition affects individual perception and cognition, and compromises social identity and functioning." | ( Fabrega, H, 1989) |
| "Schizophrenia is probably a heterogeneous group of disorders with mixed biopathology." | ( Carlsson, A, 1988) |
| "We propose that schizophrenia is a syndrome (not a disease)." | ( Farmati, O; Fudenberg, HH; Merler, E; Whitten, HD, 1983) |
| "The idea that schizophrenia is more than one illness is an old concept, but it finds increasing support in new studies of the clinical phenomenology, genetics, and biochemistry of schizophrenic patients." | ( Berger, PA, 1981) |
| "Schizophrenia is associated with multiple cognitive deficits which in turn may be related to abnormal dopamine (DA) function." | ( Apter, S; Davidson, M; Davis, KL; Harvey, PD; Kahn, RS; Keefe, RS; Mohs, RC; Neale, JM, 1994) |
| "Mood disorders in schizophrenia are common and are associated with a poor outcome, an increased risk of relapse and a high rate of suicide." | ( Azorin, JM, 1995) |
| "Schizophrenia is associated with structural changes in the brain but it is not clear whether the changes are localized." | ( Deakin, JF, 1994) |
| "(ii) The effect of schizophrenia is to increase MAE duration, and this is not due to some peripheral artefact." | ( Harris, J, 1994) |
| "Schizophrenia is the most prevalent of the major psychoses, but the underlying neurobiology of this debilitating disorder remains mysterious." | ( Hyde, TM; Weinberger, DR; Wolf, SS, 1993) |
| "If schizophrenia is in some way strictly related to brain morphological abnormalities it becomes hard to believe that a curative treatment will ever be possible." | ( Brunello, N; Markstein, R; Masotto, C; Racagni, G; Steardo, L, 1995) |
| "Late-life schizophrenia is prototypical of these chronic psychotic disorders." | ( Eastham, JH; Field, MG; Gierz, M; Harris, MJ; Jeste, DV; Lacro, JP, 1996) |
| "Once schizophrenia is diagnosed, the classification of schizophrenic symptoms as psychotic, disorganized, or negative can help clinicians predict treatment outcomes and individualize both pharmacologic and psychosocial treatment." | ( Marder, SR, 1996) |
| "When schizophrenia is first diagnosed antipsychotic therapy should be started quickly as the longer the initial psychosis remains untreated the worse the final outcome will be." | ( McCreadie, RG, 1996) |
| "Schizophrenia is a complex and severe disorder of unknown cause and pathophysiology." | ( McMurray, CT; Mikesell, MJ; Sobell, JL; Sommer, SS, 1996) |
| "The PCP model of schizophrenia is regarded as the most comprehensive pharmacological model of this disorder." | ( Davis, RE; Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Rosse, RB, 1996) |
| "Schizophrenia is a serious psychiatric illness which is responsible for a substantial proportion of mental illness worldwide." | ( Aguilar, MA; Espert, R; Miñarro, J; Rodríguez-Arias, M, 1996) |
| "Schizophrenia is a complex and severe disorder of unknown cause and pathophysiology." | ( Barron, YD; McMurray, CT; Mikesell, MJ; Nimgaonkar, VL; Sobell, JL; Sommer, SS, 1997) |
| "Individuals with schizophrenia are often treated with medications that block dopamine (DA) neurotransmission." | ( Kosten, TA, 1997) |
| "Schizophrenia is understood as an altered mode of affective-cognitive interaction based, possibly, on disturbed (loosened) affective-cognitive connections." | ( Ciompi, L, 1997) |
| "Schizophrenia is in essence a developmental disorder, but an unusual one in that the onset of symptoms is markedly delayed." | ( Fedtsova, N; Jeste, DV; Turner, EE, 1997) |
| "Schizophrenia is one of the most common and perhaps the most disabling of mental disorders, for which effective forms of treatment have not yet been established definitively." | ( Busatto, GF; Kerwin, RW, 1997) |
| "Schizophrenia is a human brain disease with well-defined symptoms and a lifelong disease course, but without a current biological explanation." | ( Tamminga, CA, 1998) |
| "Treatment-resistant schizophrenia is the object of intense interest because of recent developments in its treatment and aetiology." | ( Meltzer, HY, 1997) |
| "Since schizophrenia is a common condition and treatment is usually long-term, this has important financial implications." | ( Joubert, G; Stevens, M; van der Merwe, H; Verster, GC, 1998) |
| "Treating schizophrenia is expensive." | ( Arvanitis, LA; Carpenter, WT; Ciuryla, VT; Hong, WW; Kylstra, JW; Lehman, A; Meltzer, HY; Rak, IW; Wilson, AM, 1998) |
| "The symptoms of schizophrenia are treated through the blockade of mesolimbic and mesocortical dopamine activity." | ( Arnt, J, 1998) |
| "Schizophrenia is the most serious and disabling form of psychiatric disorder, and affects 1% of people worldwide." | ( Kane, JM, 1998) |
| "Schizophrenia is considered a neurodevelopmental disorder in which vulnerability to stress may be a contributing factor." | ( De Jonge, RC; Gademan, PJ; Gispen-de Wied, CC; Jansen, LM; Kahn, RS; van der Linden, JA, 1998) |
| "Schizophrenia is associated with cognitive deficits that are an intrinsic component of the disorder." | ( Bates, J; Javitt, D; Kane, J; Lieberman, J; Novak, G; Pollack, S; Umbricht, D, 1998) |
| "Schizophrenia is a disorder with an unclear pathophysiology, despite numerous attempts to elucidate its etiology." | ( Cardwell, D; Heimberg, C; Karson, CN; Komoroski, RA; Lawson, WB, 1998) |
| "Schizophrenia is a chronic and debilitating disorder whose effective pharmacological management is often less than optimal." | ( Kasper, S, 1998) |
| "Schizophrenia is a common complex mental disorder." | ( Chen, CH; Shih, HH; Tai, JJ; Wang-Wuu, S; Wuu, KD, 1998) |
| "Schizophrenia is the most prevalent form of psychosis, but this may also occur due to other medical conditions (e." | ( Keverne, EB, 1999) |
| "Schizophrenia is thought to be a disease of early development that ultimately affects forebrain neurons and circuits." | ( LaMantia, AS, 1999) |
| "Schizophrenia is a complicated disorder associated with high morbidity if left unmanaged." | ( Martinez, MC, 1999) |
| "Treatment of schizophrenia is often complicated by substance abuse." | ( Arana, GW; Gerding, LB; Labbate, LA; Measom, MO; Santos, AB, 1999) |
| "Schizophrenia is a severe disorder of personality which has a genetic basis." | ( Strange, PG, 1998) |
| "Since recently, schizophrenia is regarded as a composite of not only positive and negative but also affective and cognitive symptoms, in this study the effects of risperidone compared with typical neuroleptic haloperidol, on affective and cognitive functions were investigated in rats (anxiolytic, antidepressive and memory tests)." | ( Chodera, A; Kus, K; Nowakowska, E; Rybakowski, J, 1999) |
| "Schizophrenia is thought to arise from the interaction of genetically mediated and environmentally triggered abnormalities in brain function." | ( Benkelfat, C; Evans, AC; Florencio, PS; Joober, R; Lal, S; O'Driscoll, GA; Wolff, AL, 1999) |
| "The causes of schizophrenia are unknown, but there is evidence linking subtle deviations in neural development with schizophrenia." | ( Féron, F; Hirning, MH; Mackay-Sim, A; McGrath, J; Perry, C, 1999) |
| "Schizophrenia is a complex illness with multiple pathophysiologic factors that contribute to its psychopathology." | ( Adler, LE; Freedman, R; Harris, JG; Leonard, S; Olincy, A; Ross, RG; Waldo, MC, 2000) |
| "Schizophrenia is generally not associated with alterations of DAT in the striatum or SERT in the brainstem." | ( Abi-Dargham, A; Baldwin, R; D'Souza, DC; Gil, R; Innis, R; Krystal, J; Laruelle, M; Seibyl, J; van Dyck, C, 2000) |
| "Schizophrenia is also associated with aggression directed at self and others." | ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Schizophrenia is considered to be associated with a hyperfunction of the dopaminergic system and with abnormalities in hippocampal information processing." | ( Behr, J; Gloveli, T; Heinemann, U; Schmitz, D, 2000) |
| "Schizophrenia is associated with brain abnormalities and is typically evidenced by disorganized speech and behavior, delusions, and hallucinations; it usually requires extended hospitalization." | ( Luxenburg, O; Magnezi, R; Mark, M; Shemer, J; Siebzehner, M, 1999) |
| "Schizophrenia is a syndrome that is believed to have its onset during very early corticogenesis of the affected patient." | ( Brasic, J; Lafargue, T, 2000) |
| "Schizophrenia is a major psychiatric disease, which affects the centre of the personality, with severe problems of perception, cognition as well as affective and social behaviour." | ( Boesiger, P; Cuénod, M; Do, KQ; Dydak, U; Hell, D; Holsboer, F; Kirsten-Krüger, M; Lauer, CJ; Trabesinger, AH, 2000) |
| "Schizophrenia is associated with increased birth complications, suggesting that birth complications might alter CNS dopaminergic activity later in life." | ( Boksa, P; Vaillancourt, C, 2000) |
| "Schizophrenia is regarded as a spectrum disorder, with symptom clusters and behaviors ranging from positive to negative symptoms to neurocognitive dysfunction and affective instability." | ( Abbasi, QA; Barry, DJ; Buscema, CA; Lauve, TH, 2000) |
| "Schizophrenia is a devastating psychiatric illness." | ( Bressan, RA; Pilowsky, LS, 2000) |
| "Two cases of schizophrenia are reported in which insomnia developed after biperiden withdrawal or reduction." | ( Hirose, S, 2000) |
| "Schizophrenia is a seriously disturbing disorder, both for the victim and for their families." | ( Dean, B, 2000) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | ( Azorin, JM, 2000) |
| "Schizophrenia is one of the most researched, yet still one of the least understood, of the mental disorders." | ( Harrop, C; Trower, P, 2001) |
| "Schizophrenia is characterized by a complex array of symptoms that include hallucinations, delusions, abnormal affect, and cognitive deficits." | ( Finlay, JM, 2001) |
| "Schizophrenia is a common mental disorder that has an early onset and rates high as a cause of medical disability." | ( Silver, H, 2001) |
| "This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which "normalizes" with antipsychotic drug treatment." | ( Holcomb, HH; Lahti, AC; Medoff, DR; Tamminga, CA, 2001) |
| "Genetic models of schizophrenia are based on the demonstrated heritability of the disorder and more recent pharmacogenetic findings for antipsychotic medications." | ( Kilts, CD, 2001) |
| "Schizophrenia is associated with significant social, psychological and occupational dysfunction." | ( Loo, H; Olié, JP; Saleem, P, 2002) |
| "Schizophrenia is a chronic, severely disabling brain disorder with symptomatic onset in early adulthood." | ( Coyle, JT; Tsai, G, 2002) |
| "Schizophrenia is a severe neuropsychiatric disorder with a polygenic mode of inheritance which is also governed by non-genetic factors." | ( Bhatia, T; Deshpande, S; Nimgaonkar, VL; Prasad, S; Semwal, P; Thelma, BK, 2002) |
| "Individuals with schizophrenia are known to show deficits in prepulse inhibition (PPI) of the startle response." | ( Kumari, V; Sharma, T; Soni, W, 2002) |
| "Schizophrenia is a serious mental illness that affects 1% of the population." | ( Kumari, V; Sharma, T; Sheringham, J; Sumich, A, 2002) |
| "Pharmacotherapy for schizophrenia is a dynamic process." | ( Leslie, DL; Rosenheck, RA, 2002) |
| "Patients with schizophrenia are more likely to be overweight than the general population." | ( Guthrie, SK, 2002) |
| "Because schizophrenia is also likely to result from an interaction between genetic and early stressful life events, the APO-SUS rat might represent a promising animal model for studying this severe mental disorder." | ( Cools, AR; Ellenbroek, BA, 2002) |
| "The treatment of schizophrenia is therefore particularly important to reduce deficits across a large number of neurocognitive domains." | ( Cunningham, F; Hamed, A; Huang, YH; Kazis, LE; Lee, AF; Miller, DR; Ren, XS, 2002) |
| "Schizophrenia is a very common disorder, affecting 1% of the world population." | ( Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002) |
| "Studies within schizophrenia are largely limited to either the dopamine or serotonin system." | ( Frankle, WG; Laruelle, M, 2002) |
| "Schizophrenia is a serious and disabling psychiatric disorder affecting approximately 1% of the world's population, with its economic cost in the United States alone estimated to exceed that of all cancers combined." | ( Nasrallah, HA; Tandon, R, 2002) |
| "Namely, core schizophrenia is characterized by a left-temporal dysfunction associated with deficits in verbal processing." | ( Kalus, P; Müller, TJ; Strik, WK, 2001) |
| "Schizophrenia is associated with both reductions in prefrontal cortical (PFC) inhibitory markers and in neuron number in the mediodorsal thalamus (MDTN), which provides excitatory input to the PFC." | ( Lewis, DA; Volk, DW, 2003) |
| "Schizophrenia is a biologic disorder whose etiology involves a combination of genetic and environmental risk factors." | ( Faraone, SV; Gamma, F; Stone, WS; Tsuang, MT, 2003) |
| "Schizophrenia is one of the major psychiatric disorders for which effective pharmacotherapy has been available for approximately 50 years." | ( Cáceda, R; Kinkead, B; Nemeroff, CB, 2003) |
| "Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors." | ( Duggan, A; Kerwin, R; Knapp, M; Warner, J, 2003) |
| "Schizophrenia is characterized by severe abnormalities in cognition, including disordered attention." | ( Grottick, AJ; Higgins, GA; Le Pen, G; Moreau, JL, 2003) |
| "Schizophrenia is a major mental disorder with no clearly identified pathophysiology." | ( Reddy, RD; Yao, JK, 2002) |
| "Schizophrenia is a complex disorder with a multifactorial polygenic inheritance with several genes conferring susceptibility at many genetic locations, each with a small effect." | ( Buchanan, RW; Mitchell, BD; Stine, OC; Thaker, GK; Wonodi, I, 2003) |
| "Schizophrenia is a devastating psychiatric disorder whose pathophysiology has not been fully clarified yet." | ( Bressan, RA; Pilowsky, LS, 2003) |
| "Schizophrenia is a heterogeneous syndrome both at the etiological and clinical levels." | ( Baptista, T; Boksa, P; Joober, R; Zarate, JM, 2004) |
| "Schizophrenia is a serious and disabling psychiatric disorder affecting approximately 1% of the world's population." | ( Chaki, S; Hirota, S; Kawashima, N; Okuyama, S, 2003) |
| "Schizophrenia is a highly complex disorder characterized by a diversity of symptoms, psychotic and nonpsychotic, that most likely arise from heterogeneous neuroanatomical and neurochemical malfunctions." | ( Shayegan, DK; Stahl, SM, 2003) |
| "Schizophrenia is associated with a cerebral glutathione deficit, which may leave the brain susceptible to oxidants." | ( Castagné, V; Cuenod, M; Do, KQ; Rougemont, M, 2004) |
| "Schizophrenia is a relatively common but genetically complex disorder, making the identification of susceptibility genes formidable." | ( Itokawa, M; Yoshikawa, T, 2003) |
| "Schizophrenia is characterized by positive symptoms, negative symptoms and cognitive impairment." | ( Abi-Dargham, A, 2004) |
| "Schizophrenia is an aetiologically complex disorder arising from the interaction of a range of factors acting at various stages of life." | ( Arseneault, L; Boydell, J; Cannon, M; Howes, OD; McDonald, C; Murray, RM, 2004) |
| "Schizophrenia is a severe mental disorder of unknown etiology." | ( Brown, AS; Desai, M; Factor-Litvak, P; Graziano, J; Opler, MG; Schaefer, C; Susser, ES; Zheng, W, 2004) |
| "Symptoms of schizophrenia are improved by dopamine antagonists and exacerbated by dopamine-releasing agents, suggesting hyperactivity of dopamine." | ( Diaz, J; Leriche, L; Sokoloff, P, 2004) |
| "Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general population." | ( Bigger, JT; Buchanan, RW; Casey, DE; Covell, N; Davis, B; Davis, JM; Essock, SM; Friedman, A; Hall, CS; Kane, JM; Kleinberg, D; Lieberman, JA; Marder, SR; Miller, AL; Pi-Sunyer, X; Pogach, L; Schooler, NR; Shon, S; Stroup, S; Weissman, EM; Wirshing, DA; Yevich, SJ, 2004) |
| "Schizophrenia is characterized by high suicide risk and low awareness of disorder." | ( Alphs, L; Amador, X; Bourgeois, M; Cassano, GB; Hsu, C; Lindenmayer, JP; Meltzer, HY; Pini, S; Swendsen, J; Young, F, 2004) |
| "As schizophrenia is a chronic disorder, it is important that treatment be given over a long period of time to avoid relapse." | ( Brecher, M; Fitton, L; Jones, AM; Kasper, S, 2004) |
| "Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs." | ( Arlt, J; Jahn, H; Kiefer, F; Naber, D; Raedler, TJ; Schick, M; Wiedemann, K, 2004) |
| "Schizophrenia is associated with disproportionately high costs, mainly due to hospitalization rates." | ( Jarema, M; Leal, A; Mehnert, A; Remington, G; Rosillon, D, 2004) |
| "Schizophrenia is a chronic, disabling psychiatric disorder that genetic studies have shown to be highly heritable." | ( Coyle, JT, 2004) |
| "Schizophrenia is a common and devastating illness." | ( Tsai, SJ, 2004) |
| "Schizophrenia is a chronic disease characterized by psychotic symptoms as well as negative symptoms such as affective flattening, social withdrawal and occupational dysfunction." | ( Alfici, S; Bleich, A; Melamed, Y; Preisman, O; Stein-Reisner, O, 2004) |
| "Schizophrenia is a complex disorder with a polygenic inheritance." | ( Ergul, E; Kara, I; Kaya, G; Kilic, G; Kucukali, I; Sazci, A, 2004) |
| "Schizophrenia is a severe psychiatric disease with a strong genetic component." | ( Breen, G; Cheung, JK; Crombie, C; Neves-Pereira, M; Pasdar, A; Sinclair, M; St Clair, DM; Walker, N; Yates, P; Zhang, F, 2005) |
| "Schizophrenia is characterized by disturbances in sensorimotor gating and attentional processes, which can be measured by prepulse inhibition (PPI) and latent inhibition (LI), respectively." | ( Labrie, V; Lipina, T; Roder, J; Weiner, I, 2005) |
| "Schizophrenia is also associated with an overall decrease in activity of endogenous agonists at Glycine(B)/NMDA sites, whereas levels of endogenous antagonists are elevated." | ( Millan, MJ, 2005) |
| "Schizophrenia is a disorder with cognitive deficits that could stem from cholinergic dysfunction." | ( Cather, C; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Herz, L, 2005) |
| "Schizophrenia is a devastating and costly illness that affects 1% of the population in the US." | ( Botteman, MF; Diamond, RJ; Edwards, NC; Pashos, CL; Rupnow, MF, 2005) |
| "Schizophrenia is a chronic disabling disease which in the majority of cases requires long-term treatment with antipsychotic medication." | ( Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH, 2005) |
| "Schizophrenia is a heterogeneous disorder characterized by diffuse brain abnormalities that affect many facets of cognitive function." | ( Celone, K; Kiehl, KA; Krystal, JH; Kurtz, M; Stevens, MC, 2005) |
| "Schizophrenia is a chronic, debilitating psychotic illness of unknown etiology that has been the subject of many genetic studies." | ( Boffa, E; Kennedy, JL; Likhodi, O; Lipska, BK; Van Tol, HH; Weinberger, DR; Wong, AH, 2005) |
| "Schizophrenia is an expensive illness to treat even in developing countries." | ( Avasthi, A; Bhansali, A; Chakrabarti, S; Grover, S; Kulhara, P, 2005) |
| "Schizophrenia is associated with widespread cognitive deficits that have an impact on social function." | ( Green, RD; Hunter, MD; Spence, SA; Wilkinson, ID, 2005) |
| "Schizophrenia is considered to be a neurodevelopmental disorder with origins in the prenatal or neonatal period." | ( Bennett, S; Carr, V; Chahl, LA; Lynch-Frame, A; Newson, P; Roach, R, 2005) |
| "The pathology of schizophrenia is characterized by increased hippocampal activity at baseline and during auditory hallucinations." | ( Benes, FM; Bolshakov, VY; Gisabella, B, 2005) |
| "Schizophrenia is a major chronic psychiatric disorder associated with significant impairment in psychosocial functioning and reduced quality of life." | ( Faludi, G, 2005) |
| "NAs in schizophrenia are determined in part by genetic risk for the illness but the presence of premorbid schizotypal traits, and anti-psychotic medication confer additional risk for NAs." | ( Davies, N; Landau, S; Murray, RM; Picchioni, MM; Ribchester, T; Toulopoulou, T, 2006) |
| "Schizophrenia is a complex multifactorial disorder for which the pathobiology still remains elusive." | ( Bhatnagar, P; Brahmachari, SK; Chauhan, C; Gupta, S; Jain, S; Janardhan Reddy, YC; Kubendran, S; Kukreti, R; Tripathi, S, 2006) |
| "Schizophrenia is a neurodevelopmental mental disorder whose aetiology includes genetic and environmental factors." | ( Heresco-Levy, U, 2005) |
| "Schizophrenia is a severe psychiatric illness with a lifetime morbidity risk of around 1 %." | ( Fleischhacker, WW; Widschwendter, CG, 2005) |
| "Schizophrenia is a psychiatric disorder with a complicated pathophysiology, involving many biochemical abnormalities in the brain." | ( Shulman, Y; Tibbo, PG, 2005) |
| "Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse." | ( Heeg, B; Laux, G; Mehnert, A; van Hout, BA, 2005) |
| "Schizophrenia is a chronic, relapsing disease that requires more healthcare resources to manage than any other single psychiatric illness." | ( Buskens, E; Chue, PS; Heeg, B; van Hout, BA, 2005) |
| "Schizophrenia is a debilitating mental disorder affecting up to five in every thousand people." | ( Beaumont, G, 2000) |
| "Schizophrenia is a serious lifelong mental illness for which current treatments may only be partially effective." | ( Pilowsky, LS; Stone, JM, 2006) |
| "Schizophrenia is a severe and chronic illness as well as one of the most expensive illnesses to treat." | ( Bartkó, G; Fehér, L, 2005) |
| "Schizophrenia is associated with abnormalities in glucose metabolism that may lead to insulin resistance and a 3 fold higher incidence of type II diabetes mellitus." | ( Haroutunian, V; Ksiezak-Reding, H; Pasinetti, GM; Riggio, S; Zhao, Z, 2006) |
| "Schizophrenia is characterized by a specific deficit of relational memory, which is associated with impaired function of the parietal cortex and hippocampus." | ( Barreira, P; Cullen, TJ; Heckers, S; Ongür, D; Rohan, M; Wolf, DH; Zalesak, M, 2006) |
| "As schizophrenia is associated with perinatal brain trauma, we monitored changes in several functionally different proteins following injury-promoting MK801 blockade of N-methyl-D-aspartate receptors in neonatal rats." | ( Beauchamp, AS; Lema Tomé, CM; Leung, PW; Nottingham, CU; Smith, CM; Turner, CP, 2006) |
| "Cognition in schizophrenia is impaired in a variety of cognitive domains." | ( Hicks, PB; Schubert, MH; Young, KA, 2006) |
| "Childhood-onset schizophrenia is a rare but severe form of the disorder that is frequently treatment resistant." | ( Gochman, P; Gogtay, N; Greenstein, D; Lenane, M; Overman, GP; Rapoport, JL; Shaw, P; Sporn, A; Tossell, JW, 2006) |
| "A key feature of schizophrenia is the inability to screen out irrelevant sensory input." | ( Antonova, E; Ffytche, D; Geyer, MA; Kumari, V; Sharma, T; Williams, SC, 2007) |
| "Schizophrenia is increasingly recognized as a neurodevelopmental disease with an additional degenerative component, comprising cognitive decline and loss of cortical gray matter." | ( Aldenhoff, JB; Aust, C; Bohn, M; Czernik, A; Degner, D; Ehrenreich, H; Erdag, S; Falkai, P; Heinz, G; Hinze-Selch, D; Huber, M; Jahn, H; Klosterkötter, J; Knolle-Veentjer, S; Krampe, H; Maier, W; Mohr, A; Pollmächer, T; Ritzen, M; Rüther, E; Schneider, U; Sirén, AL; Stawicki, S; Wagner, M; Wilms, S, 2007) |
| "Schizophrenia is very common in our society, yet many people, both clergy and lay, are afraid of it and do not know what to do when confronted with someone who suffers from the disorder." | ( Carson, ML, 2006) |
| "Schizophrenia is a disorder of dopaminergic neurotransmission, but modulation of the dopaminergic system by glutamatergic neurotransmission seems to play a key role." | ( Muller, N; Schwarz, M, 2006) |
| "Schizophrenia is particularly interesting with regard to pipeline discontinuation, and appears to be unique in this data set because the number of discontinuations far exceeds that for other neuropsychiatric conditions." | ( Kerwin, R, 2006) |
| "Schizophrenia is associated with dysfunction of glutamatergic neurotransmission, and several studies have suggested glutamatergic abnormalities in bipolar disorder." | ( Beneyto, M; Dean, B; Kristiansen, LV; McCullumsmith, RE; Meador-Woodruff, JH; Scarr, E, 2007) |
| "Pharmacotherapy of schizophrenia is associated with the stressful side effects." | ( Jakovljevic, M; Ljubicic, D; Marcinko, D; Mihaljevic-Peles, A; Muck-Seler, D; Mustapic, M; Pivac, N; Relja, M, 2007) |
| "Schizophrenia is associated with impairments of attentional control on classic experimental paradigms such as the Stroop task." | ( Croft, RJ; Harrison, BJ; Leung, S; Nathan, PJ; O'Neill, BV; Phan, KL; Pipingas, A; Scholes, KE, 2007) |
| "Schizophrenia is generally a chronic and disabling mental illness." | ( Cassano, GB; Fagiolini, A; Lattanzi, L; Monteleone, P; Niolu, C; Sacchetti, E; Siracusano, A; Vita, A, 2007) |
| "Schizophrenia is noted for the remarkably high prevalence of substance use disorders (SUDs) including nicotine (>85%), alcohol and stimulants." | ( Coyle, JT, 2006) |
| "Schizophrenia is a severe and devastating psychiatric disorder affecting about 1 percent of the world's population, is characterized by psychotic episodes, negative symptoms and cognitive deficits." | ( Sárosi, A, 2006) |
| "For most people schizophrenia is a life-long disorder but about a quarter of those who have a first psychotic breakdown do not go on to experience further breakdowns." | ( Alkhateeb, H; Almerie, MQ; Essali, A; Matar, HE; Rezk, E, 2007) |
| "Schizophrenia is a long-term illness which concerns 1." | ( Hejza, J; Kleszczewska, E; Kleszczewski, T, 2006) |
| "The data show that schizophrenia is associated with abnormal levels of cortisol, DHEA-S, NO and AM." | ( Akyol, O; Celik, A; Cicek, HK; Herken, H; Yilmaz, N; Yürekli, M, 2007) |
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| "Schizophrenia is a debilitating disease of major public health importance, the incidence of which shows prominent worldwide variation (up to fivefold) and is about 40% greater in men than in women." | ( Di Forti, M; Lappin, JM; Murray, RM, 2007) |
| "Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide." | ( Javitt, DC, 2007) |
| "Schizophrenia is a devastating illness that is manifest through a variety of clinical signs and symptoms." | ( Hashimoto, T; Lewis, DA, 2007) |
| "Schizophrenia is a complex and debilitating disorder." | ( Lawrence, AJ, 2007) |
| "Schizophrenia is a major mental disorder." | ( Javitt, DC; Lifshitz, K; Linn, GS; O'Keeffe, RT; Schroeder, C, 2007) |
| "Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003." | ( Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B, 2007) |
| "Patients with schizophrenia are characterized by emotional symptoms such as flattened affect which are accompanied by cerebral dysfunctions." | ( Backes, V; Gaebel, W; Habel, U; Jon Shah, N; Kellermann, T; Reske, M; Schneider, F; Stöcker, T; von Wilmsdorff, M, 2007) |
| "Most models of schizophrenia are based on basal ganglia-thalamocortical (BGTC) neuronal circuits or brain structures that project to them." | ( Williamson, P, 2007) |
| "Schizophrenia is widely considered a neurodevelopmental disorder." | ( Keshavan, MS; MacMaster, FP; Montrose, DM; Nutche, J; Pettegrew, JW; Stanley, JA; Sweeney, JA; Vemulapalli, M, 2007) |
| "Schizophrenia is a common psychiatric disease affecting about 1% of population." | ( Anttila, S; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Rontu, R, 2007) |
| "Schizophrenia is characterized by an altered sense of the reality, associated with hallucinations and delusions." | ( Augier, S; Franck, N; Georgieff, N; Jeannerod, M; Posada, A, 2007) |
| "Schizophrenia is an idea whose very essence is equivocal, a nosological category without natural boundaries, a barren hypothesis." | ( Addington, J; Dutta, R; Greene, T; McKenzie, K; Murray, RM; Phillips, M, 2007) |
| "Schizophrenia is characterized by complex gene expression changes." | ( Arion, D; Levitt, P; Lewis, DA; Mirnics, K; Unger, T, 2007) |
| "Patients with schizophrenia are impaired in both emotion perception and contextual processing, however these two processes have not been thoroughly assessed simultaneously in adults with schizophrenia." | ( Barrett, JA; Glahn, DC; Green, MJ; Monkul, ES; Robinson, JL; Velligan, DI, 2007) |
| "Schizophrenia is a chronic psychiatric disorder the cause of which is unknown." | ( Chahl, LA, 2007) |
| "Schizophrenia is characterized by a range of positive and negative symptoms, and cognitive deficits." | ( Cussac, D; Depoortere, R; Newman-Tancredi, A, 2007) |
| "Schizophrenia is comprised of several debilitating symptoms." | ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
| "Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain." | ( Andreev, BV; Avedisova, AS; Bardenstein, LM; Gurovich, IY; Jackson, KA; Johnson, BG; Lowe, SL; Martenyi, F; Monn, JA; Morozova, MA; Mosolov, SN; Neznanov, NG; Patil, ST; Reznik, AM; Schoepp, DD; Smulevich, AB; Tochilov, VA; Zhang, L, 2007) |
| "Schizophrenia is a complex disorder that encompasses several clinical symptom domains and functional impairments." | ( Thaker, GK, 2007) |
| "Schizophrenia is a devastating mental disorder with multiple facets, including the impairment of learning and memory." | ( Kéri, S, 2008) |
| "Schizophrenia is a serious psychiatric disorder which impacts a broad range of cognitive, behavioural and emotional domains." | ( Featherstone, RE; Fletcher, PJ; Kapur, S, 2007) |
| "Schizophrenia is a complex multifactorial brain disorder with a genetic component." | ( Bovet, P; Chappuis, C; Conus, P; Cuénod, M; Deppen, P; Do, KQ; Gysin, R; Kraftsik, R; Preisig, M; Ruiz, V; Sandell, J; Steullet, P; Tosic, M; Werge, T, 2007) |
| "Schizophrenia is mostly a progressive psychiatric illness." | ( Heinemann, U; Juckel, G; Manahan-Vaughan, D; von Haebler, D; Winter, C, 2008) |
| "Schizophrenia is commonly associated with impairments in pre-attentive change detection as represented by reduced mismatch negativity (MMN)." | ( Croft, RJ; Leung, S; Nathan, PJ; O'Neill, BV, 2008) |
| "Because schizophrenia is attributed, in part, to an overactive dopaminergic system, persons with schizophrenia may display a reduced susceptibility toward gastrointestinal ulcers." | ( Hashemzadeh, M; Jadus, MR; Jamal, MM; Osapay, K; Ozdemir, V; Sandor, Z; Szabo, S, 2007) |
| "Schizophrenia is a complex disorder, where family, twin and adoption studies have been demonstrating a high heritability of the disease and that this disease is not simply defined by several major genes but rather evolves from addition or potentiation of a specific cluster of genes, which subsequently determines the genetic vulnerability of an individual." | ( Gallinat, J; Lang, UE; Muller, DJ; Puls, I; Strutz-Seebohm, N, 2007) |
| "People with schizophrenia are characterized by a broad range of cognitive impairments." | ( Ball, MP; Buchanan, RW; Conley, RR; Dickinson, D; Feldman, S; Gold, JM; McMahon, RP, 2008) |
| "However, schizophrenia is a heterogeneous disease." | ( Cesková, E; Kaspárek, T; Prikryl, R, 2007) |
| "Schizophrenia is a chronic, severe mental illness with profound emotional and economic burdens for those afflicted and their families." | ( Haroutunian, V; Kristiansen, LV; McCullumsmith, RE; Meador-Woodruff, JH; Oni-Orisan, A, 2008) |
| "Schizophrenia is characterized by heritable deficits in executive function." | ( Deckersbach, T; Freudenreich, O; Goff, DC; Halsted, CH; Henderson, DC; Roffman, JL; Weiss, AP; Wong, DH, 2008) |
| "Schizophrenia is a complex neuropsychiatric disorder with devastating consequences." | ( Tizabi, Y, 2007) |
| "Schizophrenia is a severe neuropsychiatric disorder." | ( Broadbelt, K; Jones, LB, 2008) |
| "Male patients with schizophrenia are liable to develop DM." | ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2008) |
| "Schizophrenia is widely acknowledged as being a syndrome, consisting of an undefined number of diseases probably with differing pathologies." | ( Cowie, TF; Dean, B; Kanellakis, S; Pantelis, C; Scarr, E; Sundram, S, 2009) |
| "Outcome of schizophrenia is reported to be better in India." | ( Jain, S; Thirthalli, J, 2009) |
| "Patients with schizophrenia are at increased risk of developing diabetes mellitus and cardiovascular disease." | ( Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD, 2008) |
| "Schizophrenia is associated with significant brain abnormalities, including changes in brain metabolites as measured by proton magnetic resonance spectroscopy (MRS)." | ( Berger, GE; McConchie, M; McGorry, PD; Pantelis, C; Proffitt, T; Velakoulis, D; Wellard, RM; Wood, SJ, 2008) |
| "Schizophrenia is a highly heritable complex psychiatric disorder with an underlying pathophysiology that is still not well understood." | ( Agartz, I; Andreassen, OA; Djurovic, S; Hall, H; Hansen, T; Jakobsen, KD; Jönsson, EG; Melle, I; Olsen, L; Timm, S; Ullum, H; Wang, AG; Werge, T, 2008) |
| "Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide." | ( Javitt, DC, 2008) |
| "Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive deficits, and positive and negative symptoms." | ( Wardas, J, 2008) |
| "Schizophrenia is a common, devastating neuropsychiatric disorder whose etiology is largely unknown." | ( Bender, HU; Steel, G; Valle, D; Willis, A, 2008) |
| "Schizophrenia is a brain disease involving progressive loss of gray matter of unknown cause." | ( Boellaard, R; Bossong, MG; Cahn, W; Caspers, E; Kahn, RS; Kloet, R; Lammertsma, AA; Luurtsema, G; Schuitemaker, A; van Berckel, BN; Windhorst, AD, 2008) |
| "Patients with schizophrenia are at increased risk for cardiovascular disease due to high rates of cigarette smoking." | ( Dervaux, A; Laqueille, X, 2008) |
| "Schizophrenia is a chronic and debilitating psychotic mental disorder that affects about 1% of the world's population." | ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009) |
| "Schizophrenia is one of the most expensive illnesses." | ( Glaser, T; Landen, H; Messer, T; Schmauss, M, 2009) |
| "Schizophrenia is a devastating and poorly understood disease for which the only accepted therapy is nonspecific antipsychotic and anti-seizure medication." | ( Hoffer, LJ, 2008) |
| "Schizophrenia is a devastating psychiatric disorder that affects approximately one percent of the world's adult population." | ( Arabul, M; Eren, MA; Gul, CB; Yilmaz, Y, 2008) |
| "Schizophrenia is characterized by impairments in working memory that are associated with reduced gamma-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex." | ( Eggan, SM; Hashimoto, T; Lewis, DA, 2008) |
| "Schizophrenia is a chronic, debilitating neuropsychological disease characterised by positive, negative, and cognitive deficits." | ( Jones, CA; McCreary, AC, 2008) |
| "Schizophrenia is a severe psychiatric disorder which affects approximately 1% of the population." | ( de Haan, L; van Beveren, NJ, 2008) |
| "Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance." | ( Bai, YM; Kuo, TB; Wang, YC; Yang, CC, 2008) |
| "Schizophrenia is associated with various abnormalities in the immune system." | ( Cao, LY; Chen, DC; Chen, S; Kosten, TA; Kosten, TR; Lu, L; Qi, LY; Song, C; Wang, F; Wu, GY; Xiu, MH; Zhang, XY; Zhang, Y, 2008) |
| "Schizophrenia is a debilitating lifelong disorder affecting up to 1% of the population worldwide, producing significant financial and emotional hardship for patients and their families." | ( Meador-Woodruff, J; Sodhi, M; Wood, KH, 2008) |
| "Schizophrenia is a chronic disorder, usually necessitating lifelong treatment." | ( Keith, S, 2009) |
| "Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder." | ( Dean, B; Scarr, E, 2009) |
| "Schizophrenia is a common, debilitating mental illness that has persisted over the generations." | ( Miller, CL, 2009) |
| "Schizophrenia is a complex disease, likely to be caused by a combination of serial alterations in a number of genes and environmental factors." | ( Dias-Neto, E; Gattaz, WF; Maccarrone, G; Martins-de-Souza, D; Rewerts, C; Schmitt, A; Turck, CW, 2009) |
| "Schizophrenia is a major mental disorder that affects approximately 1% of the population worldwide." | ( Javitt, DC, 2009) |
| "Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains." | ( Berk, M; Bole, F; D'Souza, R; Dodd, S; Gama, CS; Hustig, H; Koopowitz, L; Malloy, H; Monkhouse, A; Piskulic, D; Rowland, C; Sathiyamoorthy, S; Sundram, S, 2009) |
| "Schizophrenia is a severe disorder that disrupts the function of multiple brain systems, resulting in impaired social and occupational functioning." | ( Lewis, DA; Sweet, RA, 2009) |
| "Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems." | ( Dougherty, GG; Kaddurah-Daouk, R; Keshavan, MS; Krishnan, RR; Matson, WR; McEvoy, J; Montrose, DM; Reddy, RD; Rozen, S; Yao, JK, 2010) |
| "Schizophrenia is a complex neuropsychiatric disorder in which symptoms can be classified as either positive, such as delusions and hallucinations, or negative, such as blunted affect and social withdrawal." | ( Bortolin, T; Canever, L; Dal-Pizzol, F; de Oliveira, L; Mina, FG; Petronilho, F; Quevedo, J; Spiazzi, CM; Zugno, AI, 2009) |
| "Schizophrenia is a serious mental disorder with a challenging rational pharmacotherapy." | ( Uzbay, IT, 2009) |
| "Schizophrenia is a brain disease with differing symptomatic presentations, outcomes, and complex genetic mechanisms." | ( Tan, HY, 2009) |
| "Schizophrenia is a chronic and disabling psychiatric illness that is often refractory to treatment." | ( McGovern, RA; McKhann, GM; Mikell, CB; Moore, H; Segal, S; Wallenstein, MB, 2009) |
| "Schizophrenia is a severe neuropsychiatric disorder for which there is no adequate current treatment." | ( Javitt, DC, 2009) |
| "Schizophrenia is treated with medications that raise serum anticholinergic activity and are known to adversely affect cognition." | ( Fisher, M; Holland, C; Kirshner, MA; Pollock, BG; Vinogradov, S; Warm, H, 2009) |
| "Schizophrenia is an often devastating neuropsychiatric illness." | ( Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI, 2011) |
| "Schizophrenia is a neuropsychiatric disorder of a neurodevelopmental origin manifested symptomatically after puberty." | ( Assaf, Y; Piontkewitz, Y; Weiner, I, 2009) |
| "Schizophrenia is a disorder in which disturbances in the integration of emotion with cognition plays a central role and probably involves several different regions, including the dorsolateral prefrontal cortex, the rostral anterior cingulate cortex, the hippocampal formation, and basolateral amygdala (BLA)." | ( Benes, FM, 2010) |
| "Early-onset schizophrenia is often a long-term illness with an unfavorable prognosis." | ( Haapasalo-Pesu, KM, 2009) |
| "Schizophrenia is currently believed to result from variations in multiple genes, each contributing a subtle effect, which combines with each other and with environmental stimuli to impact both early and late brain development." | ( Ben-Shachar, D, 2009) |
| "Schizophrenia is a serious mental disorder." | ( Babić, D; Babić, R, 2009) |
| "Bipolar mania and schizophrenia are recognized as separate disorders but share many commonalities, which raises the question of whether they are the same disorder on different ends of a continuum." | ( Ferguson, EJ; Geyer, MA; Henry, BL; Kincaid, MJ; Masten, VL; Minassian, A; Paulus, MP; Perry, W; Sharp, RF; Young, JW; Zhuang, X, 2009) |
| "Schizophrenia is a psychotic illness characterized by problems in perception, learning, and memory." | ( Elhardt, M; Martinez, L; Tejada-Simon, MV, 2010) |
| "Schizophrenia is a heterogeneous disease generally considered to result from a combination of heritable and environmental factors." | ( Bellon, A; Frieling, H; Jay, TM; Krebs, MO; Mainguy, G, 2009) |
| "Schizophrenia is a life-long, severe, and disabling brain disorder that requires chronic pharmacotherapy." | ( Boules, M; Li, Z; Peris, J; Richelson, E; Williams, K, 2010) |
| "Schizophrenia is characterized by altered prefrontal activity and elevated striatal dopaminergic function." | ( Allen, P; Asselin, MC; Broome, M; Fusar-Poli, P; Grasby, PM; Howes, OD; McGuire, P; Montgomery, AJ; Valli, I, 2011) |
| "Schizophrenia is a debilitating condition associated with high morbidity and mortality." | ( Cutler, AJ, 2009) |
| "Schizophrenia is a chronic disorder that is usually characterized by relapses alternating with periods of full or partial remission." | ( Choi, TK; Kim, B; Kim, YW; Lee, E; Lee, SH; Suh, S; Yook, KH, 2010) |
| "Schizophrenia is a severe mental illness that affects 1% of the world population." | ( Melendez-Ferro, M; Perez-Costas, E; Roberts, RC, 2010) |
| "Schizophrenia is one of the most important forms of psychiatric illness and may be chronic and highly disabling." | ( Alania, M; Chikovani, M; Chkhartishvili, B; Doreulee, N; Mitaishvili, E, 2009) |
| "Schizophrenia is one of the common mental diseases." | ( Bian, SZ; Gu, ZL; Jiang, XG; Liu, WL; Sun, ZH; Zhang, J, 2009) |
| "Schizophrenia is associated with marked deficits in theory of mind (ToM), a higher-order form of social cognition representing the thoughts, emotions and intentions of others." | ( Arnold, C; Cichon, S; Erk, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Nöthen, MM; Rietschel, M; Schmitgen, MM; Schnell, K; Walter, H; Witt, SH, 2011) |
| "Schizophrenia is a devastating disorder." | ( Pletnikov, MV, 2009) |
| "Schizophrenia is a complex disorder that interferes with the function of several brain systems required for cognition and normal social behaviour." | ( Fazzari, P; Lerma, J; Lloyd, K; Luján, R; Marín, O; Paternain, AV; Pla, R; Rico, B; Valiente, M, 2010) |
| "The pathogenesis of schizophrenia is also characterized by abnormal neuronal development." | ( Becker, A; Grecksch, G; Keilhoff, G, 2010) |
| "Schizophrenia is a devastating disease that affects approximately 1% of the population across cultures." | ( Bickeböller, H; Boretius, S; Brose, N; Castaneda, S; Ehrenreich, H; El-Kordi, A; Frahm, J; Radyushkin, K; Reim, K; Ronnenberg, A, 2010) |
| "Schizophrenia is associated with a blunted flush response to niacin." | ( Hoffman, WF; Messamore, E; Yao, JK, 2010) |
| "Schizophrenia is a disorder of a neurodevelopmental origin manifested symptomatically after puberty." | ( Arad, M; Piontkewitz, Y; Weiner, I, 2011) |
| "Schizophrenia is a severe mental illness affecting around 1% of adults with a high degree of morbidity and mortality." | ( Belmonte-de-Abreu, P; Gama, CS; Hutz, MH; Kohlrausch, FB; Lobato, MI; Salatino-Oliveira, A, 2010) |
| "Schizophrenia is a severe and complex mental disorder that causes an enormous societal and financial burden." | ( Miller, GW; Qi, Z; Voit, EO, 2010) |
| "Patients with schizophrenia are at risk of undetected somatic comorbidity." | ( Kozumplik, O; Sedić, B; Uzun, S, 2010) |
| "Schizophrenia is a persistent, lifelong illness such that enduring functional improvements may only occur over the course of years [corrected]." | ( Harvey, PD; Loebel, A; Malla, A; Newcomer, JW; Potkin, SG; Romano, S; Siu, CO; Stahl, SM; Watsky, E; Weiden, PJ, 2010) |
| "Schizophrenia is associated with interpersonal difficulties related to impairments in the processing of facial emotional expressions." | ( Azim, A; Giampietro, VP; Kapur, S; Lykouras, L; Michalopoulou, PG; Morley, LA; Shergill, SS, 2010) |
| "Schizophrenia is a heterogeneous disorder with regard to pathophysiology; therefore, data reflecting the mean response of a sample of patients may fail to reveal therapeutic effects." | ( Bellinghieri, PM; Bruno, A; Cacciola, M; Campolo, D; Micò, U; Muscatello, MR; Pandolfo, G; Scimeca, G; Settineri, S; Zoccali, R, 2011) |
| "Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide." | ( Javitt, DC, 2010) |
| "Schizophrenia is a debilitating and complex mental disorder with a prevalence of approximately 1% worldwide." | ( Arinami, T; Itokawa, M; Toru, M, 2010) |
| "Schizophrenia is a complex disorder, with etiology likely due to epistasis." | ( Callicott, JH; Dean, M; Giegling, I; Gold, B; Kolachana, B; Law, AJ; Luna, A; McGee, K; Muglia, P; Nicodemus, KK; Radulescu, E; Rujescu, D; Straub, RE; Tan, HY; Vakkalanka, R; Weinberger, DR, 2010) |
| "Schizophrenia is a heterogeneous disorder in terms of patient response to antipsychotic treatment." | ( Ascher-Svanum, H; Case, M; Conley, R; Jacob, J; Kane, JM; Kapur, S; Kinon, BJ; Kollack-Walker, S; Stauffer, VL, 2011) |
| "Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms." | ( Damgaard, T; Hansen, SL; Neill, JC; Plath, N, 2011) |
| "Schizophrenia is a disorder that affects a significant portion of the population." | ( Dym, H; Movahed, R; Weiss, A, 2011) |
| "Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population." | ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011) |
| "Schizophrenia is a debilitating neurological disorder characterized by positive, negative, cognitive and/or emotional symptoms." | ( Adams-Marriott, AL; Doucette, TA; Gallant, IC; Robbins, MA; Ryan, CL; Smith, MT, 2011) |
| "Schizophrenia is associated with an anterior-to-posterior shift in introspection-related activation, as well as changes in functional connectivity, of the midline cortex." | ( Andrews-Hanna, JR; Cassidy, BS; Coombs, G; Gabrieli, JD; Goff, DC; Holt, DJ; Lee, SM; Moran, JM, 2011) |
| "Schizophrenia is a complex and heterogeneous psychiatric disorder." | ( Barbosa, L; Belmonte-de-Abreu, Pda S; Daskalakis, ZJ; de Jesus, DR; Favalli, GP; Gil, A; Lobato, MI; Magalhães, PV; Marcolin, MA, 2011) |
| "Schizophrenia is a remarkably complex disorder with a multitude of behavioral and biological perturbations." | ( Condray, R; Yao, JK, 2011) |
| "Schizophrenia is a pervasive neuropsychiatric disorder of uncertain etiology." | ( Cowan, DN; Fisher, JA; Ford, GM; Li, Y; Niebuhr, DW; Weber, NS; Yolken, R, 2011) |
| "OCS in schizophrenia are associated with antiserotonergic SGA treatment, but longitudinal studies have to prove causality." | ( Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M, 2011) |
| "Schizophrenia is a disorder of cognitive neurodevelopment with characteristic abnormalities in working memory attributed, at least in part, to alterations in the circuitry of the dorsolateral prefrontal cortex." | ( Hoftman, GD; Lewis, DA, 2011) |
| "People with schizophrenia are frequent and heavy smokers." | ( Benowitz, NL; Cottler, B; Gandhi, KK; Kumar, S; Lu, SE; Steinberg, ML; Williams, JM, 2011) |
| "Schizophrenia is a highly heritable neuropsychiatric disorder affecting ∼1% of the world's population." | ( Brandon, NJ; Chanda, P; Charych, E; Gundelfinger, ED; Moss, SJ; Pausch, MH; Popiolek, M; Ross, JF, 2011) |
| "Schizophrenia is a heritable, complex mental disorder." | ( Aguilar, A; Apiquián, R; Camarena, B; Carnevale, A; Fresán, A; Nicolini, H; Orozco, L; Urraca, N, 2011) |
| "Schizophrenia is a severe chronic psychiatric illness, characterized by hallucinations and delusions." | ( Hulshoff Pol, HE; Kahn, RS; Klomp, DW; Luijten, PR; Marsman, A; van den Heuvel, MP, 2013) |
| "Schizophrenia is a brain disorder associated with cognitive deficits that severely affect the patients' capacity for daily functioning." | ( Fish, KN; Gonzalez-Burgos, G; Lewis, DA, 2011) |
| "Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care." | ( Crivera, C; DeSouza, C; Dirani, RD; Kozma, CM; Macfadden, W; Mao, L, 2011) |
| "Schizophrenia is a devastating, chronic brain disorder afflicting about 1 percent of the population." | ( Bernstein, HG; Bogerts, B; Dobrowolny, H; Keilhoff, G; Steiner, J, 2011) |
| "Schizophrenia is a severe mental disorder that affects 0." | ( Cao, Y; Chen, T; Feng, G; He, L; Jia, W; Qi, X; Qiu, Y; Su, M; Sun, L; Wan, C; Wang, P; Wang, X; Wu, J; Yang, J; Yang, P; Zhao, A; Zhao, Z; Zhou, K, 2013) |
| "Schizophrenia is a severe chronic psychiatric disorder for which treatment compliance is important in the prevention of relapse." | ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "Heavy smoking and schizophrenia are diversely associated with nicotinic acetylcholine receptor expression, as was shown for brain and lymphocytes." | ( Ferrea, S; Henning, U; Luckhaus, C; Mobascher, A; Musso, F; Winterer, G, 2012) |
| "Schizophrenia is a devastating neuropsychiatric disorder of unknown etiology." | ( Guilarte, TR; Opler, M; Pletnikov, M, 2012) |
| "Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype." | ( Dome, P; Faludi, G; Lazary, J, 2011) |
| "Schizophrenia is associated with increased risk for multiple metabolic abnormalities, including altered glucose homeostasis, type-2 diabetes, obesity, and cardiovascular disease." | ( Giovanoli, S; Langhans, W; Meyer, U; Pacheco-López, G, 2013) |
| "Schizophrenia is a chronic psychotic disorder that remains a considerable cause of global disease burden." | ( Bloomfield, M; Fusar-Poli, P; Howes, OD; McGuire, P; Selvaraj, S, 2012) |
| "Schizophrenia is a brain disorder associated with subtle, but replicable cerebral volume loss mostly prevalent in frontal and temporal brain regions." | ( Falkai, P; Hasan, A; Wobrock, T, 2012) |
| "Schizophrenia is characterized by affective, cognitive, neuromorphological, and molecular abnormalities that may have a neurodevelopmental origin." | ( Deng, S; Edbauer, D; Elsworth, JD; Kenny, PJ; Kleiman, RJ; Lanz, TA; Lawrence, MS; Miller, BH; Roth, RH; Strathmann, J; Wahlestedt, C; Willoughby, D; Xi, L; Zeier, Z, 2012) |
| "Thus schizophrenia is increasingly believed to involve multi-neurotransmitter deficits, all of which may contribute to altered dopaminergic tone in the mesolimbic, mesocortical and other areas of the brain." | ( Bencherif, M; Kucinski, AJ; Lippiello, PM; Stachowiak, MK, 2012) |
| "Schizophrenia is usually considered an illness of young adulthood." | ( Ali, G; Essali, A, 2012) |
| "Schizophrenia is believed to result from problems during neural development that lead to improper function of synaptic transmission and plasticity, and in agreement, many of the susceptibility genes encode proteins critical for neural development." | ( Chen, YJ; Mei, L; Sathyamurthy, A; Xiong, WC; Yin, DM, 2012) |
| "Schizophrenia is characterized by disturbances in social behavior, sensorimotor gating and cognitive function, that are discussed to be caused by a termination of different transmitter systems." | ( Dobrowolny, H; Nullmeier, S; Panther, P; Schwegler, H; Wolf, R, 2012) |
| "Schizophrenia is a severe psychiatric disorder with a strong genetic predisposition." | ( Alapati, V; Bertisch, HC; Branch, CA; Delisi, LE; Jackson, C; Li, X; Xia, S, 2012) |
| "Schizophrenia is a pervasive neuropsychiatric disease of unknown cause." | ( Aisah, MY; Amal, RN; Azzubair, Z; Emelia, O; Noor Aadila, S; Ruzanna, ZZ; Shahida, H; Siti, NA; Tan, KS, 2012) |
| "Schizophrenia is a chronic and highly complex psychiatric disorder characterised by cognitive dysfunctions, negative and positive symptoms." | ( Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA, 2012) |
| "Schizophrenia is a complex dynamic disorder comprising a wide range of neurobiological alterations including dopaminergic dysfunction." | ( Dehning, S; Karch, S; Koch, W; Möller, HJ; Müller, N; Poepperl, G; Pogarell, O; Tatsch, K, 2012) |
| "Schizophrenia is a debilitating neurodevelopmental disorder affecting approximately 1% of the population and imposing a significant burden on society." | ( Mirnics, K; Schmidt, MJ, 2012) |
| "Schizophrenia is associated with perceptual and physiological auditory processing impairments that may result from primary auditory cortex excitatory and inhibitory circuit pathology." | ( Asafu-Adjei, JK; Delevich, KM; Dorph-Petersen, KA; Fish, KN; Lewis, DA; Moyer, CE; Sampson, AR; Sweet, RA, 2012) |
| "Schizophrenia is a chronic, severe and highly complex mental illness." | ( Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG, 2013) |
| "Schizophrenia is a complex psychiatric disorder characterized by positive symptoms, negative symptoms, and cognitive impairment." | ( Adachi, Y; Aleksic, B; Banno, M; Hashimoto, R; Iidaka, T; Ikeda, M; Inada, T; Iwata, N; Kawano, N; Kikuchi, T; Kohmura, K; Koide, T; Kushima, I; Nakamura, Y; Ohi, K; Okada, T; Ozaki, N; Suzuki, M; Takeda, M; Ujike, H; Yamashita, S; Yasuda, Y, 2012) |
| "Schizophrenia is a complex and debilitating disorder, characterized by positive, negative, and cognitive symptoms." | ( Clementino, KJ; Goel, A; Hall, AW; Jacklin, DL; Talpos, JC; Winters, BD, 2012) |
| "Schizophrenia is a complex psychiatric disorder clinically categorized into three main symptom domains: positive, negative and cognitive deficits." | ( Sato, K, 2012) |
| "Schizophrenia is a heartbreaking, debilitating, youth-stealing, lifetime disorder for most individuals afflicted with it." | ( Grant, JS; Keltner, NL; Moore, RL; Steele, D; Swan, NA, 2012) |
| "Schizophrenia is considered as a pathway disorder where Disrupted-In-Schizophrenia-1 (DISC1) is important molecular player that regulates multiple cellular cascades." | ( Gil, C; Lipina, TV; Martinez, A; Palomo, V; Roder, JC, 2013) |
| "Schizophrenia is a particularly difficult disease to model in rodents due to the fact that it has a plethora of symptoms ranging from paranoia and delusions of grandeur to anhedonia and negative affect." | ( Brown, RW; Cope, ZA; Kostrzewa, RM; Maple, AM; Perna, MK; Sheppard, AB, 2012) |
| "Schizophrenia is an extremely costly disease for families and society owing to the age of onset, chronicity and severity of impact in social, academic and vocational domains." | ( Chue, J; Chue, P, 2012) |
| "Schizophrenia is a debilitating and pervasive mental illness with devastating effects on psychological, cognitive and social wellbeing, and for which current treatment options are far from ideal." | ( Gavrilidis, E; Hayes, E; Heaton, V; Kulkarni, J; Worsley, R, 2012) |
| "Schizophrenia is a severe complex mental disorder affecting 0." | ( Adamski, J; Giegling, I; Hartmann, AM; He, Y; Illig, T; Kahn, R; Li, Y; Prehn, C; Rujescu, D; Wang-Sattler, R; Xie, L; Yu, Z, 2012) |
| "Schizophrenia is a severe and heritable brain disorder." | ( Bertisch, HC; Branch, CA; Delisi, LE; Li, X; Xia, S, 2012) |
| "Schizophrenia is a chronic and often severe psychotic disorder." | ( Asevedo, E; Brietzke, E; Cunha, GR; Mansur, RB; Zugman, A, 2012) |
| "The diagnosis of schizophrenia is rapidly raised, motivating further prescription of loxapine 300 mg daily in combination with clonazepam 6 mg daily." | ( Chaumartin, N; Lachaux, B; Monville, M, 2012) |
| "Schizophrenia is a complex and severe mental disorder characterized by positive, negative and cognitive symptoms." | ( Doucette, TA; Marriott, AL; Ryan, CL, 2012) |
| "Schizophrenia is a severe neuropsychiatric disorder without adequate current treatment." | ( Javitt, DC, 2012) |
| "Schizophrenia is a devastating mental disorder, affecting cognitive, emotional, and behavioral conditions, ability to work, social functioning, family stability and self-esteem of the patient." | ( Albuquerque, Md; Arida, RM; Cysneiros, RM; Scorza, FA, 2012) |
| "Schizophrenia is a severe psychiatric disorder with a complex and variable set of symptoms." | ( Gogos, A; Hill, RA; van den Buuse, M; Wu, YC, 2013) |
| "Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0." | ( Ibi, D; Mouri, A; Nagai, T; Yamada, K, 2013) |
| "Schizophrenia is a chronic debilitating mental disorder that affects about 1% of the US population." | ( Buchanan, RW; Keller, WR; Kelly, DL; Koola, MM; Kum, LM; Wehring, HJ, 2013) |
| "Schizophrenia is associated with various brain structural abnormalities, including reduced volume of the hippocampi, prefrontal lobes and thalami." | ( Johnstone, EC; Lawrie, SM; McIntosh, AM; Moorhead, TW; Owens, DG; Welch, KA, 2013) |
| "Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD." | ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013) |
| "Schizophrenia is characterized by alterations in cortico-limbic processes believed to involve modifications in activity within the prefrontal cortex (PFC) and the hippocampus." | ( Belujon, P; Grace, AA; Patton, MH, 2014) |
| "Schizophrenia is a neurodevelopmental disorder with onset early in adulthood." | ( Berger, T; Boutros, PC; Haque, FN; Lipina, TV; Mak, TW; McGirr, A; Roder, JC; Wong, AH, 2012) |
| "Schizophrenia is a debilitating psychotic disorder that affects up to 1." | ( Distler, MG; Dulawa, SC; Opal, MD; Palmer, AA, 2012) |
| "Schizophrenia is associated with extensive neurocognitive and behavioral impairments." | ( Barch, DM; Buchanan, RW; Colibazzi, T; Csernansky, JG; Dong, Z; Girgis, RR; Goff, DC; Harms, MP; Jarskog, LF; Javitt, DC; Kangarlu, A; Keefe, RS; Kegeles, LS; Lieberman, JA; Marder, SR; McEvoy, JP; McMahon, RP; Peterson, BS, 2013) |
| "Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients." | ( Carano, A; Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Lang, AP; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Valchera, A, 2013) |
| "Schizophrenia is associated with a cardiac autonomic dysregulation which is characterized by a decreased vagal modulation." | ( Bär, KJ; Schulz, S; Voss, A, 2012) |
| "2." | ( Horiguchi, J, 2012) |
| "A core feature of schizophrenia is a disturbance of associative processes." | ( Rojas, DC; Shatti, S; Tregellas, JR; Wilson, LB, 2013) |
| "Schizophrenia is a mental illness characterized by a breakdown in cognition and emotion." | ( Basu, D; Johnson, RL; Kwiecien, JM; Mishra, RK; Tan, ML, 2013) |
| "Schizophrenia is a multifactorial psychiatric disorder in which both genetic and environmental factors play a role." | ( Hida, H; Mouri, A; Noda, Y, 2013) |
| "Schizophrenia is associated with a substantially increased somatic morbidity and mortality, which may partly be caused by accelerated cellular aging." | ( Balslev Jorgensen, M; Broedbaek, K; Fink-Jensen, A; Greisen Soendergaard, M; Henriksen, T; Jepsen, P; Jorgensen, A; Knorr, U; Lykkesfeldt, J; Poulsen, HE; Weimann, A, 2013) |
| "Schizophrenia is a chronic syndrome of unknown etiology, predominantly defined by signs of psychosis." | ( Barcones, MF; Bernardo, M; Bioque, M; Castro, C; García-Bueno, B; García-Portilla, MP; González-Pinto, A; Lafuente, A; Leza, JC; Mac-Dowell, KS; Martínez-Cengotitabengoa, M; Micó, JA; Parellada, M; Pina-Camacho, L; Rodríguez-Jiménez, R; Rubio, G; Sáiz, PA; Santabárbara, J, 2014) |
| "Schizophrenia is a chronic and devastating illness." | ( Entlerova, M; Fajnerova, I; Hatalova, H; Kubik, S; Lobellova, V; Petrasek, T; Prokopova, I; Stuchlik, A; Svojanovska, B; Vales, K, 2013) |
| "Schizophrenia is a chronic brain disorder comprising a range of clinical features, including positive and negative symptoms, cognitive dysfunction and mood symptoms (particularly depression and anxiety)." | ( Bressan, RA; Castle, DJ; Cortese, L; Mosolov, SN, 2013) |
| "Schizophrenia is a group of mental disorders of unclear origin, affecting around 1% of global population, most commonly young people." | ( Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A, 2013) |
| "Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the population worldwide." | ( Cao, X; Hou, Y; Liu, Y; Mao, Z; Wu, C; Xie, G; Yang, J; Zhang, H; Zhao, Y, 2013) |
| "Schizophrenia is believed to arise from an interaction of genetic predisposition and adverse environmental factors, with stress being a primary variable." | ( Du, Y; Grace, AA, 2013) |
| "Schizophrenia is a severe mental illness with a lifetime prevalence of approximately one percent worldwide." | ( Aggarwal, A; Gopalakrishna, G; Lauriello, J, 2013) |
| "Schizophrenia is a severe, persistent, and fairly common mental illness." | ( Basu, AC; Bolo, NR; Coyle, JT; Konopaske, GT; Renshaw, PF, 2013) |
| "Schizophrenia is a chronic mental disease that disturbs several cognitive functions, such as memory, thought, perception and volition." | ( Abreu-Gonzalez, P; Morera-Fumero, AL, 2013) |
| "Schizophrenia is characterized by reduced hippocampal volume, decreased dendritic spine density, altered neuroplasticity signaling pathways, and cognitive deficits associated with impaired hippocampal function." | ( Balu, DT; Basu, AC; Benneyworth, MA; Bolshakov, VY; Coyle, JT; Li, Y; Puhl, MD; Takagi, S, 2013) |
| "Schizophrenia is one of the most disabling mental disorders that affects up to 1 % of the population worldwide." | ( Budni, J; de Oliveira, MB; Deroza, PF; Fraga, DB; Heylmann, AS; Julião, RF; Luca, RD; Pacheco, FD; Quevedo, J; Volpato, AM; Zugno, AI, 2013) |
| "Individuals with schizophrenia are at very high risk for drug abuse and addiction." | ( Samaha, AN, 2014) |
| "A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples." | ( Chase, KA; Gavin, DP; Guidotti, A; Sharma, RP, 2013) |
| "Schizophrenia is a devastating neuropsychiatric syndrome associated with distributed brain dysconnectivity that may involve large-scale thalamo-cortical systems." | ( Anticevic, A; Brumbaugh, MS; Cole, MW; Glahn, DC; Krystal, JH; Murray, JD; Pearlson, GD; Repovs, G; Savic, A; Winkler, AM, 2014) |
| "Schizophrenia is characterized by complicated symptoms and still lacks a diagnostic neuropathology, so developing schizophrenia animal models which have quantifiable measures tested in a similar fashion in both humans and animals will play a key role in new therapeutic approaches." | ( Gong, ZH; Li, SL; Su, RB; Yan, H, 2013) |
| "Schizophrenia is typically associated with higher-level cognitive symptoms, such as disorganized thoughts, delusions, and hallucinations." | ( Guggenmos, M; Sanders, LL; Seymour, K; Stein, T; Sterzer, P; Theophil, I, 2013) |
| "Schizophrenia is a neurodevelopmental disorder and is typically "triggered" by subsequent insults in life." | ( Huang, RH; Li, JT; Li, YH; Si, TM; Su, YA; Wang, XD; Zhao, YY, 2013) |
| "Schizophrenia is a mental disorder characterized by functional abnormalities in the language network." | ( Alary, M; Brazo, P; Delamillieure, P; Delcroix, N; Dollfus, S; Leroux, E; Razafimandimby, A, 2013) |
| "Schizophrenia is characterized by anomalous perceptual experiences (e." | ( Benedek, G; Kelemen, O; Kéri, S; Kiss, I, 2013) |
| "Schizophrenia is a complex psychiatric disorder that may result from defective connectivity, of neurodevelopmental origin, between several integrative brain regions." | ( Eybrard, S; Louilot, A; Meyer, F; Usun, Y, 2013) |
| "Schizophrenia is a serious neuropsychiatric disease of uncertain etiology, which causes human mental disorder and affects about 1% of the population." | ( Li, JF; Li, XN; Tang, ZH; Wang, T; Wang, X; Zhao, ZJ, 2013) |
| "Childhood onset schizophrenia is an extraordinarily rare illness that is poorly understood but seems continuous with the adult onset disorder." | ( Driver, DI; Gogtay, N; Rapoport, JL, 2013) |
| "Schizophrenia is one of the most expensive psychiatric illnesses." | ( Chow, DP; Chung, WS; Lee, EH; Lee, KK; Lee, VW; Wong, MC; Wu, DB, 2013) |
| "Schizophrenia is associated with altered tyrosine transport across plasma membranes." | ( Bongiovanni, R; Jaskiw, GE; Leonard, S, 2013) |
| "Schizophrenia is characterized by marked impairments in a broad and diverse array of social-cognitive domains." | ( Eack, SM; Keshavan, MS; Newhill, CE; Phillips, ML; Wojtalik, JA, 2013) |
| "Schizophrenia is a severe neuropsychiatric disorder with familial loading as heritable risk factor and cannabis abuse as the most relevant environmental risk factor up to date." | ( Falkai, P; Gruber, O; Hasan, A; Jatzko, A; Malchow, B; Schmitt, A; Schneider-Axmann, T; Wobrock, T, 2013) |
| "Patients with schizophrenia are at increased risk of suicide, but data from controlled studies of pharmacotherapy in relation to suicide risk is limited." | ( Bahmanyar, S; Bodén, R; Brandt, L; Ekbom, A; Jönsson, EG; Osby, U; Reutfors, J, 2013) |
| "Schizophrenia is associated with cortical thickness reductions in the brain, but it is unclear whether these are present before illness onset, and to what extent they are driven by genetic factors." | ( Conlon, GA; Hall, J; Honold, S; Job, D; Johnstone, EC; Lawrie, SM; McIntosh, AM; Moorhead, TW; Owens, DC; Papmeyer, M; Smyth, AM; Sprooten, E; Vincenz, D; Whalley, HC, 2013) |
| "Schizophrenia is characterized by marked deficits in executive and psychomotor functions, as demonstrated for goal-directed actions in the antisaccade task." | ( Cieslik, EC; Eickhoff, SB; Grefkes, C; Halfter, S; Kellermann, TS; Müller, VI, 2015) |
| "Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions." | ( Alem, A; Assefa, A; Borba, C; Fekadu, A; Gebre-Eyesus, T; Hanlon, C; Henderson, DC; Hussein, J; Lemma, MT; Medhin, G; Mesfin, M; Seboxa, T; Shibre, T; Teferra, S, 2013) |
| "Subjects with schizophrenia are impaired at reinforcement-driven reversal learning from as early as their first episode." | ( Beck, A; Deserno, L; Dolan, R; Heinz, A; Heinze, HJ; Huys, QJ; Rapp, MA; Schlagenhauf, F, 2014) |
| "Schizophrenia is associated with impaired sleep continuity." | ( Dalal, M; Dittmann, RW; Himmerich, H; Hinze-Selch, D; Kluge, M; Kraus, T; Pollmächer, T; Rummel-Kluge, C; Schacht, A; Schuld, A; Wehmeier, PM, 2014) |
| "Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers." | ( Assimakopoulos, K; Bartsakoulia, M; Iconomou, G; Mitropoulos, K; Papadima, EM; Patrinos, GP; Squassina, A; Tsermpini, EE, 2014) |
| "Schizophrenia is a pervasive neuropsychiatric disorder affecting over 1% of the world's population." | ( Snyder, GL; Vanover, KE, 2014) |
| "Schizophrenia is a neurodevelopmental disorder with altered expression of GABA-related genes in the prefrontal cortex (PFC)." | ( Bazmi, HH; Hoftman, GD; Lewis, DA; Li, S; Sampson, AR; Volk, DW, 2015) |
| "Schizophrenia is frequently accompanied by deficits in basic information processing, such as sensory gating." | ( Bak, N; Glenthøj, BY; Larsson, HB; Oranje, B; Rostrup, E, 2014) |
| "Schizophrenia is a chronic mental disorder related to hypo-functioning of glutamatergic neurotransmission." | ( Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014) |
| "Schizophrenia is associated with ToM impairments, and initial studies demonstrate similar, though more subtle deficits, in unaffected first-degree relatives, indicating that ToM deficits are a potential biomarker for the disorder." | ( DeLisi, LE; Dodell-Feder, D; Hooker, CI, 2014) |
| "Schizophrenia is a debilitating disorder comprising positive, negative and cognitive deficits with a poorly defined neurobiological aetiology; therefore, animal models with greater translational reliability are essential to develop improved therapies." | ( Alexander, SP; Fone, KC; Gaskin, PL, 2014) |
| "Schizophrenia is a severe, debilitating, chronic disease that is accompanied by morphologic changes within the brain." | ( Frank, E; Hajak, G; Kreuzer, PM; Landgrebe, M; Langguth, B; Poeppl, TB; Prasser, SJ; Rupprecht, R; Schecklmann, M, 2014) |
| "Cost of care of schizophrenia is more for those have lower level of functioning and have to visit the hospital more often." | ( Avasthi, A; Chakrabarti, S; Grover, S; Somaiya, M, 2014) |
| "Schizophrenia is a disease typically associated with an adolescent onset." | ( Chen, L; Lodge, DJ; Perez, SM, 2014) |
| "Schizophrenia is characterized by an abnormal dopamine system, and dopamine blockade is the primary mechanism of antipsychotic treatment." | ( Insel, C; Jarskog, LF; Reinen, J; Shohamy, D; Smith, EE; Wager, TD; Weber, J, 2014) |
| "Schizophrenia is highly heritable, raising the possibility that this phenotype is related to the genetic risk for the disorder." | ( Cichon, S; Erk, S; Grimm, O; Haddad, L; Heinz, A; Kirsch, P; Mattheisen, M; Meyer-Lindenberg, A; Mohnke, S; Mühleisen, TW; Nöthen, M; Plichta, MM; Pöhland, L; Rietschel, M; Romanczuk-Seiferth, N; Schäfer, A; Tost, H; Walter, H; Witt, SH, 2014) |
| "Treatment-resistant schizophrenia is a major health problem in the UK with the majority of patients treated with clozapine." | ( Chaudhry, IB; Collins, JD; Husain, N; Qurashi, I, 2014) |
| "Schizophrenia is a disorder of cognitive neurodevelopment." | ( Lewis, DA, 2014) |
| "Schizophrenia is a mental disorder characterized by a series of positive, negative or cognitive symptoms but with also the particularity of exhibiting a high rate of co-morbid use of drugs of abuse." | ( Balguerie, K; Coune, F; Jeanblanc, J; Jeanblanc, V; Legastelois, R; Naassila, M, 2015) |
| "Patients with schizophrenia are found to have self-regulatory dysfunctions." | ( Chen, EY; Lee, EH; Leung, CM; Seidman, LJ; Stone, WS, 2014) |
| "Schizophrenia is characterized by impaired cognitive functioning, and brain regions involved in cognitive control processes show marked glutamatergic abnormalities." | ( Craven, AR; Falkenberg, LE; Hugdahl, K; Johnsen, E; Kroken, RA; L Berg, EM; Specht, K; Westerhausen, R, 2014) |
| "Schizophrenia is a complex psychiatric disorder associated with the distortion of striatopallidal neurotransmission of central nervous system." | ( Adhikari, N; Halder, AK; Jha, T; Mondal, C, 2014) |
| "Schizophrenia is a complex neuropsychiatric disorder of unclear etiology." | ( Basmanav, FB; Böhmer, AC; Børglum, AD; Cichon, S; Degenhardt, F; Forstner, AJ; Frank, J; Herms, S; Hoffmann, P; Hollegaard, MV; Hougaard, DM; Janson, E; Maier, W; Mattheisen, M; Miró, X; Moebus, S; Mortensen, PB; Mössner, R; Nöthen, MM; Ophoff, RA; Priebe, L; Rietschel, M; Rujescu, D; Strengman, E; Witt, SH; Zimmer, A, 2014) |
| "Schizophrenia is a debilitating mental disorder." | ( Guo, J; Huang, T; Liu, ML; Liu, Z; Meng, HQ; Mu, J; Xie, P; Xu, Y; Zheng, P, 2014) |
| "Schizophrenia is a chronic psychiatric disease, which is treated by antipsychotic drugs." | ( Coveñas, R; Werner, FM, 2014) |
| "Schizophrenia is a severe neuropsychiatric disorder that is characterized by core psychiatric symptoms, including positive, negative, and cognitive symptoms." | ( Cheong, JH; Kim, B; Ko, SY; Lee, HE; Lee, Y; Oh, HK; Park, SJ; Ryu, JH; Shin, CY, 2014) |
| "The basis of CUD in schizophrenia is unclear and available treatments are rarely successful at limiting cannabis use." | ( Brunette, MF; Fischer, AS; Green, AI; Roth, RM; Whitfield-Gabrieli, S, 2014) |
| "Schizophrenia is a highly heritable disorder." | ( , 2014) |
| "Schizophrenia is a disease affecting up to 1% of the population." | ( Lodge, DJ; Perez, SM, 2014) |
| "Schizophrenia is associated with poor goal-directed performance, but whether this reflects a deficit in experienced or predicted value or in integrating these values with action-outcome information is unknown, as is the locus of any associated neuropathology." | ( Balleine, BW; Green, MJ; Griffiths, KR; Morris, RW; Quail, S, 2015) |
| "Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function)." | ( Parachikova, AI; Pedersen, CS; Plath, N; Sørensen, DB, 2014) |
| "Schizophrenia is associated with impaired empathy, and with a dysfunctional oxytocinergic system." | ( Abu-Akel, A; Decety, J; Fischer-Shofty, M; Levkovitz, Y; Shamay-Tsoory, S, 2014) |
| "The etiology of schizophrenia is unknown." | ( Akyol, O; Kus, I; Ozyurt, B; Ozyurt, H; Sarsilmaz, M; Songur, A, 2014) |
| "People with schizophrenia are known to process information more slowly than healthy people." | ( Corbera, S; Ikezawa, S; Wexler, BE, 2014) |
| "Women with schizophrenia are at particular risk for antipsychotic-associated weight gain, obesity, and related medical disorders such as diabetes and cardiovascular disease." | ( Ganguli, R; O'Malley, SS; Ratliff, J; Reutenauer, E; Tek, C, 2014) |
| "Schizophrenia is a complex and highly heterogeneous psychiatric disorder whose precise etiology remains elusive." | ( Brogan, JT; Bubser, M; Cho, HP; Conn, PJ; Daniels, JS; Garcia-Barrantes, PM; Hopkins, CR; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Rodriguez, AL; Venable, DF, 2014) |
| "Schizophrenia is a common serious mental health condition which has significant morbidity and financial consequences." | ( Adams, CE; Sinclair, D, 2014) |
| "Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy." | ( Arroll, MA; Neil, J; Wilder, L, 2014) |
| "Schizophrenia is a complex brain disorder that may be accompanied by idiopathic inflammation." | ( Alaedini, A; Bumb, JM; Enning, F; Gressitt, KL; Leweke, FM; Müller, JK; Rohleder, C; Schwarz, E; Severance, EG; Yolken, RH, 2015) |
| "Schizophrenia is a debilitating mental disorder that presents impairments in neurocognition and social cognition." | ( Aydemir, O; Brown, EC; Brüne, M; Cubukcoglu, Z; Erdin, S; Esen-Danaci, A; Gonzalez-Liencres, C; Onur, E; Tas, C, 2014) |
| "Schizophrenia is a disorder of the executive function of both sensory and central nervous system." | ( Abedian, F; Ajami, A; Akbarian, E; Alizadeh-Navaei, R; Hamzeh Hosseini, S; Taghipour, M, 2014) |
| "Schizophrenia is a chronic illness with a progressive course that can be marked by resistance to antipsychotic treatment." | ( Batail, JM; Bellissant, E; Bleher, S; Drapier, D; Langrée, B; Millet, B; Robert, G; Verdier, MC, 2014) |
| "Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations." | ( Gillies, D; Kalakouti, E; Kyprianou, K; McLoughlin, BC; Pushpa-Rajah, JA; Rathbone, J; Variend, H, 2014) |
| "Schizophrenia is a chronic and often debilitating disorder in which stage of illness appears to influence course, outcome, prognosis and treatment response." | ( Berk, M; Bush, AI; Dean, OM; Dodd, S; Rapado-Castro, M; Venugopal, K, 2015) |
| "Schizophrenia is a chronic and severe mental disorder characterized by the disintegration of cognitive thought processes and emotional responses." | ( Baek, SB; Kang, HS; Kim, CJ; Kim, TW; Lee, SJ; Park, JK, 2014) |
| "Schizophrenia is a psychiatric disorder that is associated with impaired functioning of the fronto-striatal network, in particular during reward processing." | ( de Leeuw, M; Kahn, RS; Vink, M, 2015) |
| "Schizophrenia is characterized by loss of brain volume, which may represent an ongoing pathophysiological process." | ( Andreychenko, A; Boer, VO; Bohlken, MM; Cahn, W; Hulshoff Pol, HE; Kahn, RS; Klomp, DW; Luijten, PR; Mandl, RC; Marsman, A, 2014) |
| "As schizophrenia is characterized by impairments in using positive and negative feedback to appropriately guide decision making, these findings suggest that these deficits in these processes may be mediated, at least in part, by abnormalities in both tonic and phasic dopamine transmission." | ( Floresco, SB; Stopper, CM, 2015) |
| "Schizophrenia is associated with abnormalities of hippocampal structure and function." | ( Heckers, S; Konradi, C, 2015) |
| "Schizophrenia is associated with atypical multisensory integration." | ( Cloke, JM; Winters, BD, 2015) |
| "Amotivation in schizophrenia is assumed to involve dysfunctional dopaminergic signaling of reward prediction or anticipation." | ( Chun, JW; Kim, JJ; Kim, SH; Koo, MS; Park, HJ; Park, IH; Park, S, 2015) |
| "Schizophrenia is a chronic, often disabling illness that affects approximately 24 million people worldwide." | ( Abi-Dargham, A, 2014) |
| "Schizophrenia is a complex illness with unknown aetiology and pathogenesis." | ( Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP, 2014) |
| "Schizophrenia is a debilitating neurodevelopmental disorder that is associated with dysfunction in the cholinergic system." | ( Alves de Castro, A; Bittencourt de Oliveira, M; Bogo, MR; Budni, J; Canever, L; Chipindo, H; da Rosa Silveira, F; Damázio, LS; Gama, CS; Gomes Wessler, P; Heylmann, AS; Kist, LW; Mastella, GA; Quevedo, J; Zugno, AI, 2015) |
| "Patients with schizophrenia are susceptible to low bone mineral density (BMD)." | ( Chang, YC; Huang, TL; Lane, HY; Lin, CH; Lin, CY; Wang, HS, 2015) |
| "As the incidence of schizophrenia is greater in males than females, these findings support the validity of the juvenile primate phencyclidine model and highlight its potential usefulness in understanding the deficits in dorsolateral prefrontal cortex in schizophrenia and developing novel treatments for the cognitive deficits associated with schizophrenia." | ( Diano, S; Elsworth, JD; Groman, SM; Jentsch, JD; Kim, JD; Leranth, C; Redmond, DE; Roth, RH, 2014) |
| "Schizophrenia is a debilitating disorder that affects 1% of the US population." | ( Aguilar, DD; Chen, L; Lodge, DJ, 2014) |
| "Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood." | ( Balu, DT; Coyle, JT, 2015) |
| "Schizophrenia is associated with increased cardiovascular disease morbidity and mortality." | ( Buckley, P; Kandhal, P; Mellor, A; Miller, BJ; Rapaport, MH, 2015) |
| "Schizophrenia is a severe psychiatric disorder with lifetime prevalence of ~1% worldwide." | ( Baghel, R; Chadda, RK; Gupta, M; Jain, S; Jajodia, A; Kaur, H; Kukreti, R; Kumari, K; Sood, M; Srivastava, A, 2015) |
| "Patients with schizophrenia are at increased risk of venous thromboembolism." | ( Chow, V; Curnow, J; Kritharides, L; Ng, AC; Pasqualon, T; Pennings, G; Reddel, C; Scott, E; Yeoh, T, 2015) |
| "Schizophrenia is a severely devastating mental disorder, the pathological process of which is proposed to be associated with the dysfunction of dopaminergic transmission." | ( Dou, H; Hu, M; Jin, M; Kang, X; Li, Q; Liu, B; Sun, X; Teng, S; Wang, C; Wang, L; Wang, S; Wu, Q; Xiong, W; Xu, H; Zhang, X; Zhou, L; Zhou, Z; Zhu, F; Zuo, P, 2015) |
| "Schizophrenia is characterized by heterogeneous pathophysiology." | ( Hong, CJ; Huang, CC; Huang, KL; Huang, NE; Lin, CP; Liou, YJ; Liu, ME; Lo, MT; Peng, CK; Tsai, SJ; Yang, AC, 2015) |
| "Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing." | ( Abe, RY; Diniz-Filho, A; Gracitelli, CP; Medeiros, FA; Paranhos, A; Vaz-de-Lima, FB, 2015) |
| "Schizophrenia is associated with high prevalence of substance abuse." | ( Bechtholt, AJ; Berg, AR; Coyle, JT; Puhl, MD, 2015) |
| "Schizophrenia is a neuropsychiatric disorder in which abnormalities in the prefrontal cortex lead to impaired synthesis of dopamine." | ( Nawaz, R; Siddiqui, S, 2015) |
| "Schizophrenia is a frequent disorder, which substantially impairs patients' quality of life." | ( Bumb, JM; Enning, F; Leweke, FM, 2015) |
| "Schizophrenia is a serious neuropsychiatric disorder." | ( Gálosi, R; Kállai, J; Kállai, V; Karádi, Z; Lénárd, L; Petykó, Z; Szabó, I; Tóth, A, 2015) |
| "Schizophrenia is associated with increased cardiovascular morbidity and mortality." | ( Fink-Jensen, A; Jorgensen, A; Jorgensen, MB; Knorr, U; Lykkesfeldt, J; Olsen, NV; Poulsen, HE; Soendergaard, MG; Staalsø, JM, 2015) |
| "The role of NO in schizophrenia is still unclear, and NO modulation is unexplored in ketamine (KET) animal models to date." | ( Abrao, J; Baker, GB; Balista, PA; Chaves, C; Dursun, SM; Evora, PR; Guimaraes, FS; Hallak, JE; Kandratavicius, L; Leite, JP; Maia-de-Oliveira, JP; Rodrigues, AJ; Wolf, DC, 2015) |
| "Schizophrenia is conceptualized as a disorder of aberrant gene transcription and regulation." | ( Bodapati, AS; Chase, KA; Feiner, B; Gin, H; Hu, E; Rosen, C; Rubin, LH; Sharma, RP, 2015) |
| "Schizophrenia is a severe, complex mental disorder." | ( Dang, W; Du, Y; Jiao, K; Liu, R; Liu, Z; Zhou, Q, 2015) |
| "Schizophrenia is a chronic disease that has been hypothesized to be linked to neurodevelopmental abnormalities." | ( Kohlhaas, KL; Robb, HM; Roderwald, VA; Rueter, LE, 2015) |
| "Schizophrenia is a neuropsychiatric disorder affecting 1% of the world's population." | ( Bahn, S; Guest, PC; Holmes, E; Rahmoune, H; Want, EJ; Wesseling, H, 2015) |
| "Schizophrenia is a severe and chronic neuropsychiatric disorder which affects 1% of the world population." | ( Caravaggio, F; Gerretsen, P; Graff-Guerrero, A; Hahn, M; Nakajima, S; Remington, G, 2015) |
| "Schizophrenia is associated with significant impairments in both higher and lower order social cognitive performance and these impairments contribute to poor social functioning." | ( Guastella, AJ; Hickie, IB; Hodge, MA; Langdon, R; Scott, EM; Shahrestani, S; Ward, PB, 2015) |
| "Animal models of schizophrenia are likely to play an important role in this effort." | ( Sigurdsson, T, 2016) |
| "Schizophrenia is a widespread and debilitating mental disorder." | ( Bai, SJ; Cheng, PF; Du, XY; Fang, Z; Huang, T; Liu, ML; Liu, Z; Qi, ZG; Shao, WH; Xie, P; Xu, XJ; Xu, Y; Zhang, XT; Zhao, LB; Zheng, P, 2015) |
| "As schizophrenia is associated with prenatal brain insults and premorbid cognitive deficits, we tested the a priori hypothesis that serologically defined maternal thyroid deficiency during early gestation to mid-gestation is associated with schizophrenia in offspring." | ( Brown, AS; Gyllenberg, D; Hinkka-Yli-Salomäki, S; McKeague, IW; Sourander, A; Surcel, HM, 2016) |
| "Schizophrenia is accompanied by increased lipid peroxidation and nitric oxide (NO) levels and by lowered antioxidant levels." | ( Barbosa, DS; Belangero, SI; Bonifácio, KL; Bressan, RA; Brietzke, E; Cordeiro, Q; Gadelha, A; Maes, M; Noto, C; Noto, MN; Nunes, SO; Ota, VK, 2015) |
| "Schizophrenia is associated with impaired cognition, especially cognition in social contexts." | ( Dettling, M; Hahn, E; Möhring, N; Neuhaus, AH; Shen, C; Ta, TM, 2015) |
| "Schizophrenia is a widespread mental disease with a prevalence of about 1% in the world population." | ( He, L; Huang, H; Li, M; Minica, C; Qin, S; Shen, L; Shi, Y; Wang, G; Wu, X; Xing, Q; Xu, Q; Yi, Z, 2016) |
| "Schizophrenia is associated with behavioral and brain structural abnormalities, of which the hippocampus appears to be one of the most consistent region affected." | ( Attali, B; Patrich, E; Peretz, A; Piontkewitz, Y; Weiner, I, 2016) |
| "Schizophrenia is a disabling, heterogeneous disorder with clinical features that can be parsed into three domains: positive symptoms, negative symptoms, and cognitive deficits." | ( Feifel, D; MacDonald, K; Shilling, PD, 2016) |
| "Amotivation in schizophrenia is a central predictor of poor functioning, and is thought to occur due to deficits in anticipating future rewards, suggesting that impairments in anticipating pleasure can contribute to functional disability in schizophrenia." | ( Biagianti, B; Fisher, M; Hooker, CI; Nagarajan, S; Subramaniam, K; Vinogradov, S, 2015) |
| "Schizophrenia is a complex and chronic mental health disease that affects nearly 1% of the population worldwide." | ( Pitsikas, N, 2015) |
| "Schizophrenia is associated with by severe disruptions in thought, cognition, emotion, and behavior." | ( Featherstone, RE; Siegel, SJ, 2015) |
| "Schizophrenia is characterized by substantial dysfunctions of reward processing, leading to detrimental consequences for decision-making." | ( Diekhof, EK; Gruber, O; Petrovic, A; Richter, A; Trost, S; Wolter, S, 2015) |
| "Meanwhile, schizophrenia is associated with alterations of cytokines in the immune system." | ( Deng, X; Ding, Y; Fan, N; He, H; Huang, X; Ke, X; Luo, Y; Ning, Y; Wang, D; Xu, K; Zhang, M, 2015) |
| "Schizophrenia is a highly prevalent and chronic disorder that comprises a wide range of symptomatology." | ( Basra, MK; Byers, A; Dutta, S; Hay, A; Sereno, M, 2015) |
| "Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder." | ( Kurachi, M; Sumiyoshi, T; Uehara, T, 2015) |
| "Schizophrenia is a severe psychiatric disorder associated with impaired fronto-striatal functioning." | ( de Leeuw, M; Hillegers, M; Kahn, RS; Pouwels, R; van den Munkhof, HE; Vink, M, 2016) |
| "Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the patients with antipsychotics." | ( Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG, 2016) |
| "Schizophrenia is a chronic multifactorial disorder." | ( Bukovskaya, O; Shmukler, A, 2016) |
| "Schizophrenia is a progressive psychotic disorder with devastating effects on the broad aspects of human emotion, perception, thought, and psychosocial interactions." | ( Duncan, E; Shim, S; Shuman, M, 2016) |
| "Schizophrenia is a severe and debilitating psychiatric disorder." | ( Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015) |
| "Schizophrenia is conceptualized as a neurodevelopmental disorder in which developmental alterations in immature brain systems are not clear." | ( Chen, X; Dai, Z; Lei, Y; Ling, S; Lui, F; Tian, Y; Yang, J; Zhang, J; Zhang, Z, 2016) |
| "Schizophrenia is characterized by deficits of context processing, thought to be related to dorsolateral prefrontal cortex (DLPFC) impairment." | ( Barch, DM; Chung, YS, 2016) |
| "Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders." | ( Abelli, M; Balestrieri, M; Dagani, J; de Girolamo, G; Di Paolo, L; Pini, S; Raimondi, S; Rocchi, MB; Saviotti, FM; Scocco, P; Sisti, D; Totaro, S, 2016) |
| "Schizophrenia is a heterogeneous, debilitating disorder characterized by three distinct sets of clinical features: positive symptoms, negative symptoms, and cognitive deficits." | ( Feifel, D; Shilling, PD, 2016) |
| "Schizophrenia is a common disease which affect about 1% of global population." | ( Giermaziak, W; Kus, K; Nowakowska, E; Ratajczak, P, 2016) |
| "Schizophrenia is a persistent chronic mental illness with an unknown pathogenic mechanism; no empirical laboratory-based tests are available to support the diagnosis of schizophrenia or to identify biomarkers correlated with the therapeutic effect of olanzapine." | ( Cao, CH; He, S; Li, HF; Qiao, Y; Wen, H; Yu, YM; Zhang, L, 2016) |
| "Schizophrenia is a genetically complex syndrome with substantial inter-subject variability in multiple domains." | ( Antonius, D; Berns, A; Chao, MV; Goetz, R; Gonen, O; Harroch, S; Hasan, S; Heguy, A; Kranz, TM; Lazar, M; Malaspina, D; Mazgaj, R; Rothman, K, 2016) |
| "Schizophrenia is a complex mental health disorder." | ( Benyhe, S; Büki, A; Horváth, G; Kékesi, G; Szűcs, E, 2016) |
| "Schizophrenia is characterized by profound cognitive deficits that are not alleviated by currently available medications." | ( Arnsten, AF; Girgis, RR; Gray, DL; Mailman, RB, 2017) |
| "Patients with schizophrenia are more vulnerable than healthy control subjects to the acute behavioral and cognitive effects of cannabinoid agonists and experience transient exacerbation of symptoms despite treatment with antipsychotic medications." | ( D'Souza, DC; Radhakrishnan, R; Ranganathan, M; Sherif, M, 2016) |
| "Schizophrenia is a chronic mental illness in which mitochondrial dysfunction has been suggested." | ( Deslauriers, J; Grignon, S; Monpays, C; Sarret, P, 2016) |
| "Schizophrenia is a severe mental disorder that is likely to be strongly determined by genetic factors." | ( Ji, Y; Lai, J; Qiao, X; Wei, S; Wu, H; Yan, P; Yin, F; Zhang, J, 2016) |
| "Patients with schizophrenia are eight times more likely than healthy individuals to become infected with the human immunodeficiency virus (hiv)." | ( Prinsen, EJ; van Oeffelt, T, 2016) |
| "People with schizophrenia are at greater risk for cardiovascular disease and their overall mortality rate is elevated compared to the general population." | ( Greene, CM; Henderson, DC; Jackson, JW; Parnarouskis, L; Ulloa, M; Vincenzi, B, 2016) |
| "Treating schizophrenia is costly for health systems." | ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| "Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition." | ( Bauer, M; Broccoli, L; Falkai, P; Frodl, T; Hansson, AC; Hirth, N; Malchow, B; Schmitt, A; Sommer, C; Spanagel, R; Steiner, J; Uhrig, S; von Wilmsdorff, M; Zink, M, 2016) |
| "Schizophrenia is a chronic severe mental disorder with a presumed neurodevelopmental origin, and no effective treatment." | ( Ciruela, F; Gracia-Rubio, I; Moscoso-Castro, M; Valverde, O, 2016) |
| "People with schizophrenia are especially impaired in the identification of negative facial emotions." | ( Gur, RE; Ji, E; Kindler, J; Lenroot, R; Skilleter, AJ; Vercammen, A; Weickert, CS; Weickert, TW; White, C, 2016) |
| "Schizophrenia is associated with abnormalities in the structure and functioning of white matter, but the underlying neuropathology is unclear." | ( Can, A; Chiappelli, J; Du, X; Fuchs, D; Hong, LE; Kochunov, P; Lowry, CA; Postolache, TT; Rowland, LM; Savransky, A; Shukla, DK; Tagamets, M; Wijtenburg, SA, 2016) |
| "Schizophrenia is a heterogenous neurological disorder, which has been hypothetically linked to oxidative imbalance and associated behavioral perturbations." | ( Aderibigbe, AO; Ajayi, AM; Ben-Azu, B; Iwalewa, EO, 2016) |
| "Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approximately 1% of the world's population." | ( Li, P; Snyder, GL; Vanover, KE, 2016) |
| "Schizophrenia is a debilitating psychiatric disorder with a significant number of patients not adequately responding to treatment." | ( Bikovsky, L; Desco, M; Hadar, R; Hamani, C; Klein, J; Pascau, J; Soto-Montenegro, ML; Weiner, I; Winter, C, 2016) |
| "Schizophrenia is associated with elevations in glutamatergic metabolites across several brain regions." | ( Egerton, A; Kempton, MJ; McGuire, PK; Merritt, K; Taylor, MJ, 2016) |
| "Schizophrenia is a psychiatric disorder with large personal and social costs, and understanding the genetic etiology is important." | ( Børglum, AD; Cuyabano, BC; Demontis, D; Rohde, PD; Sørensen, P, 2016) |
| "Schizophrenia is associated with general inflammation and disruption of glutamatergic and dopaminergic signalling." | ( de Bie, J; Guillemin, GJ; Lim, CK, 2016) |
| "Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large." | ( Gururajan, A; Malone, DT, 2016) |
| "Schizophrenia is well-known to be associated with hippocampal structural abnormalities." | ( Babb, JS; Davitz, MS; Gonen, O; Kirov, II; Lazar, M; Malaspina, D; Meyer, EJ; Tal, A, 2016) |
| "Schizophrenia is a debilitating neuropsychiatric disorder typically diagnosed from late adolescence to adulthood." | ( Coman, D; de Graaf, RA; Groman, SM; Herman, P; Hyder, F; Jiang, L; Kaneko, G; Rao, J; Rich, K; Sanganahalli, BG; Taylor, JR; Wang, H, 2017) |
| "Schizophrenia is hypothesized to have a neurodevelopmental origin, making animal models of neurodevelopmental insult important for testing predictions that early insults will impair cognitive function." | ( Fenton, AA; O'Reilly, KC; Perica, MI, 2016) |
| "Schizophrenia is a severe, chronic and debilitating mental disorder." | ( Carano, A; De Berardis, D; Di Giannantonio, M; Fornaro, M; Gambi, F; Girinelli, G; Marini, S; Martinotti, G; Orsolini, L; Santacroce, R; Valchera, A; Vellante, F, 2016) |
| "Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)." | ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017) |
| "Schizophrenia is associated with core emotional dysfunctions." | ( Lungu, O; Mendrek, A; Potvin, S; Tikàsz, A, 2017) |
| "* Schizophrenia is now broadly defined with positive psychotic symptoms, and a subgroup with primary negative symptoms is a candidate disease entity." | ( Carpenter, WT; Frost, KH; Strauss, GP; Whearty, KM, 2016) |
| "Schizophrenia is a serious mental health disorder characterized by several behavioral and biochemicel abnormalities." | ( Benyhe, S; Büki, A; Dvorácskó, S; Horváth, G; Kékesi, G; Szűcs, E; Tömböly, C, 2016) |
| "Schizophrenia is associated with excess cardiovascular comorbidity and mortality related to lifestyle factors, such as lack of physical activity, poor diet, and smoking." | ( Hämäläinen, M; Kampman, O; Klemettilä, JP; Leinonen, E; Moilanen, E; Seppälä, N; Viikki, M, 2017) |
| "People with schizophrenia are 3-4 times more likely to die from cardiovascular disease than the general population." | ( DiPaula, BA; Feldman, SM; Jose, PA; Kelly, DL; Kitchen, CA; Liu, F; Norman, SM; Sullivan, KM, 2017) |
| "Schizophrenia is a severe mental condition in which several lipid abnormalities-either structural or metabolic-have been described." | ( Bergaoui, H; De Hert, M; Delva, C; Ferreri, F; Frajerman, A; Lamaziere, A; Lapidus, N; Nuss, P; Roiser, JP; Sweers, K; Tessier, C, 2016) |
| "Schizophrenia is a chronic psychotic disorder in which genetics and environmental factors such as infection and the corresponding immune response play a role in the etiopathogenesis." | ( Bay Karabulut, A; Gönenir Erbay, L; Kartalcı, G; Kartalcı, Ş; Otlu, Ö; Porgalı Zayman, E, 2016) |
| "Schizophrenia is associated with cardiovascular co-morbidity and a reduced life-expectancy of up to 20 years." | ( Andersen, UB; Bak, N; Broberg, BV; Ebdrup, BH; Glenthøj, BY; Holst, JJ; Ishøy, PL; Jørgensen, NR; Knop, FK, 2017) |
| "Schizophrenia is a psychiatric disorder characterized by positive and negative symptoms often accompanied by depression and cognitive deficits." | ( Górska, A; Gołembiowska, K; Jurczak, A; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z, 2017) |
| "Schizophrenia is increasingly recognized as a disorder of distributed neural dynamics, but the molecular and genetic contributions are poorly understood." | ( Bassett, DS; Bilek, E; Braun, U; Erk, S; Geiger, LS; Grimm, O; Haddad, L; Heinz, A; Meyer-Lindenberg, A; Mohnke, S; Otto, K; Rausch, F; Romanczuk-Seiferth, N; Schäfer, A; Schwarz, E; Schweiger, JI; Tost, H; Walter, H; Zink, M, 2016) |
| "Schizophrenia is a heterogeneous disorder in which psychiatric symptoms are classified into two general subgroups-positive and negative symptoms." | ( Bürkner, PC; Williams, DR, 2017) |
| "Schizophrenia is associated with deficits in cortical plasticity that affect sensory brain regions and lead to impaired cognitive performance." | ( Ahissar, M; Beggel, O; Epstein, ML; Javitt, DC; Kantrowitz, JT; Lehrfeld, JM; Lehrfeld, NP; Parker, E; Reep, J; Revheim, N; Rohrig, S; Silipo, G, 2016) |
| "Schizophrenia is characterized by behavioral symptoms, brain function impairments and electroencephalographic (EEG) changes." | ( Barbosa, TM; Borges, LTN; Gularte, VN; Lima, RF; Macêdo, D; Matos, NCB; Oliveira, MN; Patrocínio, MCA; Sampaio, LRL; Vale, OCD; Vasconcelos, SMM, 2017) |
| "Schizophrenia is associated with impairment in a range of cognitive functions." | ( Gold, JM; Hahn, B; Harvey, AN; Ross, TJ; Stein, EA, 2017) |
| "Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant." | ( Egerton, A; Gillespie, AL; MacCabe, JH; Mill, J; Samanaite, R, 2017) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "Schizophrenia is a prototypical disorder of brain connectivity with altered neural activity in regions extending throughout the brain." | ( Chen, H; Chen, X; Han, S; Hu, M; Long, Z; Wang, X; Wang, Y; Yu, Y; Zong, X, 2017) |
| "Schizophrenia is associated with profound cognitive and psychosocial impairments." | ( Bak, N; Broberg, BV; Ebdrup, BH; Fagerlund, B; Glenthøj, BY; Ishøy, PL; Knop, FK, 2017) |
| "Schizophrenia is a chronic psychiatric disorder with complex genetic and environmental origins." | ( Akamatsu, W; Fujimoto, M; Fujiwara, M; Hashimoto, H; Hashimoto, R; Hayata-Takano, A; Ishikawa, M; Kasai, A; Kikuchi, M; Matsumoto, T; Matsumura, K; Nagayasu, K; Nakaya, A; Nakazawa, T; Numata, S; Okada, S; Okano, H; Shintani, N; Takuma, K; Yamamori, H; Yasuda, Y, 2017) |
| "Schizophrenia is characterized by a multiplicity of symptoms arising from almost all domains of mental function." | ( Cervenka, S; Collste, K; Engberg, G; Erhardt, S; Fatouros-Bergman, H; Flyckt, L; Goiny, M; Malmqvist, A; Orhan, F; Piehl, F; Sellgren, CM; Victorsson, P, 2018) |
| "Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential." | ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "The notion that schizophrenia is a neurodevelopmental disorder in which neuropathologies evolve gradually over the developmental course indicates a potential therapeutic window during which pathophysiological processes may be modified to halt disease progression or reduce its severity." | ( Bikovski, L; Desco, M; Ewing, S; Götz, T; Hadar, R; Hamani, C; Maier, P; Pascau, J; Schimke, J; Soto-Montenegro, ML; Voget, M; Weiner, I; Wieske, F; Winter, C, 2018) |
| "Schizophrenia is a chronic, disabling and severe mental disorder, characterised by disturbance in perception, thought, language, affect and motor behaviour." | ( Bazrafshan, A; Esmailian, S; Goughari, AS; Mazhari, S; Shah-Esmaeili, A; Zare, M, 2017) |
| "The treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease." | ( Holahan, MR; Tuplin, EW, 2017) |
| "Schizophrenia is a severe mental illness that causes major functional impairment." | ( Bradley, ER; Woolley, JD, 2017) |
| "Schizophrenia is a complex neuropsychiatric disorder with high heritability; however, family and twin studies have indicated that environmental factors also play important roles in the etiology of disease." | ( Thomas, EA, 2017) |
| "Schizophrenia is a serious mental illness of unclear aetiology." | ( Ross, BM, 2018) |
| "Schizophrenia is a neurodevelopmental disorder in which impaired decision-making and goal-directed behaviors are core features." | ( Buhusi, CV; Buhusi, M; Olsen, K, 2017) |
| "Schizophrenia is a severe mental disorder characterised by positive and negative symptoms." | ( Gago, J; Neto, D; Spínola, C, 2017) |
| "Schizophrenia is one of the most common mental illnesses in our society, affecting up to 1% of the population." | ( Dumas, JA; Makarewicz, JA; Searles, S, 2018) |
| "Schizophrenia is a neuropsychiatric disorder that features neural oxidative stress and glutathione (GSH) deficits." | ( Cressatti, M; Galindez, C; Liberman, A; Schipper, HM; Song, W; Tavitian, A, 2017) |
| "Schizophrenia is a chronic and devastating disease with an overall lifetime risk of 1%." | ( Hauser, MJ; Isbrandt, D; Roeper, J, 2017) |
| "Schizophrenia is a devastating illness that affects up to 1% of the population; it is characterized by a combination of positive symptoms, negative symptoms, and cognitive impairment." | ( Lee, BJ; Mihaljevic, M; Nucifora, FC; Sawa, A, 2017) |
| "Schizophrenia is a complex neuropsychiatric illness with marked sex differences." | ( McGregor, C; Riordan, A; Thornton, J, 2017) |
| "Schizophrenia is a complex psychiatric disorder characterized by memory impairments with delusions and hallucinations." | ( Ahmed, SSSJ; Akram Husain, RS; Ramakrishnan, V, 2017) |
| "Since schizophrenia is a developmental disorder, we examined the effects that perturbation of the one-carbon metabolism during gestation has on mice progeny." | ( Abbott, GW; Alachkar, A; Civelli, O; Hamzeh, AR; Lee, SM; Sanathara, N; Wang, L; Wang, Z; Xu, X; Yoshimura, R, 2018) |
| "Schizophrenia is a severe syndrome that affects about 1% of the world population." | ( Doron, R; Golani, I; Kremer, I; Shamir, A; Tadmor, H, 2018) |
| "Schizophrenia is a complex and devastating neuropsychiatric disease thought to result from impaired connectivity between several integrative regions, stemming from developmental failures." | ( Eybrard, S; Louilot, A; Meyer, F; Pouvreau, T; Tagliabue, E, 2017) |
| "Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's life." | ( Ekinci, A; Ekinci, O, 2018) |
| "Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life." | ( Baker, RA; Beillat, M; Eramo, A; Ettrup, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C, 2017) |
| "Schizophrenia is associated with functional challenges for patients; relapses in schizophrenia may lead to increased treatment costs and poor quality of life." | ( Gawande, S; Gundugurti, PR; Nagpal, R; Narang, P; Sheth, A; Singh, V, 2017) |
| "The risk of schizophrenia is increased in offspring whose mothers experience malnutrition during pregnancy." | ( Balan, S; Bundo, M; Hamazaki, K; Hisano, Y; Iwamoto, K; Iwayama, Y; Kimura, T; Maekawa, M; Nozaki, Y; Ohba, H; Ohnishi, T; Osumi, N; Shimamoto, C; Takahashi, E; Takashima, A; Toyoshima, M; Watanabe, A; Yoshikawa, T, 2017) |
| "Deficit schizophrenia is strongly associated with worse outcomes on VFT, MMSE, WLM, WLRecall, WLRecognition, and delayed recall savings and increased false memories." | ( Anderson, G; Carvalho, AF; Geffard, M; Hemrungrojn, S; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S; Thika, S, 2018) |
| "Schizophrenia is a chronic psychotic disorder characterized by positive, negative, and cognitive symptoms." | ( Jang, DS; Jeon, SJ; Kim, E; Kwon, Y; Lee, JS; Oh, HK; Ryu, JH; Zhang, J, 2017) |
| "Schizophrenia is a psychiatric disorder with a higher mortality than that of the general population." | ( Champika, L; Chandradasa, M; de Silva, S; Kuruppuarachchi, KALA, 2017) |
| "Schizophrenia is associated with increased levels of inflammatory markers." | ( Benros, ME; Gasse, C; Horsdal, HT; Wimberley, T, 2017) |
| "Schizophrenia is a pervasive neuropsychiatric disorder affecting over 1% of the world's population." | ( Snyder, GL; Vanover, KE, 2017) |
| "As schizophrenia is associated with glutamatergic abnormalities, we hypothesized that schizophrenia patients may have abnormal glutamatergic reactivity within the dorsal anterior cingulate cortex (dACC), a key region involved in perception of and reaction to stress." | ( Chiappelli, J; Gaston, F; Gaudiot, C; Hong, LE; Kochunov, P; Kodi, P; Quiton, R; Rowland, LM; Shi, Q; Wijtenburg, SA; Wisner, K, 2018) |
| "Schizophrenia is associated with an increased mortality from cardiovascular disease." | ( Bressan, RA; Calzavara, MB; de Mendonça Furtado, RH; Gadelha, A; Scorza, FA; Zugman, A, 2018) |
| "Schizophrenia is one of the most disabling psychiatric syndromes with the prevalence of 1% in the general population." | ( Akasheh, N; Akbari, H; Heidary, M; Sepehrmanesh, Z, 2018) |
| "Schizophrenia is a complex neuropsychiatric disorder characterized by hallucinations, delusions, anhedonia, flat affect and cognitive impairments." | ( Coronel-Oliveros, CM; Pacheco-Calderón, R, 2018) |
| "Schizophrenia is a debilitating neurodevelopmental disorder affecting 1% of the global population with heterogeneous symptoms including positive, negative, and cognitive." | ( Amitai, N; Powell, SB; Young, JW, 2019) |
| "The patients with schizophrenia are at increased risk for problems regarding metabolic parameters due to their lifestyle and antipsychotic treatment." | ( Bayram, S; Erzin, G; Fountoulakis, K; Kotan, VO; Topcuoglu, C, 2018) |
| "Schizophrenia is one of the most debilitating diseases in the United Arab Emirates." | ( El Khoury, AC; Nuhoho, S; Ribes, D; Saad, A; Saumell, G, 2018) |
| "The etiology of schizophrenia is still unclear." | ( Costa, AC; Gattaz, WF; Joaquim, HPG; Talib, LL, 2018) |
| "Schizophrenia is a chronic mental disorder reported to compromise about 1% of the world's population." | ( Cysne Filho, FMS; de Almeida, JC; de Sousa, CNS; Diniz, DDS; Macêdo, D; Patrocínio, CFV; Patrocínio, MCA; Sampaio, LRL; Vasconcelos, SMM, 2018) |
| "Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms." | ( Horder, J; Matthews, PRL; Pearce, M, 2018) |
| "Schizophrenia is a debilitating neuropsychiatric illness that is characterized by positive, negative, and cognitive symptoms." | ( Boileau, I; Khan, MS; Kolla, N; Mizrahi, R, 2018) |
| "Schizophrenia is a heterogenous and severe neuropsychiatric disorder that affects nearly 1% of the population worldwide." | ( Green, AI; Henricks, AM; Khokhar, JY; Sullivan, EDK, 2018) |
| "Schizophrenia is characterized by abnormal behavior like obsession, dampening of emotions and auditory hallucination." | ( Sehgal, SA; Tahir, RA, 2018) |
| "Schizophrenia is associated with core deficits in cognitive abilities and impaired functioning of the newly evolved prefrontal association cortex (PFC)." | ( Arnsten, AFT; Datta, D, 2018) |
| "Schizophrenia is a complex disorder lacking an effective treatment option for the pervasive and debilitating cognitive impairments experienced by patients." | ( Glausier, JR; Lewis, DA, 2018) |
| "Schizophrenia is a heterogeneous disorder that exhibits variable responsiveness to treatment between individuals." | ( Kydd, RR; McNabb, CB; Russell, BR; Soosay, I; Sundram, F, 2018) |
| "Schizophrenia is one of the most serious and common mental disorders, which is characterized by high levels of pathogenic heterogeneity as well as neuroimmune abnormalities, which require treatment with antipsychotic drugs." | ( Ershov, EE; Grunina, MN; Krupitsky, EM; Nasyrova, RF; Sosin, DN; Sosina, KA; Taraskina, AE; Zabotina, AM, 2018) |
| "Schizophrenia is among the top half of the 25 leading causes of disabilities worldwide with a 10-20 year decrease in life expectancy." | ( Burnet, PWJ; Kao, AC; Lennox, BR, 2018) |
| "Deficit schizophrenia is accompanied by a broader spectrum of cognitive impairments than nondeficit schizophrenia, including executive functions, sustained attention, episodic and semantic memory and emotion recognition." | ( Kanchanatawan, B; Maes, M, 2018) |
| "Schizophrenia is one of the psychotic mental disorders characterized by symptoms of thought, behavior, and social problems." | ( Bhidhasra, A; Dhingra, MS; Dhingra, S; Jindal, DK; Kumar, A; Parle, M; Sharma, N; Yadav, M, 2018) |
| "Schizophrenia is a mental disorder that mostly appears in the second or third decade of life with no consistent appearance." | ( Cubała, WJ; Wiglusz, MS; Włodarczyk, A, 2018) |
| "Schizophrenia is associated with significant economic burden." | ( Acurcio, FA; Barbosa, WB; Barbui, C; Bennie, M; Costa, JO; de Lemos, LLP; de Oliveira, HN; Godman, B; Gomes, RM; Guerra, AA; Ruas, CM, 2018) |
| "Schizophrenia is a chronic severe mental disorder in which immunologic imbalances have been reported." | ( Arsang-Jang, S; Eftekharian, MM; Ghafouri-Fard, S; Omrani, MD; Taheri, M, 2019) |
| "Depression and schizophrenia are burdensome, costly serious and disabling mental disorders." | ( Pilc, A; Wierońska, JM, 2019) |
| "Schizophrenia is a serious long-term mental disorder which usually presents in adolescence or early adulthood." | ( Al-Balushi, N; Harding, D; Mirza, H, 2018) |
| "Schizophrenia is a severely debilitating neurodevelopmental disorder." | ( Bertollini, C; Carleton, A; De Roo, M; Marissal, T; Müller, D; Mutel, S; Rodriguez, I; Salazar, RF, 2018) |
| "Schizophrenia is a chronic, often progressive, disorder." | ( Gonzales, SS; Kraguljac, NV; Lahti, AC; Morgan, CJ; Sivaraman, S; White, DM, 2018) |
| "Background Schizophrenia is a chronic mental disorder, characterized by positive, negative and cognitive symptoms." | ( de Sousa, FCF; Dias, KCF; Dos Santos Júnior, MA; Jucá, MM; Leal, LKAM; Silva, AH; Vasconcelos, GS; Vasconcelos, SMM; Viana, GSB; Ximenes, NC, 2018) |
| "Schizophrenia is a devastating neuropsychiatric disorder with increasing concern." | ( Cai, TJ; Cao, Y; Chen, RJ; Ji, AL; Kan, HD; Li, YF; Liang, Z; Liu, XL; Wu, L; Wu, N; Xiang, Y; Xu, C; Yao, CY, 2019) |
| "Schizophrenia is a debilitating disorder with complex and unclarified etiological factors." | ( Aivaliotis, M; Chalkiadaki, K; Chatzaki, E; Kyriazidis, E; Sidiropoulou, K; Stavroulaki, V; Velli, A; Vouvoutsis, V, 2019) |
| "Schizophrenia is a chronic and severe mental disorder affecting more than 21 million people worldwide." | ( Bai, L; Cheng, Q; Duan, J; Gao, J; Su, H; Wang, S; Xu, Z; Zhang, H; Zhang, X; Zhang, Y, 2019) |
| "Schizophrenia is a severe mental disorder with a prevalence of about 1% among the general population." | ( Dehnavieh, R; Eslami Shahrbabaki, M; Sharafkhani, R; Vali, L, 2018) |
| "Schizophrenia is a debilitating condition with three main symptom domains: positive, negative, and cognitive." | ( Citrome, L; Faden, J, 2019) |
| "Stable phase schizophrenia is characterized by altered patterning in tryptophan catabolites (TRYCATs) and memory impairments, which are associated with PHEMN (psychosis, hostility, excitation, mannerism and negative) and DAPS (depression, anxiety and physio-somatic) symptoms." | ( Kanchanatawan, B; Maes, M; Sriswasdi, S, 2019) |
| "Individuals with schizophrenia are at increased risk of developing metabolic syndrome (MetS) due to their lifestyle and antipsychotic treatment." | ( Cai, J; Fan, W; Song, L; Tang, W; Wang, W; Xu, F; Yang, F; Zhang, C; Zhang, Y, 2019) |
| "Schizophrenia is a disorder of basic self-disturbance." | ( Aarts, H; Baalbergen, H; Hillegers, MH; Kahn, RS; Prikken, M; van der Weiden, A; van Haren, NE, 2019) |
| "Schizophrenia is associated with an increased prevalence of the metabolic syndrome." | ( Goetz, RL; Miller, BJ, 2019) |
| "Schizophrenia is associated with impairments in cognitive functioning yet there are no approved drugs to treat these deficits." | ( Davison, C; Farah, Y; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Ogrinc, F; Reichenberg, A; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC, 2021) |
| "Deficit schizophrenia is characterized by an immune-inflammatory response combined with a deficit in natural IgM antibodies to oxidative-specific epitopes (OSEs), which are a first-line defense against bacterial infections." | ( Carvalho, AF; Kanchanatawan, B; Maes, M; Sirivichayakul, S, 2019) |
| "Schizophrenia is a mental disorder characterized by positive symptoms, negative symptoms, and cognitive dysfunction." | ( Bernardo, A; Daya, R; Dyck, B; Ho, J; Mishra, RK; Thomson, S; Tian, Y, 2019) |
| "The etiology of schizophrenia is multi-factorial with early neurodevelopmental antecedents, likely to result from a complex interaction of genetic and environmental risk." | ( Bolhuis, K; Hillegers, MHJ; Jaddoe, VWV; Jansen, PR; Kushner, SA; Muetzel, RL; Neumann, A; Tiemeier, H; van den Akker, ETL; van Rossum, EFC; Vernooij, MW; White, T, 2019) |
| "Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual's life and on society." | ( Coyle, JT; Uno, Y, 2019) |
| "Schizophrenia is a complex brain disease involving several neurotransmitter systems, including aberrant noradrenergic activity, which might underlie cognitive deficits." | ( Glenthøj, BY; Kruiper, C; Oranje, B, 2019) |
| "Schizophrenia is associated with progressive white matter changes, but it is unclear whether antipsychotic medications contribute to these." | ( Anthony, T; Jindal, RD; Kraguljac, NV; Lahti, AC; Marstrander, J; Melas Skefos, NH; Morgan, CJ; Reid, MA; Skidmore, FM; White, DM, 2019) |
| "Schizophrenia is a severe psychiatric disorder characterized by important cognitive deficits, which ultimately compromise the patients' ability to make optimal decisions." | ( Dumais, A; Lalonde, P; Laurelli, M; Lipp, O; Lungu, O; Potvin, S; Stip, E; Tikàsz, A, 2019) |
| "Women with schizophrenia are often noted to suffer with comorbid depression." | ( Breadon, C; Camuñas-Palacín, A; Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Lascurain, MB; Thomas, N, 2020) |
| "Schizophrenia is associated with abnormal neuroimmunoendocrine function." | ( Hubbard, DB; Miller, BJ, 2019) |
| "Schizophrenia is a chronic psychotic disorder in which patients experience positive and negative symptoms for over six months." | ( Alao, AO; Morra, JA, 2020) |
| "Schizophrenia is a complex syndrome of unknown etiology and difficult to manage." | ( Gama Marques, J; Ouakinin, S; Pommerening Dornelles, E, 2019) |
| "Schizophrenia is a mental disorder characterized by psychosis, negative symptoms and cognitive impairment." | ( Bengoetxea, H; Gutiérrez-Ceballos, A; Lafuente, JV; Miguelez, C; Morera-Herreras, T; Murueta-Goyena, A; Ugedo, L, 2019) |
| "Schizophrenia is a disabling serious mental illness that can be chronic." | ( AbouDamaah, A; Aboudamaah, S; AlMounayer, N; Diaa Aldeen, MR; Essali, A; Marwa, ME; Turkmani, K, 2019) |
| "Schizophrenia is known to be a complex and disabling psychiatric disorder." | ( Li, X; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Yin, JY; Zhang, W; Zhou, HH, 2019) |
| "Schizophrenia is associated with amotivation and reduced goal-directed behavior, which have been linked to poor functional outcomes." | ( Barch, DM; Cooper, JA; Green, MF; Horan, WP; Reddy, LF; Treadway, MT, 2019) |
| "Schizophrenia is a chronic, most devastating psychiatric illness that impairs mental and social functioning." | ( Hereta, M; Kamińska, K; Rogóż, Z, 2019) |
| "Schizophrenia is a debilitating mental illness that affects approximately 1% of the world's population." | ( Abi-Dargham, A; Clark, SD, 2019) |
| "Patients with schizophrenia are mainly characterized by negative symptoms and cognitive dysfunction." | ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "Schizophrenia is a serious chronic mental illness affecting an estimated 21 million people worldwide and there is increasing evidence linking inflammation in the brain to the pathophysiology of schizophrenia." | ( Friedel, J; Phelps, E; Schmidt, L; Shokraneh, F, 2019) |
| "Schizophrenia is a serious mental disorder and is associated with substantial economic and social burden." | ( Aguiar, PM; de Melo, DO; de Mendonça Lima, T; Henrique, ICB, 2020) |
| "Schizophrenia is a mental disorder characterized by hyperlocomotion, cognitive symptoms, and social withdrawal." | ( Deng, C; Fu, B; Liu, N; Xu, Y; Zheng, Y, 2019) |
| "Schizophrenia is a severe and debilitating psychiatric disorder believed to have neurodevelopmental origins." | ( Guest, PC; Martins-de-Souza, D; Zuccoli, GS, 2019) |
| "As schizophrenia is a complex mental disorder and the outcome of gene-gene-environmental interactions, there are different possible pathophysiological mechanisms in different schizophrenia subtypes corresponding to various risk factors." | ( Aghamaleki-Sarvestani, Z; Alaghband-Rad, J; Alipour, ME; Mostafavi-Abdolmaleky, H; Tabrizi, M; Vousooghi, N; Zarindast, MR, 2020) |
| "Schizophrenia is a chronic, disabling neurological illness." | ( Ali, A; El-Bakly, WM; El-Demerdash, E; Mohammed, A, 2020) |
| "Schizophrenia is a complex, multifactorial disease that displays heterogeneous behavioral and cognitive syndrome (Lieberman & First, 2018)." | ( Simonneau, M, 2019) |
| "Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people worldwide." | ( Ferreira, V; Grajales, D; Valverde, ÁM, 2020) |
| "Schizophrenia is a highly heritable psychiatric disorder, and recent studies have suggested that exposure to nitrogen dioxide (NO2) during childhood is associated with an elevated risk of subsequently developing schizophrenia." | ( Agerbo, E; Antonsen, S; Brandt, J; Børglum, AD; Closter, AM; Erikstrup, C; Geels, C; Grove, J; Hertel, O; Horsdal, HT; Hougaard, DM; McGrath, JJ; Mok, PLH; Mors, O; Mortensen, PB; Nordentoft, M; Pedersen, CB; Sabel, CE; Sigsgaard, T; Timmermann, A; Vilhjálmsson, BJ; Webb, RT; Werge, T, 2019) |
| "Schizophrenia is accompanied by a breakdown of gut and blood-brain-barrier (BBB) pathways, increased tryptophan catabolite (TRYCAT) levels, bacterial translocation, and lowered natural IgM and paraoxonase (PON)1 activity." | ( Barbosa, DS; Geffard, M; Kanchanatawan, B; Maes, M; Michelin, AP; Moreira, EG; Semeão, LO; Sirivichayakul, S; Vojdani, A, 2019) |
| "Schizophrenia is a psychiatric condition characterized by poor prognosis and severe symptoms that decrease the quality of life of patients." | ( Chen, X; Fu, Y; Sun, Y; Wang, Y; Yu, Q; Yu, Y; Zhang, H; Zhang, M; Zhou, N, 2020) |
| "Schizophrenia is a severe chronic neuropsychiatric disorder, and it negatively affects individuals' quality of life, but the pathogenesis of schizophrenia remains unclear." | ( Chen, F; Liao, L; Wang, X; Xie, J; Xie, R; Yan, Y; Yang, L; Ye, Y, 2020) |
| "Schizophrenia is a severe psychiatric disorder with variable therapeutic responses, the etiology and pathophysiology of which require further elucidation." | ( Correll, CU, 2020) |
| "Schizophrenia is genetically highly heterogeneous, involving severe ultrarare mutations in genes that are critical to synaptic plasticity." | ( Andrews, HF; Baldinger, A; Casadei, S; Fader, KM; Feng, M; Gibbs, RA; Gulsuner, S; Gur, RC; King, MC; Korchina, V; Majara, L; Malan, M; McClellan, JM; Mndini, MM; Mqulwana, SG; Muzny, D; Nagdee, M; Ngqengelele, LL; Ntola, OA; Pretorius, A; Ramesar, RS; Sibeko, G; Stein, DJ; Susser, ES; van der Merwe, C; Walsh, T; Willoughby, E; Zingela, Z, 2020) |
| "Schizophrenia is a mental illness which is characterised by positive and negative symptoms and by cognitive impairments." | ( Antkiewicz-Michaluk, L; Białoń, M; Wąsik, A; Żarnowska, M, 2020) |
| "Schizophrenia is a complex psychiatric disorder that exhibits an interconnection between the immune system and the brain." | ( Barichello, T; Colpo, GD; Doifode, T; Giridharan, VV; Macêdo, D; Petronilho, F; Pinjari, OF; Quevedo, J; Scaini, G; Teixeira, AL, 2020) |
| "Schizophrenia is a neurodevelopmental disorder featuring chronic, complex neuropsychiatric features." | ( Bryll, A; Kozicz, T; Krzyściak, W; Popiela, T; Skrzypek, J; Śmierciak, N; Szelągowska, M, 2020) |
| "Schizophrenia is a chronic, disabling and one of the major neurological illnesses affecting nearly 1% of the global population." | ( El-Demerdash, E; Esmat, A; George, MY; Menze, ET; Tadros, MG, 2020) |
| "Schizophrenia is a common psychiatric disease that cannot be fully treated with current antipsychotic drugs." | ( Aricioglu, F; Bekci, H; Cumaoglu, A; Unal, G; Yerer, MB, 2020) |
| "Schizophrenia is a serious, chronic psychiatric disorder requiring lifelong treatment." | ( Grubor, M; Mihaljevic-Peles, A; Muck-Seler, D; Nikolac Perkovic, M; Pivac, N; Sagud, M; Svob Strac, D; Zivkovic, M, 2020) |
| "Impulsivity in schizophrenia is a risk factor for suicide, drug abuse, and other risk-taking behaviors." | ( Baker, RA; Cox, K; Eramo, A; Kojima, Y; Okame, T; Potkin, SG; van Erp, TG, 2020) |
| "Schizophrenia is a debilitating disorder affecting just under 1% of the population." | ( Boley, AM; Carless, MA; Donegan, JJ; Glenn, JP; Lodge, DJ, 2020) |
| "Schizophrenia is a severe mental disorder that affects more than 1% of the population worldwide." | ( Al-Nema, MY; Gaurav, A, 2020) |
| "Schizophrenia is one of the most debilitating mental disorders around the world." | ( Farkhondeh, T; Forouzanfar, F; Talaei, A, 2020) |
| "Schizophrenia is a debilitating disorder affecting young adults displaying symptoms of cognitive impairment, anxiety, and early social isolation prior to episodes of auditory hallucinations." | ( Chen, HH; Cruz, SA; Qin, Z; Stewart, AFR; Zhang, L, 2020) |
| "Schizophrenia is a disabling psychiatric disorder marked by progressive loss of functionality in activities of daily living with each relapse." | ( Markovic, M; Maroney, M; Stummer, L, 2020) |
| "Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1." | ( Kim, S; Park, BJ; Seo, DE, 2020) |
| "Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 21 million people (2016)." | ( Crespo-Facorro, B; Croce, D; García-Goñi, M; Lew-Starowicz, M; Mayoral-van Son, J; Mierzejewski, P; Restelli, U; Rocca, P; Silvola, S, 2020) |
| "Schizophrenia is a chronic, severe and disabling psychiatric disorder, whose treatment is based on psychosocial interventions and the use of antipsychotic drugs." | ( Antunes, ASLM; Crunfli, F; de Almeida, V; Martins-de-Souza, D; Reis-de-Oliveira, G; Seabra, G, 2020) |
| "Patients with schizophrenia are at higher risk of cardiovascular morbidity and mortality than healthy individuals." | ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Nath, S, 2020) |
| "Schizophrenia is a chronic neuropsychiatric disorder with a poorly understood pathophysiology." | ( Avila, S; Damásio, L; de Oliveira, IH; Godoi, AK; Mastella, GA; Michels, A; Schuck, PF; Supp, AD; Zugno, AI, 2021) |
| "Schizophrenia is a chronic and disabling psychiatric disorder characterized by disturbances of thought, cognition, and behavior." | ( Hayashi-Takagi, A; Hyun, JS; Inoue, T, 2020) |
| "Schizophrenia is a disorder characterized by pervasive deficits in cognitive functioning." | ( Barch, DM; Carter, CS; Gold, JM; Luck, SJ; MacDonald, AW; Moran, EK; Ragland, JD; Silverstein, SM, 2022) |
| "Schizophrenia is a debilitating psychiatric disorder with a significant number of patients not adequately responding to treatment." | ( Bikovski, L; Goldshmit, Y; Offen, D; Perets, N; Ruban, A; Sofer, T; Tsivion-Visbord, H, 2020) |
| "Schizophrenia is a severe brain disorder with an excess morbidity and mortality partly due to a higher incidence of metabolic disturbances and cardio-vascular events." | ( Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J, 2020) |
| "Schizophrenia is a complex mental disorder whose course varies with periods of deterioration and symptomatic improvement without diagnosis and treatment specific for the disease." | ( Bryll, A; Karcz, P; Kozicz, T; Krzyściak, W; Pilecki, M; Popiela, TJ; Skrzypek, J; Śmierciak, N; Szwajca, M, 2020) |
| "Schizophrenia is characterized by reduced spindle activity that correlates with impaired sleep-dependent memory consolidation." | ( Baran, B; Callahan, CE; Correll, D; Cox, R; Demanuele, C; Fowler, RA; Henderson, D; Manoach, DS; Morgan, A; Mylonas, D; Parr, E; Seicol, BJ; Stickgold, R; Vangel, M; Vuper, TC, 2020) |
| "Schizophrenia is currently teated by dopamine antagonists and/or 5HT modulators, each with their own set of side effects." | ( Cornett, EM; Edinoff, A; Ghaffar, YT; Jani, D; Kaye, AD; Kaye, AM; Rezayev, A; Ruoff, MT; Urits, I; Viswanath, O, 2020) |
| "Schizophrenia is a common mental illness whose pathogenesis is still unknown." | ( Asman, M; Krzystanek, M; Pałasz, A; Wiaderkiewicz, R; Witecka, J, 2021) |
| "Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality." | ( Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J, 2021) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| "Schizophrenia is associated with a lowered bone mineral density." | ( Fink-Jensen, A; Jørgensen, NR; Larsen, JR; Maagensen, H; Vilsbøll, T, 2021) |
| "Schizophrenia is a neurodevelopmental disorder which is expressed in the form of disturbed behaviour and abnormal mental functions." | ( Kaur, L; Sinha, VR, 2021) |
| "Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological, and phenotypic profile." | ( Kraguljac, NV; McDonald, WM; Nemeroff, CB; Rodriguez, CI; Tohen, M; Widge, AS, 2021) |
| "Schizophrenia is a chronic and severe mental disorder that affects over 20 million people worldwide." | ( Cottrell, GS; Roosterman, D, 2021) |
| "Schizophrenia is a heterogeneous psychiatric disorder with a different, but not necessarily milder clinical presentation in women as compared to men." | ( Brand, BA; de Boer, JN; Sommer, IEC, 2021) |
| "Schizophrenia is a severe neuropsychiatric disorder characterized by a diverse range of symptoms that can have profound impacts on the lives of patients." | ( Bryant, ZK; Conn, PJ; Foster, DJ, 2021) |
| "Schizophrenia is a chronic mental devastating disease." | ( Pitsikas, N, 2021) |
| "Schizophrenia is a form of mental disorder that is behaviorally characterized by abnormal behavior, such as social function deficits or other behaviors that are disconnected from reality." | ( Chen, CH; Goh, KK; Lane, HY, 2021) |
| "Schizophrenia is a severe psychiatric disease while its etiology and effective treatment are not completely clear." | ( Chen, Y; Cui, A; Gao, W; Han, X; Li, G; Liu, X; Ma, G; Ma, H; Song, Z; Sun, F; Tang, X; Wang, Y; Zhang, L; Zhao, S, 2021) |
| "Schizophrenia is considered one of the most disabling and severe human diseases worldwide." | ( Canever, L; Damázio, LS; Mastella, GA; Quevedo, JL; Valvassori, SS; Varela, R; Zugno, AI, 2021) |
| "Schizophrenia is a serious long-term disorder in which the metabolic complications and abnormalities of the brain-derived neurotrophic factor (BDNF) can be found." | ( Kalejahi, P; Kheirouri, S; Noorazar, SG; Sanayei, M, 2021) |
| "Schizophrenia is a severe mental disorder and one of its characteristics is cognitive impairments." | ( Becklén, M; Cervenka, S; Erhardt, S; Fatouros-Bergman, H; Flyckt, L; Orhan, F; Piehl, F; Sellgren, CM, 2021) |
| "Schizophrenia is a devastating complex disorder characterised by a constellation of behavioral deficits with the underlying mechanisms not fully known." | ( Aguilar-Alonso, P; Di Cerbo, A; Flores, G; Iannitti, T; Morales-Medina, JC, 2021) |
| "Schizophrenia is a neurodevelopmental disorder that NMDA receptor (NMDAR) hypofunction appears centrally involved." | ( Chen, X; Cui, D; Hu, Y; Liu, W; Ma, Y; Wang, X; Xue, T, 2021) |
| "Schizophrenia is a severe mental disorder with complex etiopathogenesis." | ( da Silva, FER; de Lucena, DF; Dos Santos Júnior, MA; Lima, CNC; Macedo, DS; Medeiros, IDS; Monte, AS; Moreira Lima Neto, AB; Teixeira, AL; Vasconcelos, GS; Vasconcelos, SMM, 2021) |
| "Schizophrenia is a complex illness that currently has no cure." | ( Armendáriz-Vázquez, Y; Becerra-Palars, C; Corlay-Noriega, IS; Escamilla-Orozco, RI; Herrera-Estrella, MA; Llamas-Núñez, RE; Meneses-Luna, Ó; Quijada-Gaytán, JM; Reyes-Madrigal, F; Rosado-Franco, A; Rosel-Vales, M; Saucedo-Uribe, E, 2021) |
| "Schizophrenia is a complex psychiatric disorder where genetic, epigenetic, and environmental factors play a role in disease onset, course of illness, and treatment outcome." | ( Chen, CC; Kennedy, JL; Lisoway, AJ; Tiwari, AK; Zai, CC, 2021) |
| "Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide population." | ( Pitsikas, N; Zoupa, E, 2021) |
| "Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms." | ( Edinoff, AN; Girma, B; Kaye, AD; Kaye, AJ; Kaye, AM; Kaye, JS; Leethy, KN; Maxey, BS; Mychaskiw, G; Odisho, A; Ren, AL; Urits, I; Viswanath, O; Wu, NW, 2021) |
| "Schizophrenia is a mental illness characterized by episodes of psychosis, apathy, social withdrawal, and cognitive impairment." | ( Gu, LH; Li, L; Li, XM; Ma, DL; Sun, ZY; Wang, MY; Yang, CC; Zhang, JW; Zhang, L, 2021) |
| "Schizophrenia is one of the foremost psychological illness around the world, and recent evidence shows that inflammation and oxidative stress may play a critical role in the etiology of schizophrenia." | ( Dai, Z; Liu, J; Sui, Y; Wang, X, 2021) |
| "Schizophrenia is characterized by a high disease burden." | ( Hu, J; Huang, S; Li, G; Li, X; Liu, S; Shang, D; Wang, Z; Wen, Y; Xiao, T; Zhu, X, 2021) |
| "Schizophrenia is considered a multifactorial disease, where one of the pathogenetic links is oxidative stress; however, the results of studies are often contradictory, largely due to significant heterogeneity among study methods." | ( Blagonravova, AS; Kasyanov, ED; Kostina, OV; Lyakhova, AA; Mazo, GE; Piatoikina, AS; Semennov, IV; Shcherbatyuk, TG; Zhilyaeva, TV; Zhukova, ES, 2022) |
| "Schizophrenia is associated with higher parental consanguinity, suggesting a role for multiple recessive risk alleles in its etiology." | ( Agarwal, V; Christopher, R; Gangadhar, BN; Kumar, CN; Nimgaonkar, V; Rawat, VS; Reddy, KS; Thirthalli, J; U Arunachal, G; Wood, J, 2021) |
| "Schizophrenia is a debilitating mental illness." | ( Castillo-Avila, RG; Genis-Mendoza, AD; González-Castro, TB; Hernández-Díaz, Y; Juárez-Rojop, IE; López-Narváez, ML; Ramos-Méndez, MÁ; Tovilla-Zárate, CA, 2021) |
| "Schizophrenia is a neuropsychiatric disorder characterized by various symptoms including autonomic imbalance." | ( Büki, A; Horvath, G; Kekesi, G; Vécsei, L, 2021) |
| "Schizophrenia is a severe psychiatric disorder affecting 21 million people worldwide." | ( Bearden, CE; Karlsgodt, KH; Millard, SJ; Sharpe, MJ, 2022) |
| "Schizophrenia is a chronic mental disorder that disturbs feelings and behavior." | ( Biala, G; Kruk-Slomka, M, 2021) |
| "Schizophrenia is a severe psychiatric disorder." | ( Chan, HW; Huang, CY; Yen, YC, 2021) |
| "Schizophrenia is a common psychiatric disorder which affects approximately 1% of the population worldwide." | ( Huang, L; Sperlágh, B, 2021) |
| "Schizophrenia is a heterogeneous psychiatric disorder, which can severely impact social and professional functioning." | ( de Vries, EFJ; Doorduin, J; Guerrin, CGJ; Sommer, IE, 2021) |
| "Treatment-resistant schizophrenia is prevalent and difficult to manage, as patients fail multiple antipsychotic trials before being considered as treatment-resistant." | ( Baig, AI; Bazargan-Hejazi, S; Ebrahim, G; Rodriguez-Lara, J, 2021) |
| "Schizophrenia is severe neuropsychiatric disease, which is commonly accompanied not only by positive or negative symptoms, but also by cognitive impairment." | ( Brozka, H; Jandourkova, P; Maleninska, K; Nekovarova, T; Stuchlik, A, 2022) |
| "Schizophrenia is a major psychotic disorder affecting nearly 23." | ( Aamir, A; Awan, HA; Awan, S; De Berardis, D; de Filippis, R; Di Giannantonio, M; Diwan, MN; Fornaro, M; Irfan, M; Martinotti, G; Pettorruso, M; Ullah, I; Vellante, F; Ventriglio, A, 2021) |
| "Schizophrenia is a persistent psychotic disorder often accompanied by severe disability and premature mortality." | ( Baker, A; Bruxner, G; Clarke, L; Cocchi, L; Donovan, P; Gordon, A; Hartel, G; Moudgil, V; P J Ungerer, J; Robinson, G; Roy, D; Scott, JG; Sohal, R; Whittle, E, 2021) |
| "Schizophrenia is a disabling neuropsychiatric disorder of adulthood onset with high heritability." | ( Abdullah, U; Ali, Z; Asif, M; Baig, SM; Farooq, M; Fatima, A; Mang, Y; Mehrjouy, MM; Tommerup, N, 2021) |
| "Schizophrenia is a disorder characterized by cognitive impairment and psychotic symptoms that fluctuate over time and can only be mitigated with the chronic administration of antipsychotics." | ( Bellotti, E; Contarini, G; Decuzzi, P; Drago, F; Geraci, F; Leggio, GM; Papaleo, F; Piazza, C; Torrisi, SA, 2022) |
| "Schizophrenia is a neurodevelopmental disorder with dendrite and dendritic spine dysfunction." | ( Chen, P; Fei, E; Zhang, Q; Zhong, Y; Zhou, T, 2022) |
| "Schizophrenia is ranked among the top 25 leading causes of disability worldwide in 2013 which resulting in social and economic burden." | ( Bai, L; Liu, J; Su, L; Wang, Q; Yang, L; Zou, L, 2022) |
| "When people with schizophrenia are responsible for their own treatment, partial or non-adherence is common and usually results in relapse." | ( Brissos, S; Taylor, D, 2022) |
| "Schizophrenia is a debilitating psychiatric disorder affecting approximately 1% of the population worldwide." | ( Cao, Y; Chen, C; Cui, X; Li, Z; Liu, M; Pan, Y; Sun, J; Zhao, F, 2022) |
| "Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness." | ( Alamiri, B; Naguy, A; Pridmore, S; Rushdy, R; Singh, A, 2022) |
| "Schizophrenia is a psychiatric disorder including multiple clinical symptoms such as severe psychosis and cognitive dysfunction." | ( Chen, X; Gu, LH; Li, L; Ma, DL; Sun, ZY; Zhang, L, 2022) |
| "The onset of schizophrenia is determined by biological and social risk factors operating predominantly during development." | ( Bora, E; Modinos, G; Murray, RM; Vernon, A, 2022) |
| "Schizophrenia is a psychotic disorder with high heritability." | ( Melkersson, K; Persson, B, 2022) |
| "Schizophrenia is a psychiatric disorder that affects over 20 million people globally." | ( Anisimova, M; Barragan, EV; Gray, JA; Park, DK; Petshow, S; Stein, IS; Zito, K, 2022) |
| "Schizophrenia is a complex disease which is best treated with multitarget drugs, such as atypical antipsychotics." | ( Castro, M; Kaczor, AA; Kondej, M; Koszła, O; Leandro Martínez, A; Loza, MI; Paz, A; Stępnicki, P; Targowska-Duda, KM; Wróbel, TM; Wronikowska-Denysiuk, O; Zięba, A, 2022) |
| "Schizophrenia is a serious mental disorder that affects 1% of the world's population." | ( Picazo Picazo, O; Roldán Roldán, G; Suárez-Santiago, JE, 2022) |
| "Schizophrenia is a complex, chronic mental health disorder whose heterogeneous genetic and neurobiological background influences early brain development, and whose precise etiology is still poorly understood." | ( Bezzi, P; Calì, C; de Oliveira Figueiredo, EC; Petrelli, F, 2022) |
| "Schizophrenia is associated with persistent cognitive deficits, which worsen treatment outcomes despite increasing antipsychotic doses." | ( Behdani, F; Dadgarmoghaddam, M; Eslamzadeh, M; Hassanzadeh, B; Hebrani, P; Moradi, M; Shamsaki, N, 2022) |
| "Schizophrenia is a chronic mental disorder associated with substantial morbidity and mortality affecting 0." | ( Bessonova, L; Cichewicz, A; Doane, MJ; Harvey, PD; Hughes, R; Martin, A; O'Sullivan, AK; Snook, K; Weiden, PJ, 2022) |
| "Schizophrenia is a debilitating mental disorder that affects up to 1." | ( Bessonova, L; Cichewicz, A; Doane, MJ; Harvey, PD; Hughes, R; Martin, A; O'Sullivan, AK; Snook, K; Weiden, PJ, 2022) |
| "Schizophrenia is a common mental disorder affecting patients' thoughts, behavior, and cognition." | ( Nawwar, DA; Sayed, RH; Zaki, HF, 2022) |
| "Schizophrenia is a complex and heterogeneous neurodevelopmental psychiatric disorder characterized by a variety of symptoms classically grouped into three main domains: positive (hallucinations, delusions, and thought disorder) and negative symptoms (social withdrawal, lack of affect) and cognitive dysfunction (attention, working and episodic memory functions, and processing speed)." | ( Brandão-Teles, C; Chaves Filho, AJM; Crippa, JA; Crunfli, F; Del-Bel, E; Gomes, FV; Macêdo, DS; Pedrazzi, JFC; Silva-Amaral, D; Vieira, GM; Zuccoli, GS, 2022) |
| "Treating schizophrenia is a challenge currently handled with the use of antipsychotic drugs." | ( Antunes, ASLM; Ramos-da-Silva, L, 2022) |
| "Schizophrenia is a chronic psychiatric disorder characterized by disrupted thoughts, perception, mood, and behavior." | ( Bandiwadekar, T; Bhatia, N; Doshi, G; Godad, A; Kale, P; Kulkarni, D; Naik, J; Pandya, A; Ved, H, 2023) |
| "Schizophrenia is a neuropsychiatric disorder characterized by a variety of clinical manifestations." | ( Akbari, M; Akhavan-Bahabadi, M; Badrlou, E; Eghtedarian, R; Eslami, S; Ghafouri-Fard, S; Mahmud Hussen, B; Neishabouri, SM; Taheri, M, 2022) |
| "Schizophrenia is a serious mental health condition characterised by distortions in thought processes, perception, mood, sense of self, and behaviour." | ( Afonso, D; Dymond, A; Green, W, 2022) |
| "Schizophrenia is frequently accompanied with social cognitive disturbances." | ( Aguglia, E; Aguilar, EJ; Akdede, B; Alptekin, K; Altınyazar, V; Amoretti, S; Andric-Petrovic, S; Arango, C; Arrojo, M; Atbaşoğlu, C; Bernardo, M; Binbay, T; Bobes, J; Cankurtaran, EŞ; Carracedo, A; Cihan, B; Delespaul, P; Erzin, G; Fusar-Poli, L; García-Portilla, MP; González-Peñas, J; Guloksuz, S; Gümüş-Akay, G; Jiménez-López, E; Kaymak, SU; Kenis, G; Lin, BD; López, G; Luykx, JJ; Maric, NP; Mezquida, G; Mihaljevic, MM; Mirjanic, T; Parellada, M; Pençe, AY; Pries, LK; Radhakrishnan, R; Rutten, BP; Saiz, PA; Saka, MC; Sanjuan, J; Santos, JL; Soygür, H; Üçok, A; Ulaş, H; van Os, J; Yalınçetin, B, 2022) |
| "Schizophrenia is a serious neuropsychiatric disorder characterized by the presence of positive symptoms (hallucinations, delusions, and disorganization of thought and language), negative symptoms (abulia, alogia, and affective flattening), and cognitive impairment (attention deficit, impaired declarative memory, and deficits in social cognition)." | ( Picazo, O; Roldán, GR; Suárez Santiago, JE, 2023) |
| "Schizophrenia is a prevalent psychiatric illness, which causes significant financial and social burden on the population overall." | ( Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C, 2023) |
| "Schizophrenia is a mental illness affecting the normal lifestyle of adults and early adolescents incurring major symptoms as jumbled speech, involvement in everyday activities eventually got reduced, patients always struggle with attention and memory, reason being both the genetic and environmental factors responsible for altered brain chemistry and structure, resulting in schizophrenia and associated orphan diseases." | ( Ahmad, I; Bhardwaj, T; Somvanshi, P, 2023) |
| "Schizophrenia is the most common psychotic mental disorder, and those affected have two to four times higher mortality than the general population." | ( Crawford, P; Go, KV, 2022) |
| "Schizophrenia is a group of severe mental disorders." | ( Han, B; Ji, H; Liu, Y; Pan, B; Wang, Y; Weng, J; Xu, L; Zhu, X, 2022) |
| "Schizophrenia is a devastating condition characterized by frequent recurrences, cognitive decline, and emotional and functional disabilities." | ( Charkazi, A; Jahanshahi, R; Jazayeri, SMMZ; Shahini, N, 2022) |
| "Schizophrenia is a group of severe mental disorders." | ( Han, B; Ji, H; Liu, Y; Pan, B; Wang, Y; Weng, J; Zhu, X, 2023) |
| "Schizophrenia is a life disabling, multisystem neuropsychiatric disease mostly derived from complex epigenetic-mediated neurobiological changes causing behavioural deficits." | ( Agu, GO; Ajayi, AM; Akaenyi, DE; Ben-Azu, B; Chijioke, BS; Chilaka, KC; Edigbue, NL; Esiekpe, UV; Jarikre, TA; Nwangwa, KE; Ofili, EC; Omonyeme, MG; Ozege, CB; Uruaka, CI; Warekoromor, EB, 2023) |
| "Schizophrenia is a mental disorder characterized by episodes of psychosis; major symptoms include hallucinations, delusions, and disorganized thinking." | ( Ghaderi, A; Hosseini Hooshiar, S; Jafarnejad, S; Rabiee, R, 2023) |
| "Susceptibility to schizophrenia is mediated by genetic and environmental risk factors." | ( Handunnetthi, L; Johnson, T; Saatci, D, 2022) |
| "Susceptibility to schizophrenia is mediated by genetic and environmental risk factors." | ( Handunnetthi, L; Johnson, T; Saatci, D, 2022) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "Schizophrenia is a neurological disorder that alters the behavior and affects the quality of life of a patient." | ( Akhtar, A; Kuhad, A; Kumar, A; Sah, SP, 2023) |
| "Schizophrenia is one of the most severe chronic mental disorders that is currently diagnosed and categorized through subjective clinical assessment of complex symptoms." | ( Danilova, E; Nosyrev, A; Porozova, N; Senshinov, I; Tsakalof, A, 2022) |
| "Schizophrenia is a chronic and debilitating mental disorder, with unknown pathophysiology." | ( Ben Shachar, D; Gurwitz, D; Hertzberg, L; Katz Shroitman, N; Yitzhaky, A, 2023) |
| "Schizophrenia is a chronic mental illness presented by cognitive deficits that precede its positive and negative symptoms." | ( Abdelfattah, AM; Abuelezz, SA; Hendawy, N; Khalil, AMM; Nawishy, SAEK; Negm, EA, 2023) |
| "Schizophrenia is a severe psychiatric disorder with periods of remission and relapse." | ( Bar Haim, M; Bitter, I; Davidson, M; Fleischhacker, WW; Galderisi, S; Glenthøj, B; Hasan, A; Kahn, RS; Kemmler, G; Kupchik, M; Leucht, C; Leucht, S; Luykx, J; Psota, G; Rocca, P; Schurr, T; Stefanis, N; Teitelbaum, A; Weiser, M; Winter-van Rossum, I, 2023) |
| "Schizophrenia is one of the most baffling mental disorders." | ( Biyani, KR; Das, S; Dhawale, SA; Gawai, AA; Mokale, SN; Tapadiya, GG, 2023) |
| "Treatments for schizophrenia are not effective in ameliorating cognitive deficits." | ( Burgess, M; Grayson, B; Harte, MK; Landreth, K; Lorusso, JM; Neill, JC; Watson, L, 2023) |
| "Schizophrenia is a major psychiatric disorder with unknown aetiology." | ( Donohoe, G; McKernan, DP; Patlola, SR, 2023) |
| "Schizophrenia is a chronic and severe mental disorder with high heterogeneity in its symptoms clusters." | ( Cañete, T; Corda, MG; Fernández-Teruel, A; Giorgi, O; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Tobeña, A, 2023) |
| "Schizophrenia is a serious mental disorder, and existing antipsychotic drugs show limited efficacy and cause unwanted side effects." | ( An, D; Chen, H; Chen, Z; Dai, H; Hu, W; Jiang, L; Ma, Q; Ping, Y; Wang, Y; Zhang, X, 2023) |
| "Schizophrenia is a devastating psychiatric disorder with complex symptoms and neurobiology." | ( Bozkurt, NM; Unal, G, 2023) |
| "Schizophrenia is associated with disadvantageous decision-making, as subjects pursue uncertain risky rewards less than controls." | ( Bangert, BM; Bloomer, BF; Brown, JW; Dolan-Bennett, K; Hetrick, WP; Kim, DJ; Lundin, NB; Moussa-Tooks, AB; O'Donnell, BF; Purcell, JR; Tullar, RL; Wisner, KM, 2023) |
| "Schizophrenia is a complex disorder that remains poorly understood, particularly at the systems level." | ( Bilkey, DK; Speers, LJ, 2023) |
| "Schizophrenia is a severe brain disorder that usually produces a lifetime of disability." | ( González-Maeso, J; Saha, S, 2023) |
| "Schizophrenia is a mental disorder with sex bias in disease onset and symptom severity." | ( Cardozo, PL; Cordeiro, RC; Cruz, BF; da Silva, FER; de Carvalho Lima, CN; de Lucena, DF; Macedo, DS; Monte, AS; Nicolato, R; Ribeiro, FM; Sanders, LLO; Seeman, MV; Vasconcelos, GS; Vasconcelos, SMM, 2023) |
| "Schizophrenia is a disabling disorder that profoundly affects functioning and quality of life." | ( Correll, CU; Cutler, AJ; Jain, R; Kantrowitz, JT, 2023) |
| "Schizophrenia is a severe mental illness which can cause lifelong disability." | ( Alcin, OF; Guo, Y; Li, Y; Siuly, S; Wang, H; Wen, P, 2023) |
| "Schizophrenia is a severe psychiatric disorder, with heritability around 80%, but a not fully understood pathophysiology." | ( Hertzberg, L; Wolf, A; Yitzhaky, A, 2023) |
| "Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide and is conceptualized as a disorder of synaptic plasticity and brain connectivity." | ( Barone, A; Ciccarelli, M; de Bartolomeis, A; De Simone, G; Mazza, B; Vellucci, L, 2023) |
| "Schizophrenia is characterised by deficits across multiple cognitive domains and altered glutamate related neuroplasticity." | ( Amirsadri, A; Chowdury, A; Daugherty, AM; Diwadkar, VA; Haddad, L; Khatib, D; Rajan, U; Richter Gorey, C; Stanley, JA; Thomas, P, 2023) |
| "To examine whether schizophrenia is associated with impairments in effort-cost decision-making." | ( Bastin, J; Blouzard, E; Dondé, C; Polosan, M; Pouchon, A, 2023) |
| "Schizophrenia is a severe mental disorder with a chronic, progressive course." | ( Błaszczak, K; Danielewski, M; Gaweł-Dąbrowska, D; Jawień, P; Kowalski, K; Matuszewska, A; Merwid-Ląd, A; Piasny, J; Szeląg, A; Szeląg, E; Tomkalski, T; Wiatrak, B, 2023) |
| "Schizophrenia is analysed as one of the diseases with the highest rate of Disability-Adjusted Life Years - DALY." | ( Anczewska, M; Balicki, M; Droździkowska, A; Gorczyca, P; Janus, J; Paciorek, S; Plisko, R; Zięba, M, 2022) |
| "Schizophrenia is a chronic mental disorder that is not satisfactorily treated with available antipsychotics." | ( Bartyzel, A; Budzyńska, B; Castro, M; Chodkowski, A; Fornal, E; Kaczor, AA; Mirecka, K; Stępnicki, P; Szałaj, K; Targowska-Duda, KM; Turło, J; Wróbel, MZ; Wróbel, TM; Wronikowska-Denysiuk, O; Zięba, A, 2023) |
| "Schizophrenia is a psychiatric disorder that presents with hallucinations, delusions, thought disorders, and cognitive dysfunctions." | ( Hashimoto, R; Yamada, H, 2023) |
| "Schizophrenia is a neuropsychiatric condition that is associated with impaired attentional processing and performance." | ( Blumenthal, SA; Burk, JA; Maness, EB, 2023) |
| "Schizophrenia is a self-disorder characterized by disrupted brain dynamics and architectures of multiple molecules." | ( Duan, M; He, H; Hou, C; Jiang, S; Li, H; Liu, M; Luo, C; Yao, D; Yao, G; Zhang, L, 2023) |
| "Schizophrenia is a severe and debilitating psychiatric disorder characterized by early cognitive deficits, emotional and behavioral abnormalities resulted by a dysfunctional gene x environment interaction." | ( Matrisciano, F, 2023) |
| "Schizophrenia is a chronic mental health condition treated with antipsychotics." | ( Boydstun, C; DiGenova, P; Lynch, S, 2023) |
| "Schizophrenia is marked by deficits in facial affect processing associated with abnormalities in GABAergic circuitry, deficits also found in first-degree relatives." | ( Adebimpe, A; Bassett, DS; Cornblath, EJ; Gur, RC; Gur, RE; Kahn, AE; Larsen, B; Lydon-Staley, DM; Mahadevan, AS; Parkes, L; Satterthwaite, TD; Wolf, DH; Zhou, D, 2023) |
| "Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life." | ( Bellomo, A; De Berardis, D; Dell'Osso, B; Di Giannantonio, M; Maria Conca, AP; Salvi, V; Siracusano, A; Zaffora, C, 2023) |
| "Schizophrenia is characterized by complex metabolic dysregulations and their consequences." | ( Aleksandrovych, V; Bryll, A; Donicz, P; Karcz, P; Krzyściak, W; Pilecki, M; Popiela, TJ; Śmierciak, N; Szwajca, M; Turek, A, 2023) |
| "Schizophrenia is a multi-systemic disorder that is associated with lipid profile disturbances, altered glucose homeostasis and subclinical inflammation." | ( Bochen, P; Kowalski, K; Misiak, B; Samochowiec, J; Szponar, B; Żebrowska-Różańska, P; Łaczmański, Ł, 2023) |
| "Schizophrenia is a chronic and debilitating mental health condition that significantly impacts quality of life and can shorten patients' lifetime by decades." | ( Citrome, L; Meyer, JM, 2023) |
| "Schizophrenia is a disabling psychiatric disorder related with an aberrant functional coupling between hippocampus and prefrontal cortex that might be crucial for cognitive dysfunction." | ( Bengoetxea, H; Bulnes, S; Lafuente, JV; Picó-Gallardo, M, 2023) |
| "Depression and schizophrenia are 2 serious mental disorders." | ( Chen, F; Li, C; Lian, B; Liu, Y; Sun, L; Tao, X; Wang, D; Wang, L; Wang, Y; Zhu, X, 2023) |
| Excerpt | Reference |
|---|
| "If dialysis is successful for the treatment of schizophrenia, the artificial kidney must be removing something which the human kidney cannot, unless other nonspecific factors are involved." | ( Cohen, IM; Scheiber, SC; Yamamura, H, 1979) |
| "It is a contribution to a treatment of schizophrenia, in which the coexistence of biological and psychological factors is taken into consideration." | ( Benedetti, G, 1975) |
| "The ability to use pharmacological treatment for schizophrenia is progressing in a most efficacious fashion, while the risk of adverse effects is declining." | ( Kane, JM, 1992) |
| "Twenty-one state hospital patients with treatment-resistant schizophrenia or schizoaffective disorder were weighed weekly for 12 weeks before clozapine treatment and during the first 16 weeks of treatment." | ( Downs, M; Higgins, P; Leadbetter, R; Pavalonis, D; Shutty, M; Vieweg, V, 1992) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | ( Cookson, JC, 1991) |
| "Remoxipride is thus effective in acute treatment of schizophrenia at both dosage levels and has an advantage over haloperidol in neurological acceptability." | ( Agussol, P; Alby, JM; Brion, S; Burnat, G; Castelnau, D; Deluermoz, S; Dufour, H; Ferreri, M; Goudemand, M; Patris, M, 1990) |
| "A 31-year-old woman with untreated chronic schizophrenia developed extreme polydipsia which rapidly led to coma and death due to cerebral edema." | ( Ezri, T; Konichezky, S; Kushnir, M; Schattner, A, 1990) |
| "Clozapine has been used to treat schizophrenia, nonschizophrenic psychotic states, depression, neuroses, and behavioral disorders." | ( Ereshefsky, L; Tran-Johnson, TK; Watanabe, MD, 1989) |
| "It has been investigated as a candidate treatment for schizophrenia on the assumption that the illness is associated with an imbalance between CCK and dopamine in the mesolimbic dopamine system." | ( Green, MC; Montgomery, SA, 1988) |
| "As outpatient treatment of schizophrenia increases, cases of over-dose with phenothiazine drugs may be expected to increase also." | ( Barry, D; Becker, CE; Meyskens, FL, 1973) |
| "Neuroleptic treatment of schizophrenia reduces CSF cyclic AMP in clinical responders after a mean of 8 weeks of treatment." | ( Belmaker, RH; Dasberg, H; Ebstein, RP, 1980) |
| "In recent years, the complex treatment of schizophrenia has been extended by the neuroleptic large-dose therapy." | ( Pethö, B; Ungvári, G, 1981) |
| "Although neuroleptics are the major treatment for schizophrenia, there are no effective measures to determine the appropriate or necessary length of neuroleptic maintenance." | ( Brenner, R; Gadaleta, D; Kane, JM; Kinon, B; Lesser, MS; Lieberman, JA, 1984) |
| "The use of lithium salts in the treatment of schizophrenia remains as contested as the concept of schizo-affective disorders." | ( Lôo, H; Matot, JP; Olié, JP, 1983) |
| "A number of new agents to treat schizophrenia have been, or will soon be, introduced that address the limitations of traditional neuroleptics." | ( MacEwan, GW, 1993) |
| "The prevalence of treatment-resistant schizophrenia ranges from 5 to 30% patients." | ( Martin, P, 1995) |
| "Since the 1950s, the main treatment for schizophrenia has been the use of neuroleptic therapy." | ( Littrell, K; Magill, AM, 1993) |
| "In addition, patients with non-treatment-resistant schizophrenia were randomly assigned to clozapine (N = 24) or typical neuroleptics (N = 23)." | ( Lee, MA; Meltzer, HY; Thompson, PA, 1994) |
| "Clozapine is a great advance in the treatment of schizophrenia." | ( Meltzer, HY, 1993) |
| "Considering this scenario, treatment of schizophrenia will be restricted to symptomatic and preventive therapy and therefore, more effective and better tolerated antipsychotics are necessary." | ( Brunello, N; Markstein, R; Masotto, C; Racagni, G; Steardo, L, 1995) |
| "A 28-year-old woman, treated for schizophrenia, developed severe hypotonic hyponatremia (serum Na: 109 mEq/L) after several days of compulsive water drinking." | ( Chagnac, A; Floro, S; Gruzman, C; Ish-Tov, E; Korzets, A; Ori, Y; Weinstein, T; Zevin, D, 1996) |
| "We describe two patients with treatment-resistant schizophrenia characterized by unremitting delusions, thought disorder and self-neglect who had a sustained improvement in their symptoms soon after starting risperidone." | ( Gledhill, JA; Wakeling, A; Warner, JP, 1996) |
| "The pharmacologic treatment of schizophrenia still suffers from two major problems: (1) most antipsychotic drugs still induce severe neurologic (extrapyramidal) side effects; (2) few antipsychotic drugs are effective in treating the negative symptoms of schizophrenia." | ( Cools, AR; Ellenbroek, BA; Lubbers, LJ, 1996) |
| "Risperidone may be an alternative for treatment-resistant schizophrenia, but this has not yet been clearly proved." | ( Citrome, L, 1997) |
| "This study supports the safety of the treatment of schizophrenia with pramipexole and haloperidol as a combination therapy." | ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "Modern strategies for treating schizophrenia profit from the existence of interaction between serotonin and dopamine systems." | ( Masek, K; Sevcík, J, 1997) |
| "Accordingly, treatment of schizophrenia with an immunosuppressant might be of potential benefit." | ( Deckmann, M; Feraro, R; Gutman, J; Handzel, ZT; Kimhi, R; Levine, J; Levy, P; Leykin, I; Shinitzky, M, 1997) |
| "The advantages of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of mesolimbic compared with motor and tuberoinfundibular dopaminergic pathways." | ( Daniel, DG; Whitcomb, SR, 1998) |
| "For comprehensive treatment of schizophrenia, the author advocates a polydimensional approach encompassing psychopharmacology, psychotherapy, psychosocial interventions (particularly with family members), and vocational training." | ( Ballús, C, 1997) |
| "A 43-year-old man, who had been treated for chronic schizophrenia, was admitted to our hospital with the chief complaint of urinary retention." | ( Himura, I; Kase, T; Matsushima, M; Miyashita, Y; Okamoto, S; Sato, D; Sawamura, Y; Tajima, M; Tokuda, N, 1997) |
| "The actual definition of treatment-resistant schizophrenia is, however, still controversial." | ( Meltzer, HY, 1997) |
| "Clozapine and risperidone are used in treatment-resistant schizophrenia." | ( Altman, S; Flynn, SW; Fredrikson, DH; Honer, WG; Kopala, LC; MacEwan, GW; Smith, GN, 1998) |
| "The increase of serum neopterin during treatment of schizophrenia may reflect an up-regulation of dopamine turnover, rather than immunological activity." | ( Arolt, V; Kirchner, H; Korte, S; Peters, M; Rothermundt, M; Weitzsch, C, 1998) |
| "Clozapine, indicated for treatment-resistant schizophrenia, has been evaluated in uncontrolled, mirror-image studies; clinical decision analysis models; and prospective, randomized clinical trials." | ( Revicki, DA, 1999) |
| "Clozapine has an established role in treatment-resistant schizophrenia." | ( Buckley, PF, 1999) |
| "The main objective in the treatment of schizophrenia should be to optimize individual patient functioning and quality of life." | ( Andersen, SW; Tollefson, GD, 1999) |
| "Six disturbed patients with treatment resistant schizophrenia were given a course of 12 ECT over 6 weeks." | ( Gray, NS; James, DV, 1999) |
| "In patients with treatment-resistant schizophrenia (TRS), this study compared the efficacy of continuation treatment with flupenthixol alone, continuation electroconvulsive therapy (ECT) alone, and combined continuation ECT and flupenthixol." | ( Buppanharun, W; Chakrabhand, ML; Chanpattana, W; Kirdcharoen, N; Kitaroonchai, W; Kongsakon, R; Sackeim, HA; Techakasem, P; Tuntirungsee, Y, 1999) |
| "Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia." | ( Bullmore, ET; Honey, GD; Sharma, T; Soni, W; Varatheesan, M; Williams, SC, 1999) |
| "The pharmacologic treatment of schizophrenia remains a critical component in the short- and long-term management of this disease." | ( Kane, JM, 1999) |
| "People prescribed clozapine for treatment-resistant schizophrenia have mandatory haematological monitoring through a case register for identifying reversible neutropenia." | ( Andrews, C; Arana, A; Kerwin, R; Mortimer, A; Munro, J; O'Sullivan, D, 1999) |
| "Long-term drug treatment of schizophrenia with conventional antipsychotics has limitations: 25-33% of patients have illnesses that are treatment-resistant." | ( Cheine, M; Essali, MA; Wahlbeck, K, 2000) |
| "The mainstay of treatment for schizophrenia is the antipsychotic group of drugs." | ( David, A; Quraishi, S, 2000) |
| "Anti-psychotic drugs are the mainstay treatment for schizophrenia and similar psychotic disorders." | ( David, A; Quraishi, S, 2000) |
| "Anti-psychotic drugs are the mainstay treatment for schizophrenia and similar psychotic disorders." | ( David, A; Quraishi, S, 2000) |
| "Anti-psychotic drugs are the mainstay treatment for schizophrenia." | ( Adams, CE; David, A; Quraishi, S, 2000) |
| "It is used for treatment of schizophrenia and other psychoses." | ( Disayavanish, C; Srisurapanont, M; Taimkaew, K, 2000) |
| "But one of the major challenge in the treatment of schizophrenia remains the lack of efficacy of antipsychotics on negative symptoms of schizophrenia." | ( Farisse, J; Lancon, C; Llorca, PM; Scotto, JC, 2000) |
| "A 40-year-old patient being treated for schizophrenia developed elevated plasma levels of haloperidol (HAL) in combination with chlorpromazine (CPZ) and during overlap treatment with clozapine." | ( Allen, SA, 2000) |
| "Current trends in the treatment of schizophrenia indicate that some atypical antipsychotics are being recommended as first-line therapy." | ( Jain, KK, 2000) |
| "In the long term treatment of schizophrenia, amisulpride maintained antipsychotic efficacy over a 12-month period in an open randomized study." | ( Blin, O, 2000) |
| "A 57-year-old African-American man, treated for schizophrenia with haloperidol for several years, developed NMS within 48 hours of the addition of low doses of risperidone and mirtazapine to his regimen." | ( Mack, JE; Reeves, RR; Torres, RA, 2001) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]." | ( Aizenberg, D; Bodinger, L; Munitz, H; Shiloh, R; Valevski, A; Weizman, A; Zemishlany, Z, 2002) |
| "It appears to be an effective agent in treating schizophrenia for what are characterised as positive and negative symptoms." | ( Green, B, 2002) |
| "Most clinical trials defined treatment-resistant schizophrenia according to Kane's criteria, while the majority of observational studies adopted implicit criteria." | ( Barale, F; Barbui, C; Brambilla, P; Caverzasi, E; Tognoni, G, 2002) |
| "There is a consensus that current treatments of schizophrenia do not offer satisfactory efficacy for negative and cognitive symptoms." | ( Danysz, W, 2002) |
| "Clinical trials for the treatment of schizophrenia now often include cognitive assessments in addition to clinical ratings of symptoms." | ( Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E, 2003) |
| "Patients with treated schizophrenia had higher rates of cardiac arrest and ventricular arrhythmia than controls, with rate ratios ranging from 1." | ( Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2002) |
| "Atypical antipsychotic drugs for the treatment of schizophrenia provide effective treatment of psychotic symptoms with a safety profile superior to conventional antipsychotic medications." | ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Clinicians treating schizophrenia face increasingly diverse ethnic populations." | ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2003) |
| "Fifty patients with treatment-resistant schizophrenia hospitalized on a research unit participated in a double-blind longitudinal study of the effects of drug washout after chronic treatment with a typical antipsychotic and before prospective treatment with clozapine." | ( Bartko, JJ; Pickar, D, 2003) |
| "The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective." | ( Duggan, A; Kerwin, R; Knapp, M; Warner, J, 2003) |
| "Chronically ill, never-treated people with schizophrenia in south India (n=70) and their first-degree relatives (n=181) were examined for dyskinesia using the Abnormal Involuntary Movements Scale (AIMS) and for parkinsonism by the Simpson and Angus scale." | ( McCreadie, RG; Padmavathi, R; Srinivasan, TN; Thara, R, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved." | ( Chang, CC; Chen, PS; Chiu, NY; Lee, IH; Lee, JR; Yang, YK, 2003) |
| "The importance of antipsychotics in the treatment of schizophrenia has been documented in numerous clinical trials." | ( Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Kurz, M; Kurzthaler, I, 2003) |
| "However, in terms of treatment-resistant schizophrenia (TRS) almost only psychopharmacological treatments are available and psychosocial interventions such as OT had not proved to be effective." | ( Buchain, PC; Elkis, H; Henna Neto, J; Vizzotto, AD, 2003) |
| "Haloperidol-treated schizophrenia subjects exhibited an additional and consistent pattern of reduced attention (fixation) to salient features for neutral and happy." | ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "Atypical antipsychotics successfully treat schizophrenia and other conditions, with a lower incidence of extrapyramidal side effects than other agents used in treatment of these disorders." | ( Acholonu, WW; Bengtson, MA; Renner, BT; Ried, LD; Wilcox, BM, 2003) |
| "To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic." | ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003) |
| "A subgroup of 99 clozapine-treated schizophrenia patients was also tested for the genetic effects of this polymorphism, as evidenced by clinical manifestation, and clozapine-related therapeutic outcome and body-weight change." | ( Hong, CJ; Lin, CH; Liu, LL; Tsai, SJ; Yu, YW, 2003) |
| "In a 12-week study of patients with treatment-resistant schizophrenia, ziprasidone demonstrated overall efficacy comparable to that of chlorpromazine, with superior improvement in negative symptoms." | ( Kane, JM, 2003) |
| "Seventeen olanzapine- or risperidone-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover treatment trial with." | ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "Antipsychotic agents are used often for treatment of schizophrenia, a condition that appears to be associated with DM also in untreated subjects." | ( Cohen, D, 2004) |
| "Side effects of pharmacological treatment in schizophrenia continue to be a major issue in spite of the development of new antipsychotics." | ( Chong, MY; Lung, FW; Yen, YC, 2004) |
| "Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years." | ( Buckley, PF; Glazer, W; Sebastian, CS, 2004) |
| "It is prescribed in the treatment of schizophrenia and is under the treatment of schizophrenia and schizoaffective investigation for treatment of bipolar disorder." | ( Green, B, 2004) |
| "Aripiprazole may be effective for the treatment of schizophrenia, but it is not much different from typical antipsychotics and atypical antipsychotics with respect to treatment response, efficacy or tolerability." | ( El-Sayeh, HG; Morganti, C, 2004) |
| "In cases of treatment-resistant schizophrenia the combined application of antipsychotic drugs often becomes necessary." | ( Dressing, H; Mase, E; Zink, M, 2004) |
| "Recently approved for the treatment of schizophrenia, aripiprazole represents the sixth second-generation antipsychotic (SGA) introduced to the US market." | ( Crismon, ML; DeLeon, A; Patel, NC, 2004) |
| "Antipsychotic drugs are the mainstay treatment for schizophrenia." | ( Adams, CE; David, A; Quraishi, SN; Wong, D, 2004) |
| "Thirty-eight treatment-resistant schizophrenia inpatients receiving conventional and atypical antipsychotics enrolled in a 10-week, double-blind, placebo-controlled study, in which they were randomized in a 2:1 ratio to receive adjuvant treatment with lamotrigine, gradually titrated to a 400 mg/day dose, or placebo." | ( Bar, G; Blanaru, M; Gorelik, I; Heresco-Levy, U; Javitt, DC; Kremer, I; Vass, A, 2004) |
| "Augmentation strategy in the treatment of schizophrenia with the NMDA receptor co-agonist glycine has demonstrated significant improvement in patient symptoms." | ( Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB, 2004) |
| "Thirty patients with acute untreated schizophrenia were clinically evaluated with the Positive and Negative Syndrome Scale, underwent COMT Val/Met genotyping, and entered an 8-week prospective study of olanzapine treatment." | ( Altamura, M; Bellomo, A; Bertolino, A; Blasi, G; Caforio, G; Callicott, JH; De Candia, M; Latorre, V; Mattay, VS; Nappi, G; Nardini, M; Papa, S; Petruzzella, V; Scarabino, T; Weinberger, DR, 2004) |
| "Thus, a possible avenue for the treatment of schizophrenia would be to address this GABAergic functional deficit using positive allosteric modulators of the action of GABA at GABAA receptors." | ( Costa, E; Davis, JM; Dong, E; Grayson, DR; Guidotti, A; Tremolizzo, L; Veldic, M, 2004) |
| "Adjunctive risperidone treatment in schizophrenia patients partially responsive to clozapine does not significantly improve psychopathology or quality of life compared to placebo in a 6-week period." | ( Alptekin, K; Anil Yağcioğlu, AE; Ertuğrul, A; Göğüş, A; Jayathilake, K; Kivircik Akdede, BB; Meltzer, HY; Tümüklü, M; Tunca, Z; Turgut, TI; Yazici, MK, 2005) |
| "We present a patient with treatment resistant schizophrenia and a prolactin-secreting microadenoma of the pituitary who was intolerant of clozapine therapy." | ( Dunkley, MJ; Reveley, MA, 2005) |
| "Thirty-nine risperidone- or olanzapine-treated schizophrenia patients participated in a double-blind, placebo-controlled, 6-week crossover trial with 30 mg/kg/day D-serine added to their antipsychotic medication." | ( Bar, G; Catinari, S; Ebstein, R; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P; Vass, A, 2005) |
| "We present results of a study of treated rates of schizophrenia among the Iban of Sarawak, Malaysia." | ( Barrett, R; Chant, D; Jerah, E; Loa, P; Mowry, B; Nancarrow, D, 2005) |
| "A total of 100 cases of untreated schizophrenia were recruited, of whom 28% had never received antipsychotic medication and the remaining 72% had not been on medication for the past 6 months." | ( Chandrashekari, CR; Chisholm, D; Kishore Kumar, KV; Sekar, K; Srinivasa Murthy, R; Thomas, T, 2005) |
| "It is indicated for the treatment of schizophrenia, but has also often been used off-label for other uses." | ( Baldassano, C; Ballas, C; Ballas, P; O'Reardon, J; Yang, C, 2004) |
| "Total treatment costs in schizophrenia were significantly higher in those who were unemployed, those who visited the hospital more often, and were more severely ill and disabled." | ( Avasthi, A; Bhansali, A; Chakrabarti, S; Grover, S; Kulhara, P, 2005) |
| "We propose new strategies for the treatment of schizophrenia using a combination of anti-dopaminergic and anti-glutamatergic drugs." | ( Goff, DC; Large, CH; Webster, EL, 2005) |
| "Two controlled trials deal with OCS treatment in schizophrenia: the first, with clomipramine; and the second, with fluvoxamine." | ( Dardennes, R; Faucher, S; Ghaëm, O; Guelfi, JD, 2005) |
| "(1) Neuroleptics are the standard treatment for schizophrenia." | ( , 2005) |
| "Fifty-one patients with treatment-resistant schizophrenia were put on a fixed dose of clozapine at 300 mg/day for 6 weeks." | ( Chan, KT; Choi, WK; Hon-Kee Cheung, H; Lai, J; Leung, SP; Mak, T; Ng, RM; Wai-Kiu Tsang, A; Wong, JO, 2006) |
| "According to zero hypothesis in the treatment of schizophrenia at University hospitals in FBiH new antipsychotic drugs are in use, small doses are proscribed (up to 20 mg), not more then one antipsychotic drug is used simultaneously, antipsychotics are administrated once a day and alongside with antipsychotics other medicaments are not co-administrated, especially antiparkinsons." | ( Fiseković, S; Kusturica, J; Loga, S; Loga-Zec, S; Mulabegović, N; Zulić, I, 2005) |
| "Aripiprazole was effective for the treatment of schizophrenia and schizoaffective disorder in a general psychiatry outpatient practice setting." | ( Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R, 2006) |
| "In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown." | ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Current treatments for schizophrenia target the dopamine system." | ( Javitt, DC, 2006) |
| "Aripiprazole may be effective for the treatment of schizophrenia, but it does not differ greatly from typical and atypical antipsychotics with respect to treatment response, efficacy or tolerability." | ( El-Sayeh, HG; Morganti, C, 2006) |
| "Two patients were treated for schizophrenia for many years prior to a diagnosis of Niemann-Pick type C." | ( Fahey, M; Fietz, M; Leane, P; Lubman, DI; Sullivan, D; Velakoulis, D; Walterfang, M, 2006) |
| "It may be effective for treatment of schizophrenia, but in terms of tolerability and global outcomes it shows little difference from existing antipsychotics." | ( Adams, CE; El-Sayeh, HG; Morganti, C, 2006) |
| "Around 40-70% patients with treatment-resistant schizophrenia fail to respond to clozapine." | ( Harborne, GC; Karunakaran, K; Tungaraza, TE, 2007) |
| "In untreated schizophrenia, psychotic decompensation is associated with profound insomnia, one of the prodromal symptoms associated with psychotic relapse." | ( Benson, KL, 2006) |
| "Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy." | ( Kropp, S; Wittmann, G; Ziegenbein, M, 2006) |
| "Eleven patients with treatment-resistant schizophrenia participated in this clinical trial and received a combination of aripiprazole and clozapine." | ( Kropp, S; Wittmann, G; Ziegenbein, M, 2006) |
| "Antipsychotic drugs are the mainstay treatment for schizophrenia and similar psychotic disorders." | ( Abhijnhan, A; Adams, CE; David, A; Ozbilen, M, 2007) |
| "Although the treatment of schizophrenia with many second generation antipsychotics is known to be associated with metabolic changes, such as hyperglycemia or hypercholesterolemia, the underlying mechanisms of these adverse reactions remain unclear." | ( Beck, G; Becker, A; Bleich, S; Frieling, H; Roessner, V; Weber, A, 2007) |
| "Long-term treatment of stable schizophrenia focuses on treatment effectiveness, addressing direct efficacy plus treatment adherence, treatment burden, and impact on factors such as weight gain." | ( Thomas, P, 2007) |
| "Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated." | ( Bonhaus, DW; Burstein, ES; Lameh, J; Taylor, E; Vanover, KE; Weiner, DM, 2007) |
| "Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day." | ( Gursoy, B; Kirli, S; Sarandöl, E; Sipahioglu, D; Sivrioglu, EY, 2007) |
| "Diverse beliefs about the cause and treatment of schizophrenia are common among patients and their relatives." | ( Charles, H; Jacob, KS; Manoranjitham, SD, 2007) |
| "Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits." | ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008) |
| "We studied 32 minimally treated schizophrenia patients and 21 healthy subjects with single-voxel proton magnetic resonance spectroscopy ((1)H-MRS) of the frontal and occipital lobes, caudate nucleus, and cerebellum." | ( Brooks, WM; Bustillo, JR; Hammond, R; Hart, B; Jung, R; Lauriello, J; Qualls, C; Rowland, LM, 2008) |
| "Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD)." | ( Kim, D; Kim, JH; Marder, SR, 2008) |
| "Guidelines for the treatment of schizophrenia recommend the combination of pharmacologic and psychosocial interventions." | ( Hundemer, HP; Linden, M; Pyrkosch, L, 2008) |
| "Guidelines for treating schizophrenia have consistently recommended antipsychotic monotherapy." | ( Chen, YY; Hung, GC, 2009) |
| "Clozapine is the drug of choice for treatment-resistant schizophrenia." | ( Lang, UE; Malte Tugtekin, S; Matschke, K; Schmeisser, A; von Golitschek, R; Willbring, M, 2008) |
| "Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects." | ( Cochran, SM; Egerton, A; Morris, BJ; Pratt, JA; Winchester, C, 2008) |
| "Ziprasidone has been used to treat schizophrenia since 2000." | ( D'Agostino, RB; Eng, SM; Faich, GA; Kane, JM; Reynolds, RF; Ruskin, JN; Strom, BL, 2008) |
| "Quetiapine's effectiveness in treating schizophrenia and bipolar disorder is well-known; however, growing evidence has indicated that it may be useful in the treatment of various substance use disorders." | ( Hanley, MJ; Kenna, GA, 2008) |
| "Switching medications is common in the treatment of schizophrenia." | ( Ascher-Svanum, H; Faries, DE; Kinon, BJ; Nyhuis, AW, 2008) |
| "7658 outpatients treated for schizophrenia were enrolled in the study, who needed an antipsychotic therapy to initiate or switch." | ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| "Eight-four Chinese Han untreated schizophrenia patients in 70 nuclear families were recruited." | ( Mou, XD; Shi, JB; Sun, J; Zhang, XR; Zhang, ZJ, 2008) |
| "Outpatients with treatment-resistant schizophrenia were prescribed clozapine at expected rates; however, treatment was delayed longer than recommended." | ( Wheeler, AJ, 2008) |
| "Antipsychotic drugs are the mainstay of treatment in schizophrenia." | ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009) |
| "Aripiprazole is indicated for the treatment of schizophrenia in Europe and the United States, and for bipolar disorders in the latter." | ( Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B, 2008) |
| "Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia." | ( Joe, SH; Jung, HG; Jung, SW; Ko, YH; Lee, CH; Lee, MS; Lew, YM, 2008) |
| "Atypical antipsychotics are effective treatments of schizophrenia and manic symptoms, presumably in part by antagonizing DA receptors." | ( Caron, MG; Geyer, MA; Ong, JC; Powell, SB; Young, JW, 2008) |
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "These approaches may provide novel treatments to schizophrenia, provided that some of the known adverse effects associated with existing GlyT1 agents can be safely and adequately dealt with." | ( Svensson, KA; Yang, CR, 2008) |
| "Clozapine treatment of schizophrenia is effective only in 30-60% of individuals." | ( Belmonte-de-Abreu, P; Gama, CS; Hutz, MH; Kohlrausch, FB; Lobato, MI; Salatino-Oliveira, A, 2008) |
| "The comparison of the clozapine-treated schizophrenia patients and the healthy controls showed significant difference in IgG aCL level [mean+/-SD: 1." | ( Chen, J; Cui, Q; Li, R; Shen, H; Xiao, H; Zhou, Q, 2009) |
| "Olanzapine is widely used for the treatment of schizophrenia and is considered a first line medication in India." | ( Deshpande, SN; Lerer, B; Mathur, P; Nimgaonkar, VL; Singh, A; Srivastava, V; Thelma, BK; Thomas, P, 2008) |
| "Disability in untreated schizophrenia patients remains unchanged over time." | ( Arunachala, U; Gangadhar, BN; Kishorekumar, KV; Subbakrishna, DK; Thirthalli, J; Venkatasubramanian, G; Venkatesh, BK, 2009) |
| "Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant." | ( Al-Haj Haasan, N; Essali, A; Li, C; Rathbone, J, 2009) |
| "Soon after its approval in Germany for treatment of schizophrenia, a 12-month post-marketing surveillance study was initiated that included 1 096 patients cared for by 408 office-based psychiatrists and/or neurologists in private practice." | ( Bergmann, F; Ebrecht, M; Kungel, M; Modell, S; Nass, A; Spevakné-Göröcs, T; Urban, R; Werner, C; Zacher, A, 2009) |
| "Besides that, she was treated with schizophrenia." | ( Bács, E; Czeizel, E; Gidai, J, 2009) |
| "Blonanserin was effective in the treatment of acute schizophrenia and showed greater efficacy in negative symptoms compared with placebo and haloperidol." | ( Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y, 2009) |
| "Therefore, one proposed approach to the treatment of schizophrenia is via the inhibition of GlyT1-mediated transport." | ( Javitt, DC, 2009) |
| "It is being developed for the treatment of schizophrenia and bipolar mania." | ( McCormack, PL; Weber, J, 2009) |
| "Efficacy in the treatment of acute schizophrenia is supported by 2 of 4 completed phase II/III randomised, placebo and active-controlled 6-week trials, principally at a dose of 5 mg bid." | ( Citrome, L, 2009) |
| "A total of 14 minimally treated schizophrenia patients and 10 healthy subjects were studied with single-voxel proton magnetic resonance spectroscopy ((1)H-MRS) of the AC, frontal white matter and thalamus at 4 T." | ( Brooks, WM; Bustillo, JR; Chen, H; Hammond, R; Jung, R; Lauriello, J; Mullins, P; Qualls, C; Rowland, LM, 2010) |
| "Clozapine is indicated for the treatment of schizophrenia and related psychotic disorders." | ( Rao, LV; Snyder, ML; Vallaro, GM, 2009) |
| "Iloperidone's indication for the acute treatment of schizophrenia in adults is supported by two of the four principal registration studies completed by the manufacturer." | ( Citrome, L, 2010) |
| "Clozapine is still the gold standard in treatment-resistant schizophrenia." | ( Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C, 2010) |
| "The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics." | ( Caccia, S; Nobili, A; Pasina, L, 2010) |
| "Clinical trial registry information-Treatment of Schizophrenia and Related Disorders in Children and Adolescents; URL: http://www." | ( Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Johnson, JL; Kaufman, EM; Lieberman, JA; Lingler, J; Maloney, AE; McClellan, J; McNamara, NK; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Vitiello, B, 2010) |
| "An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI)." | ( Brunner, E; Corya, SA; Detke, HC; McDonnell, DP; Sorsaburu, S; Stefaniak, VJ; Zhao, F, 2010) |
| "Amisulpride is used for the treatment of schizophrenia and part of its safety profile is that is has no effect on the QT interval in therapeutic doses." | ( Stevenson, RJ, 2010) |
| "for the acute and maintenance treatment of schizophrenia in adults." | ( Owen, RT, 2010) |
| "After optimising treatment for schizophrenia we used Rivastigmine, an AchEI, as an adjunct to treat her symptoms successfully." | ( Attard, A; Jacobsen, P; Patel, SS; Shergill, S, 2010) |
| "Food and Drug Administration for treatment of schizophrenia in 1997, and it received its second indication for the treatment of mania-associated bipolar disorder in 2004." | ( Magni, V; Ribolsi, M; Rubino, IA, 2010) |
| "Paliperidone ER is effective for the treatment of schizophrenia and is at present the only antipsychotic approved in the USA for treatment of schizoaffective disorder." | ( Battisti, WP; Canuso, CM, 2010) |
| "The antipsychotic treatment of schizophrenia is still marked by poor compliance, and drug discontinuation; the development of more effective and safer drugs still remains a challenge." | ( Bruno, A; Micò, U; Muscatello, MR; Pandolfo, G; Settineri, S; Zoccali, R, 2010) |
| "In the treatment of schizophrenia, all currently available oral antipsychotics are administered at least once daily, with strict adherence strongly encouraged to minimize risk of relapse." | ( Feingold, A; Kapur, S; Mann, S; Remington, G; Seeman, P; Shammi, C, 2011) |
| "Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects." | ( Malhotra, AK; Zhang, JP, 2011) |
| "Food and Drug Administration for the treatment of schizophrenia." | ( Citrome, L, 2011) |
| "The efficacy for the treatment of schizophrenia has also been proven in a clinical trial." | ( Chaki, S; Hikichi, H, 2011) |
| "Long-term treatment of schizophrenia with antipsychotics is crucial for relapse prevention, but a prolonged blockade of D(2) dopamine receptors may lead to the development of supersensitivity psychosis." | ( Hashimoto, K; Iyo, M; Kanahara, N; Okamura, N; Sekine, Y; Tadokoro, S, 2012) |
| "Each is indicated for the treatment of schizophrenia, and asenapine has an additional indication for bipolar disorder." | ( Howland, RH, 2011) |
| "All 3 agents are approved for the treatment of acute schizophrenia in adults, and asenapine is also approved for the maintenance treatment of schizophrenia and as a monotherapy or as an adjunct to lithium or valproate for the treatment of bipolar manic or mixed episodes." | ( Citrome, L, 2011) |
| "This study supports a novel treatment of schizophrenia that targets abnormal HPC output, which in turn normalizes dopaminergic neuronal activity." | ( Aras, S; Cook, JM; Gill, KM; Grace, AA; Lodge, DJ, 2011) |
| "When treating schizophrenia, improving patients' productivity level is a major goal considering schizophrenia is a leading cause of functional disability." | ( Ascher-Svanum, H; Gomez, JC; Jen, KY; Liu-Seifert, H; Osuntokun, O, 2011) |
| "The limitations of antipsychotics for treatment of schizophrenia have led to investigation of the usefulness of pharmacological augmentation strategies." | ( Behdani, F; Hebrani, P; Rafee, E; Rezaei Ardani, A, 2011) |
| "Aripiprazole may be effective for the treatment of schizophrenia." | ( Belgamwar, RB; El-Sayeh, HG, 2011) |
| "Antipsychotic drugs are the mainstay treatment for schizophrenia." | ( Adams, CE; Purgato, M, 2011) |
| "Sixty-three first-episode treatment-naïve schizophrenia (FES) patients and 63 age-, gender- and education level-matched healthy controls were recruited." | ( Chen, ZF; Collier, DA; Deng, W; He, ZL; Li, ML; Li, T; Ma, X, 2012) |
| "Aripiprazole is widely used to treat schizophrenia." | ( Chen, CK; Lin, SK; Liu, YL, 2011) |
| "The efficacy of asenapine in treating schizophrenia was evaluated in four 6-week studies in which placebo and active controls (risperidone, olanzapine, and haloperidol) were used." | ( Fuller, MA; Henry, JM, 2011) |
| "The pharmacologic treatment of schizophrenia and bipolar disorder leaves much to be desired." | ( Davis, JM; Torrey, EF, 2012) |
| "Current drug treatments for schizophrenia are inadequate for many patients, and despite 5 decades of drug discovery, all of the treatments rely on the same mechanism: dopamine D(2) receptor blockade." | ( Abi-Dargham, A; Howes, OD; Kambeitz, J; Kapur, S; Kim, E; Slifstein, M; Stahl, D, 2012) |
| "Despite its unsurpassed efficacy in treatment-resistant schizophrenia, clozapine remains underutilized." | ( Nielsen, J; Røge, R; Schjerning, O; Sørensen, HJ; Taylor, D, 2012) |
| "Normobaric hyperoxia may be a potential treatment for schizophrenia." | ( Agam, G; Amar, S; Applebaum, J; Azab, AN; Belmaker, RH; Bersudsky, Y; Bloch, Y; Osher, Y, 2012) |
| "The long-term treatment of schizophrenia is one of the most challenging tasks for practicing physicians." | ( Herold, R, 2012) |
| "Patients with difficult-to-treat schizophrenia received either mirtazapine (n = 19) or placebo (n = 18) in a double-blind fashion for six weeks." | ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "The three drugs are indicated for the treatment of acute schizophrenia." | ( Stahl, SM; Tarazi, FI, 2012) |
| "Potential effects of treating schizophrenia patients with antipsychotic-induced weight gain with GLP-1 analogs are discussed." | ( Ebdrup, BH; Fagerlund, B; Glenthøj, B; Ishøy, PL; Knop, FK; Lublin, H; Rostrup, E, 2012) |
| "There is an unmet need in the treatment of schizophrenia for effective medications with fewer adverse effects." | ( Guarino, J; Kimura, T; Nakamura, M; Ogasa, M, 2013) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "Influential protocols in the treatment of schizophrenia recommend the use of antipsychotics in monotherapy." | ( Bitter, I; Gazdag, G; Tolna, J, 2012) |
| "In addition, patients with treatment-resistant schizophrenia were on polypharmacy at higher rate than non resistant patients." | ( Borlido, C; De Luca, V; Kennedy, JL; Teo, C, 2013) |
| "Both drugs showed good efficacy for treating schizophrenia." | ( Kato, M; Kinoshita, T; Nishida, K; Okugawa, G; Sakai, S; Suwa, A; Takekita, Y; Wakeno, M, 2013) |
| "A proposed approach to treatment of schizophrenia, therefore, is inhibition of GlyT1-mediated transport." | ( Javitt, DC, 2012) |
| "Twelve patients with treatment-resistant schizophrenia, twelve patients with schizophrenia who had responded to antipsychotics, and twelve healthy volunteers matched for gender, age, ethnicity, weight, and cigarette smoking underwent [(18)F]-DOPA PET scanning." | ( Demjaha, A; Howes, OD; Kapur, S; McGuire, PK; Murray, RM, 2012) |
| "Antipsychotic drugs are the mainstay treatment for schizophrenia." | ( Adams, CE; Purgato, M, 2012) |
| "A substantial number of patients with treatment-resistant schizophrenia respond only partially to clozapine." | ( D'Souza, DC; Forselius-Bielen, K; Gueorguieva, R; Gunduz-Bruce, H; Kaliora, S; Oliver, S; Petrides, G; Ray, S; Tek, C; Zimolo, Z, 2013) |
| "Forty patients with treatment-resistant schizophrenia were evaluated during 8 weeks of clozapine monotherapy." | ( Kim, JH; Kim, YS; Lee, J; Yi, SH, 2013) |
| "Asenapine is an approved treatment for schizophrenia in the United States." | ( Cazorla, P; Fennema, H; Mackle, M; Szegedi, A; van Duijnhoven, W; Verweij, P, 2012) |
| "As a potential target for the treatment of schizophrenia, the dual cAMP/cGMP hydrolyzing enzyme PDE10A has attracted a significant amount of attention." | ( Gao, Q; Gao, W; Guo, H; Han, C; Li, D; Li, Y; Wang, J; Wu, Q; Yang, L, 2013) |
| "Antipsychotic drugs are the mainstay of treatment for schizophrenia." | ( Bromet, EJ; DeRosse, P; Geisler, S; Lencz, T; Malhotra, AK; Zhang, JP, 2013) |
| "Japan approved clozapine for treatment-resistant schizophrenia in June 2009." | ( Chekuri, R; Correll, CU; Fujita, K; Furukawa, O; Hattori, M; Iwata, N; Kane, JM; Kishi, T; Moriwaki, M; Nitta, M; Suzuki, T; Tsunoka, T, 2013) |
| "Clinicians treating schizophrenia routinely employ high doses and/or antipsychotic switching to achieve response." | ( Agid, O; Arenovich, T; Fervaha, G; Foussias, G; McDonald, K; Remington, G; Sajeev, G; Schulze, L, 2013) |
| "Adults treated for schizophrenia with lurasidone are predicted to have lower 12-month MH costs compared to those treated with quetiapine XR due to fewer relapses and relapse-related hospitalizations." | ( Loebel, A; Meyer, K; O'Day, K; Pikalov, A; Rajagopalan, K, 2013) |
| "There is need to treat schizophrenia as a priority area in the current and future national S & T plans of India." | ( Bala, A; Gupta, BM, 2013) |
| "When treating schizophrenia and other psychotic disorders, clinicians often encounter the problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life." | ( Csekey, L; Kálmán, J; Sümegi, A, 2013) |
| "Flupentixol has a stable place in the treatment of schizophrenia in spite of the introduction of different SGAs." | ( Engel, RR; Grohmann, R; Möller, HJ; Rüther, E; Stübner, S; van der Velden, JW, 2014) |
| "It is recommended as third-line treatment for schizophrenia in national and local guidelines." | ( Gee, S; Howes, O; Taylor, D; Vergunst, F, 2014) |
| "The use of clozapine (CLZ) for treatment-resistant schizophrenia is well established in adults." | ( Corrigall, R; Frangou, S; Hayes, D; Kyriakopoulos, M; Schneider, C, 2014) |
| "Twenty-two patients with treatment-resistant schizophrenia treated with clozapine and 22 age- and sex-matched healthy controls were enrolled." | ( Fujimoto, M; Hashimoto, K; Hashimoto, R; Ishima, T; Ito, A; Kishi, F; Ohi, K; Takeda, M; Umeda-Yano, S; Yamamori, H; Yasuda, Y, 2013) |
| "Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D(2)-type dopamine receptors." | ( Abi-Dargham, A; Girgis, RR; Javitt, DC; Kantrowitz, JT; Kegeles, LS; Lieberman, JA; Poels, EM; Slifstein, M, 2014) |
| "F DA for cariprazine for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar I disorder was submitted in November 2012." | ( Gründer, G; Paulzen, M; Veselinović, T, 2013) |
| "When introducing clozapine for treatment-resistant schizophrenia, it is important to administer it as a monotherapy, slowly increase the dosage to reduce side effects, and achieve a treatment effect at the minimum required dosage." | ( Ashizawa, Y; Enomoto, T; Hayakawa, T; Ito, T; Sekine, K; Tsukada, K; Uju, Y; Yasui, R, 2013) |
| "Clozapine is used in the management of treatment-resistant schizophrenia and is effective in reducing aggression; however a subgroup of patients is poorly responsive." | ( Basu, A; Brooman-White, RS; Das, M; Gupta, N; Hotham, JE; Humphreys, SA; Larkin, F; Ross, CC; Simpson, PJ, 2014) |
| "Forty patients with treatment-resistant schizophrenia were comprehensively evaluated for subjective well-being, schizophrenic symptoms, and depressive symptoms before and 8 weeks after the initiation of treatment with clozapine." | ( Han, AY; Kim, JH; Kim, YB; Lee, J, 2014) |
| "Existing treatments for schizophrenia have limited efficacy against cognitive impairment." | ( Boggs, DL; Carlson, J; Cortes-Briones, J; D'Souza, DC; Krystal, JH, 2014) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Current psychopharmacological treatment of schizophrenia is suboptimal and the available antipsychotic medications have little or no effect on negative and cognitive symptom domains of the disorder." | ( Okusaga, OO, 2014) |
| "Current treatments for schizophrenia, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction." | ( Citrome, L, 2014) |
| "Antipsychotics are effective in treating schizophrenia symptoms." | ( Freeman, N; Gagliano, SA; Kennedy, JL; Knight, J; Lieberman, JA; Meltzer, HY; Müller, DJ; Tiwari, AK, 2014) |
| "Asenapine's efficacy in the treatment of schizophrenia and in the acute management of bipolar manic or mixed episodes, within the recommended therapeutic dose range of 5 - 10 mg twice a day, is evidenced by a broad clinical development program." | ( Citrome, L, 2014) |
| "Modafinil treatment in schizophrenia augments middle-frequency cortical oscillatory power associated with rule selection, and may subserve diverse subcomponent processes in proactive cognitive control." | ( Carter, CS; Cheng, Y; Minzenberg, MJ; Yoon, JH, 2014) |
| "A problem in the treatment of schizophrenia is poor patient compliance leading to the recurrence of psychotic symptoms." | ( Coveñas, R; Werner, FM, 2014) |
| "Current treatments for schizophrenia have an effect on positive symptoms but have a limited efficacy on negative or cognitive symptoms." | ( Cheong, JH; Kim, B; Ko, SY; Lee, HE; Lee, Y; Oh, HK; Park, SJ; Ryu, JH; Shin, CY, 2014) |
| "Antipsychotic drugs are the core treatment for schizophrenia." | ( Dold, M; Engel, RR; Leucht, S; Tardy, M, 2014) |
| "Antipsychotic drugs are the core treatment for schizophrenia." | ( Engel, RR; Huhn, M; Kissling, W; Leucht, S; Tardy, M, 2014) |
| "Antipsychotic drugs are the core treatment for schizophrenia." | ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| "Current pharmacological treatments for schizophrenia target G protein-coupled receptors (GPCRs), including dopamine receptors." | ( Funk, AJ; Haroutunian, V; McCullumsmith, RE; Meador-Woodruff, JH, 2014) |
| "Up to 70% of patients with treatment-resistant schizophrenia do not respond to clozapine." | ( Bailine, SH; Braga, RJ; Goldberg, TE; John, M; Kane, JM; Malhotra, AK; Malur, C; Mendelowitz, A; Petrides, G; Sanghani, S; Schooler, NR, 2015) |
| "Two hundred and thirty-seven clozapine-treated Finnish schizophrenia patients were genotyped for CHRM1, CHRM3, CLOCK and ADRA2A polymorphisms, and their salivary dysfunction was assessed with two questions." | ( Kampman, O; Lehtimäki, T; Leinonen, E; Mäkelä, KM; Mononen, N; Seppälä, N; Solismaa, A; Viikki, M, 2014) |
| "Antipsychotic drugs are the core treatment for schizophrenia." | ( Dold, M; Engel, RR; Leucht, S; Tardy, M, 2014) |
| "Twenty-two patients with treatment-resistant schizophrenia and 22 age- and gender-matched healthy controls were enrolled." | ( Fujimoto, M; Fujita, Y; Hashimoto, K; Hashimoto, R; Ito, A; Numata, S; Ohi, K; Ohmori, T; Takeda, M; Umeda-Yano, S; Yamamori, H; Yasuda, Y, 2014) |
| "Here, we treated schizophrenia rat models with a systematic injection of MK-801 (0." | ( Fang, Y; Xu, L; Zhang, C, 2014) |
| "Antipsychotic drugs are the core treatment for schizophrenia." | ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| "Patients with treatment-resistant schizophrenia commonly receive nonrecommended drug regimens, including antipsychotic polypharmacy, sometimes in lieu of clozapine." | ( Carroll, C; Fairman, K; Lage, MJ; Velligan, DI, 2015) |
| "Abilify (aripiprazole), a drug used to treat human schizophrenia patients, was used as the positive control." | ( Baek, SB; Kang, HS; Kim, CJ; Kim, TW; Lee, SJ; Park, JK, 2014) |
| "Given the indication of clozapine for treatment-resistant schizophrenia (TRS) and the negative impacts of depressive symptoms on clinical outcomes in schizophrenia, further research is warranted to investigate antidepressant effects of clozapine in TRS with an MDE." | ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "Those with treatment-resistant schizophrenia had higher total glutamate + glutamine levels scaled to creatine in the putamen than the first-line responders (mean difference = 0." | ( Anderson, VM; Goldstein, ME; Kydd, RR; Pillai, A; Russell, BR, 2015) |
| "A total of 33 patients with treatment-resistant schizophrenia and 31 healthy controls matched for age and gender underwent structural MRI brain scans at baseline and 6-9 months after commencing clozapine." | ( Ahmed, M; Barker, GJ; Cannon, DM; Hallahan, B; Holleran, L; Langan, C; McCarthy, P; McDonald, C; McFarland, J; Scanlon, C; Schmidt, H, 2015) |
| "There may be subtypes in treatment-resistant schizophrenia (TRS), and one of the subtypes may be related to dopamine supersensitivity psychosis (DSP)." | ( Iyo, M; Kanahara, N; Kimura, H; Suzuki, T; Takase, M; Watanabe, H; Yamanaka, H, 2015) |
| "Better treatments for schizophrenia are urgently needed." | ( Abrao, J; Baker, GB; Balista, PA; Chaves, C; Dursun, SM; Evora, PR; Guimaraes, FS; Hallak, JE; Kandratavicius, L; Leite, JP; Maia-de-Oliveira, JP; Rodrigues, AJ; Wolf, DC, 2015) |
| "The efficacy of clozapine for the treatment of schizophrenia has been demonstrated." | ( Berk, M; Dodd, S; Hyde, N; O'Neil, A; Purdie, C; Venugopal, K, 2015) |
| "Current treatments for schizophrenia have modest, if any, efficacy on cognitive dysfunction, creating a need for novel therapies." | ( Ballard, TM; Haman, M; Janhunen, SK; Kumar, G; Lerdrup, L; Plath, N; Ruby, T; Steckler, T; Svärd, H; Talpos, J; Wyler, R, 2015) |
| "Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms." | ( Goyal, A; Tharoor, H, 2015) |
| "Clozapine is frequently used to treat schizophrenia in China." | ( Cai, MY; Cao, XL; Chiu, HF; Hou, CL; Jia, FJ; Li, Y; Lin, YQ; Ma, XR; Ng, CH; Shinfuku, N; Ungvari, GS; Xiang, YT; Zang, Y; Zhong, BL, 2015) |
| "The recommended dose for the treatment of schizophrenia is 2-4 mg/day and that for MDD, 2 mg/day." | ( Citrome, L, 2015) |
| "Whether treating schizophrenia with risperidone plus add-on DM is more effective than risperidone (RISP) alone, and the association between the ALDH2 polymorphism and treatment response were investigated." | ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2015) |
| "Despite pharmacological advances in the treatment of schizophrenia, significant number of patients continue to be treatment-resistant." | ( Šagud, M, 2015) |
| "An urgent need exists for new treatments of schizophrenia that are effective against a broad range of symptoms and free of limiting safety issues." | ( Correll, CU; Davis, RE; Goff, DC; Kane, JM; Lieberman, JA; Mates, S; Tamminga, CA; Vanover, KE, 2016) |
| "Use of asenapine for the treatment of schizophrenia was associated with reduced levels of health care utilization and cost during the 6-month period immediately following therapy initiation, primarily due to reduced levels of inpatient care." | ( Boulanger, L; Chitnis, A; Dixit, S; Sun, SX; Tawah, A; Wang, R, 2015) |
| "Food and Drug Administration for the treatment of schizophrenia in July 2015." | ( Citrome, L; McEvoy, J, 2016) |
| "The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time." | ( Bo, QJ; Li, AN; Li, XB; Ma, X; Wang, CY; Wang, ZM, 2016) |
| "As oxytocin is a putative treatment for schizophrenia, the effect of repeated dosing of OT on OT levels, clinical symptoms and the relationship between the two is of interest." | ( Buchanan, RW; Kelly, DL; Lee, MR; Linthicum, J; Liu, F; McMahon, RP; Rubin, LH; Strauss, GP; Verbalis, JG; Wehring, HJ, 2016) |
| "Therapeutic treatments for schizophrenia do not alleviate symptoms for all patients and efficacy is limited by common, often severe, side-effects." | ( Charney, AW; Dudley, JT; Hultman, CM; Kähler, AK; Keiser, MJ; Kenny, PJ; Kidd, BA; Moran, JL; Purcell, SM; Readhead, B; Ruderfer, DM; Scott, SA; Sklar, P; Sullivan, PF, 2016) |
| "Patients with treatment-resistant schizophrenia had an excess of rare disruptive variants in gene targets of antipsychotics (347 genes, p=0·0067) and in genes with evidence for a role in antipsychotic efficacy (91 genes, p=0·0029)." | ( Charney, AW; Dudley, JT; Hultman, CM; Kähler, AK; Keiser, MJ; Kenny, PJ; Kidd, BA; Moran, JL; Purcell, SM; Readhead, B; Ruderfer, DM; Scott, SA; Sklar, P; Sullivan, PF, 2016) |
| "We used a treatment-based proxy for treatment-resistant schizophrenia to identify candidate predictors of treatment resistance at first hospital contact with a schizophrenia diagnosis." | ( Gasse, C; Horsdal, HT; MacCabe, JH; Støvring, H; Sørensen, HJ; Wimberley, T, 2016) |
| "Our main proxy definition of treatment-resistant schizophrenia was the earliest instance of either clozapine initiation or hospital admission for schizophrenia after having had two periods of different antipsychotic monotherapy." | ( Gasse, C; Horsdal, HT; MacCabe, JH; Støvring, H; Sørensen, HJ; Wimberley, T, 2016) |
| "It is an approved treatment for schizophrenia and mania in bipolar disorder type 1." | ( Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016) |
| "In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects." | ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
| "Clozapine is the only drug approved for treatment-resistant schizophrenia." | ( Haraldsson, M; Ingimarsson, O; Jónsdóttir, H; MacCabe, JH; Sigurdsson, E, 2016) |
| "Although treatment-resistant schizophrenia (TRS) was described 50 years ago and has a gold standard treatment with clozapine based on well-defined criteria, there is still a matter of great interest and controversy." | ( Buckley, PF; Elkis, H, 2016) |
| "The application of BS from untreated schizophrenia patients induced dystrophic alterations of astrocytes, BS from patients who received olanzapine during 8 weeks did not influence the astrocyte ultrastructure." | ( Kolomeets, NS; Uranova, NA; Vostrikov, VM, 2016) |
| "Veterans with treatment-resistant schizophrenia who were treated in the Veterans Health Administration (VHA) were studied." | ( Gören, JL; Ney, JP; Rose, AJ; Smith, EG, 2016) |
| "We present the case of a young man with treatment resistant schizophrenia who underwent a successful re-challenge of clozapine, having previously ceased treatment due to an eosinophilia associated with treatment." | ( Kolur, U; Korman, N; McArdle, PA; Parker, S; Purushothaman, S; Siskind, DJ, 2016) |
| "In this case series treatments of 5 schizophrenia patients who still had symptoms despite clozapine treatment were augmented with paliperidone during 6 months of follow up." | ( Çelik, M; Kalenderoğlu, A, 2016) |
| "It has been commonly used in the treatment of schizophrenia, however, with the advent of atypical antipsychotic medications, use has declined over the years." | ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016) |
| "Food and Drug Administration for the treatment of schizophrenia in September 2015." | ( Citrome, L, 2016) |
| "This is commonly referred to as treatment-resistant schizophrenia." | ( Barnes, TR; Bowe, S; Byrne, R; Davies, L; Dudley, R; French, P; Griffiths, H; Gumley, A; Hutton, P; Kingdon, D; MacLennan, G; McLeod, HJ; Morrison, AP; Norrie, J; Pyle, M; Schwannauer, M; Syrett, S; Turkington, D, 2016) |
| "placebo/ongoing antipsychotic treatment in schizophrenia-spectrum disorders." | ( Chiu, HF; Correll, CU; Li, XB; Ungvari, GS; Xiang, YQ; Xiang, YT; Zheng, W, 2016) |
| "The first relatively specific treatment of schizophrenia started about 60 years ago with the antipsychotic chlorpromazine." | ( Jovicic, MJ; Maric, NP; Mihaljevic, M; Miljevic, C, 2016) |
| "The low TGF- level in treatment-resistant schizophrenia patients in the symptom exacerbation period indicates that there is inadequate Th1/Th2 balance." | ( Bay Karabulut, A; Gönenir Erbay, L; Kartalcı, G; Kartalcı, Ş; Otlu, Ö; Porgalı Zayman, E, 2016) |
| "Clozapine, an antipsychotic used in treatment-resistant schizophrenia, causes slow gastrointestinal transit in 50-80% of patients." | ( Dunn, H; Ellis, PM; Every-Palmer, S; Grant, E; Huthwaite, M; Nowitz, M; Stanley, J, 2017) |
| "valproate alone is an effective treatment for schizophrenia and schizoaffective psychoses; and2." | ( Helfer, B; Leucht, S; Li, C; Wang, Y; Xia, J, 2016) |
| "Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required." | ( Osborne, AL; Solowij, N; Weston-Green, K, 2017) |
| "After treatment, schizophrenia patients showed a further increase in 8-iso-PGF2α (p = 0." | ( Bahn, S; Bernstein, HG; Brigadski, T; Dobrowolny, H; Frodl, T; Guest, PC; Isermann, B; Jordan, W; Lessmann, V; Pilz, J; Rodenbeck, A; Schiltz, K; Schwedhelm, E; Steiner, J; Tumani, H; Wiltfang, J, 2018) |
| "We argue that clozapine-treated schizophrenia patients utilise the clinical dichotomy between mental and physical domains of health to rework what health means to them." | ( Brown, JEH; Dennis, S, 2017) |
| "Expert opinion: In the treatment of schizophrenia and schizoaffective disorders the safety profile has a central role because it can enhance patient compliance." | ( Altamura, AC; Di Pace, C; Mauri, MC; Paletta, S; Reggiori, A, 2017) |
| "Brexpiprazole showed efficacy for the treatment of schizophrenia in the range of 2 to 4 mg/d and as an adjunct to antidepressant therapy in MDD when dosed at 2 to 3 mg/d." | ( Gallipani, A; Markovic, M; Maroney, M; Patel, KH, 2017) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "Current drug treatments for schizophrenia (SCZ) can alleviate positive symptoms, but have little effect on the negative symptoms and cognitive deficits that are difficult to translate into preclinical models for drug development." | ( Forsberg, MM; Gröhn, O; Ihalainen, J; Lehtonen, M; Leikas, JV; Paasonen, J; Salo, RA; Savolainen, K, 2017) |
| "Chlorpromazine has been the mainstay treatment for schizophrenia for decades, yet available evidence comparing this drug to metiapine fails to provide high-quality trial based data." | ( Bazrafshan, A; Zare, M, 2017) |
| "Clozapine (CLZ) is an effective treatment for schizophrenia, producing improvements in both negative symptoms and cognitive impairments." | ( Dziedzicka-Wasylewska, M; Faron-Górecka, A; Kolasa, M; Kuśmider, M; Pabian, P; Solich, J; Szlachta, M; Żurawek, D, 2017) |
| "Even in treatment-resistant schizophrenia, clozapine use is endorsed before combining antipsychotics." | ( Anderson, C; Jacobs, S; McMillan, SS; Mihala, G; Robinson, G; Theodoros, T; Wheeler, AJ; Wilson, L, 2017) |
| "Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed." | ( Huband, N; Subramanian, S; Völlm, BA, 2017) |
| "Treatment of patients with Treatment-resistant Schizophrenia (TRS), who fail to respond to multiple antipsychotic trials, including clozapine (CLZ), is challenging." | ( Birur, B; Lentowicz, I; Li, L; Rayikanti, R, 2017) |
| "However, data on treatment of schizophrenia with paliperidone palmitate (PP) among patients with comorbid SA are limited." | ( Bhak, RH; DerSarkissian, M; Duh, MS; Joshi, K; Lefebvre, P; Muser, E; Shiner, B; Young-Xu, Y, 2017) |
| "The use of clozapine for treatment-resistant schizophrenia is underutilized, and better understanding of the barriers to prescribing clozapine is necessary given the implications for patient's quality of life and hospital admission rates." | ( Behan, C; Clarke, M; Doyle, R; Hynes, C; Keating, D; Kelly, A; Kinsella, A; Lawlor, E; Madigan, K; Masterson, S; OʼKeeffe, D; Sheridan, A, 2017) |
| "In Canada, it is approved for the treatment of schizophrenia." | ( Higashi, K; Ishigooka, J; Iwashita, S; Liew, EL; Tadori, Y, 2018) |
| "It is cost-effective for treating chronic schizophrenia in the Netherlands." | ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| "Primary treatments for schizophrenia relieve the positive symptoms but are less effective against the negative and cognitive symptoms." | ( Jang, DS; Jeon, SJ; Kim, E; Kwon, Y; Lee, JS; Oh, HK; Ryu, JH; Zhang, J, 2017) |
| "Clozapine is the drug of choice for treatment-resistant schizophrenia." | ( Jacob, KS; Jacob, M; Rajagopal, VM; Rajkumar, AP, 2018) |
| "Clinical studies that focused on treating schizophrenia showed that Calculus Bovis Sativus (CBS), a substitute of Calculus Bovis, when used in combination with haloperidol could significantly lower the dosage of haloperidol compared with treatment with haloperidol alone, whereas efficacy was maintained." | ( He, GF; He, GZ; Lei, K; Li, J; Li, XP; Liu, D; Liu, YN; Ren, XH; Zhang, CL, 2018) |
| "In addition to its effects in treatment-resistant schizophrenia, clozapine has been shown to decrease suicidality, which occurs at an increased rate in patients with schizophrenia." | ( Green, AI; Henricks, AM; Khokhar, JY; Sullivan, EDK, 2018) |
| "The superior efficacy of clozapine in treatment resistant schizophrenia has been clearly demonstrated, yet there are often delays in the commencement of clozapine." | ( Bardell-Williams, M; Bowtell, M; Downey, L; Eaton, S; McGorry, P; O'Donoghue, B; Ratheesh, A; Thien, K, 2018) |
| "Clozapine is uniquely effective for treatment-resistant schizophrenia, and so treatment continuation is essential." | ( Gee, SH; Shergill, SS; Taylor, DM, 2018) |
| "Continuous clozapine treatment in schizophrenia patients was associated with a significantly lower long-term all-cause mortality rate compared to other antipsychotic use." | ( Correll, CU; de Haan, L; Sutterland, AL; van de Kerkhof, MPJ; van Rooijen, G; Vermeulen, JM, 2019) |
| "Overall, in the treatment of schizophrenia, and in adjunctive treatment of MDD, brexpiprazole and aripiprazole have a similar effect on body weight over the course of 1 year." | ( Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P, 2018) |
| "To date, clinical data on tnOT treatment of schizophrenia patients does not unequivocally support a general therapeutic effect on the psychopathology but suggests positive effects on higher integrated social cognitive performance, such as empathy and mentalization." | ( Hurlemann, R; Juckel, G; Luckhaus, C, 2019) |
| "Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used." | ( Ayhan, Y; Karahan, S; Koçyiğit, Y; Yazıcı, MK; Yoca, G, 2018) |
| "On the 14th day of treatment, schizophrenia-like symptoms were evaluated by the prepulse inhibition of the startle reflex (PPI), locomotor activity evaluated by the open field test (OFT), spatial recognition memory evaluated by the Y-maze task and social interaction test (SIT)." | ( de Sousa, FCF; Dias, KCF; Dos Santos Júnior, MA; Jucá, MM; Leal, LKAM; Silva, AH; Vasconcelos, GS; Vasconcelos, SMM; Viana, GSB; Ximenes, NC, 2018) |
| "Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States." | ( Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR, 2018) |
| "In this study, the treatment of schizophrenia patients with aripiprazole once-monthly (AOM) was evaluated under real-life conditions in a naturalistic setting." | ( Beck, E; Correll, CU; Janetzky, W; Luedecke, D; Schöttle, D; Wiedemann, K, 2018) |
| "In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important." | ( Sakamoto, S; Sato, K; So, R; Tsukahara, M; Yoshimura, B; Yoshimura, Y, 2019) |
| "Fourteen inpatients diagnosed with treatment-resistant schizophrenia, treated with clozapine and suffering from hypersalivation were randomized to receive hyoscine 0." | ( Evans, A; Hodsoll, J; MacCabe, JH; Segev, A; Shergill, S; Sheriff, RS; Whiskey, E, 2019) |
| "Clozapine has the greatest efficacy for Treatment Resistant Schizophrenia (TRS) but the greatest negative impact on cardiometabolic health." | ( Silva, E; Till, A, 2019) |
| "Long-term remission is an important treatment goal in schizophrenia." | ( Correll, CU; Earley, W; Harsányi, J; Potkin, SG; Szatmári, B; Zhong, Y, 2019) |
| "As the first-line treatment for schizophrenia in China, olanzapine-ODT is cost-effective compared to olanzapine-SOT and olanzapine-SOT is cost-effective compared to aripiprazole-SOT." | ( Cheng, Y; Jiang, K; Li, Q; Lin, Z; Xuan, J; Zhang, Y; Zhao, J, 2019) |
| "To look at whether patients with treatment resistant schizophrenia (TRS) are able to provide a valid self-assessment of symptoms, the present study investigated patient versus rater evaluation of clinical symptoms." | ( Borlido, C; Burton, L; De Luca, V; Remington, G; Song, J, 2019) |
| "Medications are frequently used for treating schizophrenia, however, anti-psychotic drug use is known to lead to cases of pneumonia." | ( Cheng, LC; Huang, CH; Kuo, KM; Talley, PC, 2019) |
| "Antipsychotic medications for the treatment of schizophrenia have limitations, and new treatments are needed." | ( Brown, HE; Fan, X; Fava, M; Freudenreich, O; Goff, D; Harrington, AL; Heard, SO; Hoeppner, B; Judge, H; Kane, JM; Perlis, RH; Petrides, G, 2019) |
| "Although APs remain the cornerstone treatment for schizophrenia they are associated with severe metabolic complications and fail to address premorbid cognitive deficits, which characterize the disorder of schizophrenia." | ( Agarwal, SM; Asgariroozbehani, R; Caravaggio, F; Castellani, L; Chintoh, A; Costa-Dookhan, KA; Graff-Guerrero, A; Hahn, M; Kowalchuk, C, 2020) |
| "The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly effective against the positive symptoms (e." | ( Babic, I; Huang, XF; Lum, JS; Newell, KA; Osborne, AL; Solowij, N; Weston-Green, K, 2019) |
| "Among patients with treatment-resistant schizophrenia (TRS), some exhibited further clozapine resistance (CR)." | ( Chan, HY; Chen, WJ; Lin, AS; Peng, YC, 2019) |
| "ultra-treatment-resistant schizophrenia, UTRS)." | ( Brown, EE; Gerretsen, P; Graff-Guerrero, A; Hahn, M; Iwata, Y; Kim, J; Nakajima, S; Remington, G; Sanches, M; Shah, P; Takeuchi, H, 2020) |
| "Clozapine is the drug of choice for treatment-resistant schizophrenia." | ( Dzahini, O; Oloyede, E; Taylor, D; Whiskey, E, 2020) |
| "A total of 39 clozapine-treated schizophrenia patients were recruited to the study." | ( Bar, L; Gaughran, F; Hochman, E; Hornfeld, SH; Krivoy, A; Satz, J; Shoval, G; Taler, M; Weizman, A, 2020) |
| "However, only 40% of patients with treatment-resistant schizophrenia have response to clozapine." | ( Chen, CH; Chiu, YH; Hsu, CY; Lu, ML, 2020) |
| "Early treatment of schizophrenia improves outcomes." | ( Jones, R; Liu, X; MacCabe, JH; Price, MJ; Upthegrove, R, 2020) |
| "A 36-year-old man with treatment-resistant schizophrenia was admitted to the Psychiatric Unit for therapy assessment." | ( Barcella, L; Butera, R; Eleftheriou, G; Falanga, A, 2020) |
| "Patients with treatment-resistant schizophrenia display progressive subcortical volume deficits after switching to clozapine despite experiencing symptomatic improvement." | ( Ahmed, M; Akudjedu, TN; Cannon, DM; Hallahan, B; Holleran, L; McDonald, C; Tronchin, G, 2020) |
| "The MK801-treated rats showed schizophrenia-like behavior and variations in the shape and volume of the hippocampus." | ( Huang, H; Li, X; Liu, Y; Liu, Z; Luo, C; Mao, X; Wang, X; Zhao, J; Zhou, H, 2020) |
| "Clozapine is indicated for treatment-resistant schizophrenia (TRS), but only 30%-60% of patients will respond." | ( Grimminck, R; Oluboka, O; Rutherford, DL; Sihota, M; Yeung, H, 2020) |
| "Lurasidone is a more effective drug for treatment of schizophrenia from a pharmacoeconomic point of view in comparison with paliperidone and sertindole." | ( Dyakov, IN; Egorova, DA; Juperin, AA; Mosolova, ES; Zyryanov, SK, 2020) |
| "Smoking behavior among clozapine-treated schizophrenia patients might delineate a cohort with an earlier onset of the disease." | ( Falkai, P; Gutwinski, S; Hasan, A; Kleymann, P; Luykx, JJ; Maurus, I; Morgenroth, CL; Okhuijsen-Pfeifer, C; Oviedo-Salcedo, T; Pelzer, N; Schneider-Axmann, T; Schreiter, S; Strube, W; Wagner, E, 2020) |
| "All patients receiving clozapine treatment for schizophrenia at one outpatient clinic were eligible for inclusion." | ( Hjorth, P; Launholt, TL; Nielsen, CT; Petersen, SM, 2021) |
| "The pharmacological treatment of schizophrenia is often performed with the simultaneous use of two or more antipsychotic agents to achieve the desired control of psychotic symptoms Available AP include both conventional (typical) and new (atypical) antipsychotic medications." | ( Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P, 2020) |
| "Motivation deficits remain an unmet treatment need in schizophrenia." | ( Fischer, MW; Holden, R; Johnson-Kwochka, AV; Lapish, CL; Luther, L; McCormick, B; Minor, KS; Salyers, MP, 2020) |
| "Amisulpride is effective in the treatment of schizophrenia and improving depression symptoms." | ( Ni, Y; Pan, A; Wang, G; Zheng, L; Zhou, B, 2020) |
| "We recruited 81 untreated schizophrenia patients and 96 healthy controls." | ( Bao, C; Hu, G; Huang, X; Li, Z; Lv, Q; Wu, H; Yi, Z; Zhao, J, 2021) |
| "Clozapine is effective in treatment-resistant schizophrenia; however, adverse effects often result in discontinuation of clozapine therapy." | ( Csukly, G; Déri, M; Fekete, F; Kiss, Á; Menus, Á; Monostory, K; Sirok, D; Tóth, K, 2020) |
| "Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction." | ( Hei, G; Li, R; Wu, R; Yang, Y; Zhao, J, 2020) |
| "Aripiprazole-treated schizophrenia was associated with a decreased risk of death compared with olanzapine-treated disease." | ( Chae, JH; Kim, TS; Nam, H; Oh, J; Park, S, 2021) |
| "However, incarcerated patients with treatment-resistant schizophrenia (TRS) often are not offered clozapine, the only medication for this debilitating illness approved by the U." | ( Pruette, ME; Sheitman, BB; Williams, JB; Zarzar, TR, 2021) |
| "Clozapine (CLZ) is a key drug in treatment-resistant schizophrenia." | ( Hayakawa, Y; Iwabuchi, R; Kikuchi, M; Kobayashi, D; Maekawa, M; Mano, N; Ogura, J; Sato, T; Sato, Y; Suzuka, M; Takasaki, S; Tsukamoto, T; Yokota, M, 2021) |
| "Acute phase quetiapine treatment for schizophrenia patients was strongly associated with increased risk of developing new-onset hypothyroidism, with a clear dose-response association." | ( Li, M; Retnakaran, R; Sun, Z; Wen, SW; Yuan, X; Zhai, D; Zhang, R; Zhao, Y, 2021) |
| "The pharmacological treatment of schizophrenia is currently based on the employment of antipsychotic medications showing an antagonism of dopaminergic and serotoninergic inhibitors." | ( Bellomo, A; Borraccino, L; Cuoco, F; De Berardis, D; Delle Monache, S; Fornaro, M; Gianfelice, G; Magnifico, G; Piccininni, C; Ricci, F; Rinaldi, A; Ventriglio, A, 2021) |
| "Retrospective cohort of patients with treatment-resistant schizophrenia, aged between 15 and 60 years, that initiated clozapine between 2014 and 2017." | ( Castañeda, CP; Crossley, NA; Diaz, C; González-Valderrama, A; Iruretagoyena, B; Maccabe, JH; Mena, C; Nachar, R; Ramirez-Mahaluf, JP; Undurraga, J, 2021) |
| "He was diagnosed with treatment-resistant schizophrenia and started on clozapine with dose titration to 500 mg/day over 3 months." | ( Gürsu Hariri, A; Kök Kendirlioğlu, B, 2021) |
| "Clozapine (CLZ) is the superior drug in treatment of schizophrenia." | ( Molden, E, 2021) |
| "Two distinct subtypes of treatment-resistant schizophrenia (TRS) have been recently reported, including early-treatment resistance (E-TR) and late-treatment resistance (L-TR)." | ( Chen, J; Chen, Y; Fang, T; Huang, G; Li, B; Li, Q; Lin, C; Liu, J; Ma, X; Shao, H; Tian, H; Wang, H; Xu, S; Xu, Y; Yang, A; Yang, W; Yao, C; Yu, X; Zhou, C; Zhuo, C, 2021) |
| "As the burden of treatment-resistant schizophrenia (TRS) on patients and society is high it is important to identify predictors of response to medications in TRS." | ( Ahmed, A; Corripio, I; Hirvonen, N; Isohanni, M; Jääskeläinen, E; Koponen, H; Lehtiniemi, H; Miettunen, J; Pylvänäinen, J; Seppälä, A; Seppälä, J, 2021) |
| "The study included 23 clozapine-treated schizophrenia patients (CT-SCZ), 19 risperidone-treated schizophrenia patients (RT-SCZ), 23 never-treated schizophrenia patients (NT-SCZ), and 35 healthy controls (HCs)." | ( Cao, H; Gong, Q; Lencer, R; Lui, S; Tao, B; Xiao, Y; Yang, C; Zhang, W, 2021) |
| "All patients admitted for treatment of schizophrenia being euthyroid at admission and reevaluated for thyroid function during hospitalization were recruited and followed until discharge." | ( Guan, Q; Han, J; Hao, W; Huang, X; Retnakaran, R; Shi, J; Sun, J; Wang, Q; Wen, SW; Yang, J; Zhai, D; Zhang, R; Zhang, X; Zhao, Y, 2022) |
| "A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment." | ( Agbedjro, D; Bak, N; Casetta, C; Christensen, SR; Downs, J; Fonseca de Freitas, D; Francis, E; Hayes, RD; Kadra-Scalzo, G; Kinon, BJ; MacCabe, JH; Pritchard, M; Ridler, I; Segev, A; Shetty, H; Smart, SE; Stahl, D, 2022) |
| "Clozapine is the most efficacious treatment for schizophrenia and is associated with lower overall mortality than are other antipsychotic drugs, despite the risk of agranulocytosis." | ( Bell, JS; Dawson, JL; Kataja, V; Taipale, H; Tanskanen, A; Tiihonen, J, 2022) |
| "Antipsychotics remain the main treatment for schizophrenia, but their effectiveness is challenging to compare." | ( Chan, HY; Chen, WJ; Kuo, PH; Lin, YH; Liu, CC; Wu, CS, 2022) |
| "However, the treatment of schizophrenia is important, and neurologists must treat tardive dyskinesia in collaboration with psychiatrists taking care of patients with tardive dystonia." | ( Nomoto, M, 2022) |
| "Olanzapine/samidorphan is an effective treatment for schizophrenia and bipolar I disorder with less weight gain than olanzapine monotherapy." | ( Corrao, MM; Nelson, LA, 2022) |
| "Although clozapine is effective for treatment-resistant schizophrenia (TRS), the rate of clozapine prescription is still low." | ( Atake, K; Fujimoto, M; Furihata, R; Hasegawa, N; Hashimoto, N; Hashimoto, R; Hishimoto, A; Hori, H; Ichihashi, K; Iga, JI; Iida, H; Inada, K; Kashiwagi, H; Kido, M; Kishimoto, T; Kodaka, F; Komatsu, H; Makinodan, M; Matsumoto, J; Miura, K; Muraoka, H; Nagasawa, T; Numata, S; Ochi, S; Ohi, K; Onitsuka, T; Tagata, H; Takaesu, Y; Takeshima, M; Tokutani, A; Tsuboi, T; Ueno, SI; Usami, M; Watanabe, K; Yamada, H; Yasui-Furukori, N, 2022) |
| "In the treatment of schizophrenia, suboptimal adherence, antipsychotic switching, and antipsychotic augmentation were all associated with high costs of care in comparison to patients who were adherent and did not require antipsychotic switching or augmentation." | ( Bessonova, L; Cichewicz, A; Doane, MJ; Harvey, PD; Hughes, R; Martin, A; O'Sullivan, AK; Snook, K; Weiden, PJ, 2022) |
| "Clozapine has the greatest efficacy for treatment-resistant schizophrenia (TRS), even though its underutilization is not uncommon across different countries." | ( Khazaie, H; Nazari, A; Rezaie, L; Safari-Faramani, R; Shohaimi, S, 2022) |
| "Patients with treatment-resistant schizophrenia (TRS) suffer severe, long-term psychotic symptoms and chronic stress." | ( Chiappelli, J; Hong, LE; Huang, J; Kochunov, P; Li, Y; Tan, S; Tan, Y; Tian, B; Tian, L; Tong, J; Wang, Z; Yang, F; Zhang, P; Zhou, Y, 2022) |
| "Current antipsychotics used to treat schizophrenia have associated problems, including serious side effects and treatment resistance." | ( Kaibuchi, K; Liao, J; Liu, Y; Miyagawa, Y; Mizoguchi, H; Nagai, T; Ozaki, N; Sawahata, M; Sobue, A; Takase, S; Tanaka, R; Yamada, K, 2022) |
| "Lurasidone is a cost-saving first-line treatment for schizophrenia for both adolescents and adults." | ( Afonso, D; Dymond, A; Green, W, 2022) |
| "Thirty-eight never treated schizophrenia patients and 38 demographically matched individuals (healthy controls) were assessed at baseline and at 8-week follow-up with symptom ratings, and cognitive and functional imaging procedures, at which time a blood draw for DNAm studies was performed." | ( Bishop, JR; Chen, C; Chen, X; Giase, G; He, Y; Hu, M; Li, B; Li, Z; Liao, Y; Liu, C; Rubin, LH; Sweeney, JA; Tang, J; Wang, Y; Xia, Y; Zong, X, 2022) |
| "Clozapine treatment for schizophrenia is typically long-term and is associated with a high rate of diabetes." | ( Assur, Y; Brakoulias, V; Bramwell, S; Ganapathy, R; Jayaballa, R; Maberly, G; Meyerowitz-Katz, G; Vasani, D; Zheng, Y, 2023) |
| "Clozapine, the only approved drug for treatment-resistant schizophrenia (TRS), involves the GABAergic system as one of its targets." | ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Antipsychotic drugs used to treat schizophrenia have many side effects." | ( Ghaderi, A; Hosseini Hooshiar, S; Jafarnejad, S; Rabiee, R, 2023) |
| "Its expression is altered in treated schizophrenia patients, and cannabinoids modulate CDK5 levels in the brain of rodents." | ( Barrera-Conde, M; Bergé, D; de la Torre, R; Garcia-Quintana, J; Gomis-Gonzalez, M; Martínez-Sadurní, L; Perez, V; Pujades, M; Robledo, P; Trabsa, A; Veza-Estévez, E, 2023) |
| "Its expression is altered in treated schizophrenia patients, and cannabinoids modulate CDK5 levels in the brain of rodents." | ( Barrera-Conde, M; Bergé, D; de la Torre, R; Garcia-Quintana, J; Gomis-Gonzalez, M; Martínez-Sadurní, L; Perez, V; Pujades, M; Robledo, P; Trabsa, A; Veza-Estévez, E, 2023) |
| "They are considered first-line treatments for schizophrenia and gradually replace typical antipsychotics." | ( Hamsa, A; Kariyarambath, P; Karumandampalayam Shanmugaramasamy, K; Kathirvel, S, 2023) |
| "They are considered first-line treatments for schizophrenia and gradually replace typical antipsychotics." | ( Hamsa, A; Kariyarambath, P; Karumandampalayam Shanmugaramasamy, K; Kathirvel, S, 2023) |
| "Guidelines recommend clozapine for treatment-resistant schizophrenia." | ( Bighelli, I; Davis, JM; Dong, S; Hamza, T; Hansen, WP; Leucht, S; Salanti, G; Schneider-Thoma, J; Siafis, S, 2023) |
| "The most common way to treat schizophrenia is antipsychotic medication." | ( Alladi, CG; Bacq-Daian, D; Bélivier, F; Boland-Auge, A; Deleuze, JF; Jamain, S; Latapie, V; Lokmer, A; Marie-Claire, C; RajKumar, RP; Shewade, DG; Troudet, R, 2023) |
| "Considering that psychosocial treatments for schizophrenia spectrum disorders often focus on cognition, these results underscore the importance of identifying whether these domains or other treatment targets may be better in addressing racial disparities in functioning." | ( Elliott, T; Halverson, TF; Jarskog, LF; Merritt, CC; Pedersen, CA; Penn, DL, 2023) |
| "Existing medications for the treatment of schizophrenia work primarily by improving positive symptoms such as agitation, hallucinations, delusions, and aggression." | ( Ago, Y; Asano, S; Sakamoto, K, 2023) |
| "Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS)." | ( Bittner, RA; Qubad, M; Reif, A, 2023) |
| "Thus, personalized treatment for schizophrenia should consider the age of onset." | ( Chen, S; Cui, Y; Hong, LE; Huang, J; Li, S; Tan, S; Tan, Y; Tian, B; Tong, J; Tong, Y; Wang, Z; Yang, F; Yin, Y, 2023) |
| "Due to its unique efficacy in treatment-resistant schizophrenia, discontinuation of treatment with clozapine is frequently associated with a significant worsening of symptoms, but also with an increased risk of suicide." | ( Berger, SJ; Hofer, A, 2023) |
| "It is reserved for treatment-resistant schizophrenia." | ( Agaciak, M; Allison, S; Bastiampillai, T; Chan, SKW; Looi, JCL; Yee, B, 2023) |
| "Despite advances in pharmacology, the treatment of schizophrenia (SZ) remains a challenge due to relapse after antipsychotic discontinuation and multiple adverse effects of antipsychotics." | ( Lang, X; Wu, F; Xiu, M; Xue, M; Zang, X; Zhang, X, 2023) |
| "Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability." | ( Bellomo, A; De Berardis, D; Dell'Osso, B; Di Giannantonio, M; Maria Conca, AP; Salvi, V; Siracusano, A; Zaffora, C, 2023) |
| "Clozapine has unique effectiveness in treatment-resistant schizophrenia and is known to cause immunological side-effects." | ( Blackman, G; Jones, R; Kornblum, D; Legge, SE; MacCabe, JH; Morales-Munoz, I; Pritchard, M; Shields, A; Upthegrove, R, 2023) |
| "For decades, treatment for schizophrenia has focused on antipsychotics (APs) that reduce excess dopamine signaling to the associative striatum, which also blocks dopamine signaling in the dorsal striatum, creating movement disorders." | ( Citrome, L; Meyer, JM, 2023) |